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A methyl group deposited on cytosines incorporated into the sequence of the DNA, so 
called DNA methylation, decorates the genomes of a large number of species, from 
archaea to man. Over the last two decades, a large body of research discovered that 
this small chemical moiety elicits a profound effect on the gene expression program. In 
particular, DNA methylation restricts transcriptionally active regions of the genome, 
therefore ensuring a faithful interpretation of the regulatory information encoded in the 
DNA sequence. This fundamental role played by the methylation of DNA helps define 
cell identity at a molecular level, thus it enables a biologically complex transition such as 
from a zygote to an organism to occur in a unidirectional and orchestrated manner. 
Perturbations in the pattern of DNA methylation have been frequently found in 
pathological processes such as tumorigenesis. 
The pattern of DNA methylation decorating the genome of a cell is precisely copied 
during cell division by maintenance machinery composed of the DNMT1 enzyme and its 
associated proteins. The absence of DNMT1 elicits a wide-range of deleterious effects, 
from loss of cell fitness of in vitro cultured cells to embryonic lethality and loss of 
homeostasis of somatic tissues. Previous studies reported pleiotropic effects and 
mutually exclusive phenotypes of DNMT1 knockout depending on the design of the study 
– from apoptosis and genomic instability to accelerated cell cycle and trans-
differentiation. How exactly these phenotypes arise in a response to DNMT1 deficiency 
is unknown. 
We employed the state-of-the-art next generation sequencing technologies and coupled 
them with molecular and cell biology techniques to elucidate the causes for the loss of 
fitness of DNMT1-deficient human embryonic stem cells. In contrast to previous studies, 
we did not observe the proposed DNA damage or genomic instability. Our work 
demonstrated that an acute depletion of DNMT1 results in a uniform decay of DNA 
methylation that we characterized in depth at a single cell level. Interestingly, our 
transcriptome profiling in single cells followed by functional validations revealed a change 
in the way how the transcriptional machinery interprets the genome in the absence of 
DNMT1. The loss of global DNA methylation without its maintenance machinery resulted 
in transcriptional changes mainly related to some gonad-specific genes and also a few 
genes encoding key players of a signaling transduction pathway. This finding inspired us 
to discover that the cells deficient for DNMT1 display a lower threshold for activating 
transcription once challenged with external stimuli. Our findings therefore provide new 
insights into how genome deficient for cytosine methylation becomes transcriptionally 
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amenable, thus capable to integrate and respond to new signals from the environment. 
Our work lays a foundation for future studies on how such process leads to 





























Methylgruppen an in die DNA eingebauten Cytosinbasen, die sogenannte DNA-
Methylierung, zieren die Genome einer großen Anzahl von Arten, von den Archaea bis 
zu den Menschen. In den letzten zwei Jahrzehnten hat eine Vielzahl von 
Forschungsarbeiten ergeben, dass diese kleine chemische Einheit eine tiefgreifende 
Auswirkung auf das Genexpressionsprogramm hat. Insbesondere beschränkt die DNA-
Methylierung die transkriptionell aktiven Regionen des Genoms und gewährleistet so 
eine genaue Interpretation der in der DNA-Sequenz kodierten regulatorischen 
Informationen. Diese grundlegende Rolle der Methylierung von DNA hilft dabei, die 
Zellidentität auf molekularer Ebene zu definieren und ermöglicht so, dass biologische 
komplexe Übergänge, wie z.B. von der Zygote zum Organismus, auf unidirektionaler und 
orchestrierter Art und Weise stattfinden können. Störungen im Muster der DNA-
Methylierung werden häufig bei pathologischen Prozessen wie der Tumorentstehung 
gefunden. 
Das Muster der DNA-Methylierung auf dem Genom einer Zelle wird während der 
Zellteilung durch eine Wartungsmaschinerie, die aus dem DNMT1-Enzym und damit 
verbundenen Proteinen bestehen, präzise kopiert. Die Abwesenheit von DNMT1 hat 
eine Vielzahl von schädlichen Auswirkungen, von einem Verlust der Tauglichkeit von in 
vitro kultivierten Zellen bis zur embryonalen Letalität und einem Verlust der Homöostase 
von somatischen Geweben. Frühere Studien wurden pleiotrope Effekte und sich 
gegenseitig ausschließende Phänotypen des DNMT1-Knockouts in Abhängigkeit vom 
Studiendesign beschrieben–von Apoptose und genomischer Instabilität bis hin zu einem 
beschleunigten Zellzyklus und der Transdifferenzierung von Zellen. Wie genau diese 
Phänotypen bei einer Reaktion auf einen DNMT1-Mangel auftreten, ist nicht bekannt. 
Wir setzten die neuesten Sequenzierungstechnologien ein und kombinierten diese mit 
molekularen und zellbiologischen Techniken, um die Ursachen für den Fitnessverlust 
von menschlichen embryonalen Stammzellen mit DNMT1-Mangel aufzuklären. Im 
Gegensatz zu bisherigen Studien haben wir keine DNA-Schädigung oder genomische 
Instabilität beobachtet. Unsere Arbeit zeigte, dass eine akute Reduktion von DNMT1 zu 
einem gleichmäßigen Abbau der DNA-Methylierung führt, den wir auf Einzelzellebene 
eingehend charakterisierten. Interessanterweise ergab unsere Auswertung des 
Transkriptoms einzelner Zellen, gefolgt von funktionellen Validierungen, dass sich die 
Art und Weise, wie die Transkriptionsmaschinerie das Genom interpretiert, in 
Abwesenheit von DNMT1 verändert. Der Verlust der globalen DNA-Methylierung ohne 
ihre Erhaltungsmaschinerie führte zu Veränderungen der Transkription einiger 
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gonadenspezifischer Gene und einigen wenigen Genen, die die Hauptakteure eines 
Signaltransduktionswegs kodieren. Dieser Befund führte zu unserer Entdeckung, dass 
die Zellen, denen DNMT1 fehlt, eine niedrigere Schwelle für die Aktivierung der 
Transkription aufweisen, sobald sie mit externen Stimuli in Kontakt gebracht werden. 
Unsere Ergebnisse liefern daher neue Erkenntnisse darüber, wie Genome, denen die 
Cytosinmethylierung fehlt, transkriptionszugänglich werden und somit in der Lage sind, 
neue Signale aus der Umwelt zu integrieren und auf diese zu reagieren. Unsere Arbeit 
bildet die Grundlage für zukünftige Studien darüber, wie ein solcher Prozess zu 

























Through the process of cell division and subsequent differentiation, a single cell can form 
all the tissues of a multicellular organism. This is possible, because all the cells share 
the same genome – a deoxyribonucleic acid (DNA) entity, which encodes genes. Intrinsic 
and extrinsic signals cooperate to shape the expression of genes resulting in 
morphologically and functionally diverse cells. Inability to secure the proper gene 
expression profile can be detrimental to a cell by changing its properties, restricting 
differentiation potential or altering its interaction with the surrounding environment. This 
simple principle lays a foundation for each process in biology such as development, 
tissue homeostasis or aging. How this complex process gene expression is executed 
and regulated has been one of the fundamental questions in biology. 
 
3.1 Regulation of gene expression 
 
The genes are expressed in the process of transcription, where a specialized protein 
machinery uses DNA as a template to produce molecules of messenger RNA (mRNA), 
which then serve to instruct the synthesis of proteins. The decision which DNA sequence 
is transcribed depends mainly on two factors: (1) the presence and engagement of 
transcription factors (TFs), instructed in cis by the so-called TF binding motifs encoded 
in the DNA and (2) an additional layer of information independent on the DNA sequence 
that influences the accessibility of the DNA. The latter is largely defined by chromatin – 
the assembly of proteins and DNA, which serves to compact the genetic information in 
the cell nucleus. The basic unit of chromatin is the nucleosome – a composite of DNA 
wound around an octamer of histone proteins. The N-terminal tails of histones are 
substrates for post-translational modification by enzymes, which in turn recruits or 
inhibits the binding of large chromatin-modifying complexes that control the accessibility 
of the chromatin and thus impact transcription1.  
Not only the nucleosomes, but also the nitrogenous bases of the DNA can be modified 
by enzymes in a manner that does not change the DNA base pairing. Such modification 
of may be instructive for DNA-binding proteins and, indirectly, regulate the transcriptional 
potential of underlying genes. Collectively, heritable modifications affecting gene 
expression without modifying the DNA sequence are called “epigenetic modifications”. 
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Among many possible modifications of the DNA, methylation of the 5th carbon in cytosine 
ring embedded in the DNA (referred thereafter as the DNA methylation) was identified in 
19252 and has been extensively studied for decades. This small modification is highly 
conserved, present in bacteria, through the earliest eukaryotes3, plants4, fungi5 and 
animals6. Interestingly, DNA methylation is absent in some model organisms, such as 
yeast, C. elegans or the fruit fly7. Why some organisms do not possess DNA methylation 
remains unknown.  
Technological advances over the last decades enabled both quantitative (mass 
spectrometry8) and qualitative (DNA sequencing9) studies of modification of nucleotides 
present in the DNA. Mass spectrometry experiments performed on mammalian genomic 
DNA identified methylation of about 1-2% cytosines in the genome of mammalian cells, 
which makes the cytosine methylation the predominant modification found in the 
mammalian DNA. The DNA methylation occurs in the context of CpG dinucleotides and, 
to a lesser extent, CpA dinucleotides10. The methyl group is deposited on cytosines in 
the DNA by specialized enzymes, called the DNA methyltransferases (DNMTs)11. 
 
3.2 The establishment of DNA methylation 
 
To date, three enzymes were identified to deposit methyl groups onto previously 
unmodified cytosines (de novo methylation), thus establishing a genome-wide DNA 
methylation pattern. DNA methyltransferase 3A and 3B (DNMT3A and DNMT3B)12 are 
expressed across various cell types, while the recently-identified DNMT3C13 is restricted 
to the male germline of mice and rats, and is not in the scope of this study. 
In order to secure the specificity and fidelity of their enzymatic activity, DNMTs are 
composed of multiple domains. 
DNA methyltransferase domain. Cytosine methylation is performed by a highly 
conserved methyltransferase (MTase) domain present at the C-terminus of all 
catalytically active DNMTs14. The catalytic activity of DNMT3A and B is enhanced by 
DNMT3L15 (an inactive DNA methyltransferase) in the germline. Two chromatin-
recognizing domains restrict the substrate specificity of de novo methyltransferases.  
ADD domain. The ATRX-DNMT3-DNMT3L (ADD) domain binds unmodified N-terminal 
tail of histone H3 and it is repelled by modification on lysine 4 (H3K4)16. Unless the 
binding to H3K4 occured, the ADD domain has autoinhibitory properties and hinders the 
MTase domain17.  
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PWWP domain. The Proline-Tryptophan-Tryptophan-Proline (PWWP) domain 
specifically binds the methylated histone H3 at the lysine 36 (H3K36me3), which is 
sufficient for DNMT3B recruitment18. As the methylation of H3K36 is a co-transcriptional 
process19, it is believed that the PWWP domain confers specificity for methylation of 
actively-transcribed genes by DNMT3A and B.  
 
3.3 Maintenance of DNA methylation 
 
Cytosines are methylated in the context of a CpG dinucleotide, the symmetry of which 
allows maintenance of this mark over DNA replication. Specifically, when nascent the 
strand is synthesized, by the virtue of DNA complementarity, a CpG dinucleotide on the 
parental strand will be paired with another CpG on the new strand. The existence of an 
enzyme that can recognize mCpG:CpG pairing (so-called “hemimethylated DNA”) and 
methylate the nascent strand CpG using the parental strand as a template had been 
predicted20 and, eventually, the responsible protein was identified. The DNA 
methyltransferase 1 (DNMT1) faithfully maintains the genome-wide DNA methylation 
over cell divisions21.  
DNMT1 is structurally different from the de novo DNMTs even though they all share the 
MTase domain. In addition, DNMT1 contains different N-terminal domains and also 
distinct interacting proteins that altogether dictate its specificity to hemimethylated DNA, 
as well as its stability22.  
BAH domains. In contrast to DNMT3A and 3B, the isolated MTase domain of DNMT1 
is catalytically inactive and its proper folding depends on two bromo-adjacent homology 
(BAH) domains, which adopt a dumbbell-like shape in close contact with the catalytic 
domain23. 
RFTS domain. Similarly to the ADD domain in DNMT3 enzymes, DNMT1 is auto-
inhibited by an replication foci targeting sequence (RFTS) domain24. In order to release 
the MTase domain, RFTS binds the ubiquitinated N-terminal tail of histone H3. This mark 
is bestowed upon histones by DNMT1 binding partner – Ubiquitin-like with PHD and Ring 
Finger Domains 1 (UHRF1)25,26.  
DNMT1-interacting protein, UHRF1. This E3 ubiquitin-protein ligase recognizes 
hemimethylated DNA through its SET- and RING- associated (SRA) domain25,26. 
Furthermore, its tandem TUDOR-PHD (TTD- PHD) domain allows for binding to 
methylated lysine 9 on histone H3 (H3K9me2 and me3)27, facilitating the recruitment of 
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DNMT1 to heterochromatin. In agreement with UHRF1 being required for DNMT1 
function, UHRF1 knockout phenocopies the DNMT1 knockout in vivo26.  
CxxC domain. Although DNMT1 possesses a CXXC domain, which is known to bind 
unmethylated CpG-rich DNA regions28, it is unclear whether this domain regulates the 
DNMT1 enzyme specificity29.  
PCNA-interacting domain. The faithful maintenance of the methylated cytosine pattern 
on both strands of DNA occurs during DNA replication in the S-phase of the cell cycle. 
Indeed, DNMT1 interacts with the DNA polymerase complex through Proliferating Cell 
Nuclear Antigen (PCNA), which ensures that the entire genome becomes a substrate for 
copying the methyl mark30.  
PTMs regulating DNMT1. Besides the protein-protein interactions dictating the spatial 
distribution of DNMT1, DNMT1 is also restricted temporally based on its abundance via 
post-translational modifications (PTMs). A number of PTMs on DNMT1 were described 
so far. For example, the ubiquitination of DNMT1 on lysine K142 occurs in late S-phase 
and marks the protein for proteasomal degradation in a cell-cycle dependent manner, so 
that it is not present outside of the S-phase31. In contrary, a phosphorylation of serine 
S143 stabilizes DNMT132. Another mode of the proteasomal degradation of DNMT1 may 
be proceeded and promoted by acetylation of lysine residues followed by the UHRF1-
mediated DNMT1 ubiquitination33. This mode of DNMT1 degradation is antagonized by 
a specific set of deacetylases and deubiquitinases34,35. 
Altogether, multiple enzymes and mechanisms act on DNMT1 to restrict its function in a 
spatial and temporal manner, and to secure the process of maintaining the pattern of 
DNA methylation. 
 
3.4 Genome-wide distribution of DNA methylation 
 
The distribution of DNA methylation across the genome is non-random. This is because 
the distribution of substrate cytosines in CpG dinucleotide is not uniform across the 
genome. Less than 10% of CpGs occur in the highly CpG-dense regions of high cytosine 
and guanine content termed the CpG islands (CGIs)36. This DNA sequence feature is 
enriched in the promoters of two thirds of genes and virtually all housekeeping genes37. 
In contrast, the “open sea” CpG dinucleotides (outside of the CGIs) are mostly 
methylated. Overall, out of about 28 million CpGs in the human genome, 60-80% are 
methylated in somatic cells38,39. In the following section, we will further discuss the 
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function of DNA methylation across the genomes and focus on its role in (1) controlling 
transcription and (2) as a source of mutagenesis. 
DNA methylation controls gene expression on sex chromosomes.  
Male and female genomes differ with respect to the so-called sex chromosomes. While 
females have two X chromosomes, males have an X and a Y chromosome. This poses 
a challenge for the female genome, which has to reduce the dose of the gene products 
present on the X chromosomes, so that it equals the transcriptional output of the X 
chromosome in the male genome. This so-called dosage compensation process occurs 
during early embryonic development via a transcriptional shutoff of one of the X 
chromosomes in the process termed X chromosome inactivation (XCI)40. The inactivated 
X becomes coated in the Xist lnc-RNA, which leads to transcriptional silencing, followed 
by chromatin remodeling41. The transcriptional silencing process requires the CGIs of 
the inactive X chromosome to become methylated by DNMT3B42.  
 
DNA methylation controls of gene expression on autosomes.  
Imprinted and germline-specific genes. A number of studies reported the function of 
DNA methylation in suppressing the expression of imprinted genes43. A selective DNA 
methylation of either the maternal or the paternal allele of certain genomic regions, 
known as the imprint control regions (ICR), leads to monoallelic transcription of 
neighboring genes44. The exact mechanism of imprinting is not known, however, loss of 
imprinting is associated with multiple human diseases45,46. In addition, high levels of DNA 
methylation are found on the promoters of germline-specific genes47. It is thought that 
this mark restricts the expression of such genes outside the gonads.  
Transposable elements. About a half of the human genome consists of mobile selfish 
genetic elements, termed transposable elements (TEs). Such genetic elements have 
been debated as a potential source of new genes and cis-regulatory elements therefore 
contributing to genetic variation48. However, an uncontrolled expression and 
transposition of these genetic elements leads to a random mutagenesis, thus potentially 
impairing cell fitness49. Therefore, multiple mechanisms are deployed in gonads and 
somatic cells to restrict the expression of these genetic elements.  
In gonads, the PIWI-interacting small RNAs (piRNAs) pathway acts to recognize 
transcriptionally active transposons and repress their transcription of transposons using 
chromatin modification, such as histone H3 methylation and DNA methylation50. Specific 
details of the piRNA pathway-induced TE silencing in mammals have not been yet 
elucidated.   
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While the piRNA pathway operates on evolutionary young TEs, another TE silencing 
pathway operates on evolutionary old TEs in the somatic cells. Here, the hundreds of 
Krüppel-associated box domain zinc finger proteins (KRAB-ZFPs) evolved to recognize 
DNA sequence motifs of TEs51. ZFPs recruit KRAB-associated protein 1 (KAP1), which 
acts as a scaffold for assembling gene-silencing complexes operating on chromatin. This 
includes the chromatin-modifying NuRD complex, as well as SETDB1 histone 
methyltransferase and HP1 chromodomain protein52. Upon the removal of active histone 
marks by the NuRD, SETDB1 methylates histone 3 lysine 9, which is recognized by HP1, 
a protein which compacts the chromatin. Subsequently, the DNMTs are recruited to the 
site, which results in hypermethylation of transposable element sites53.  
Genomic repeats. DNA methylation is enriched in tandem repeat regions and is 
believed to act to restrict their latent transcriptional activity54. An example of that are 
pericentromeric repeats, which consist of thousands of tandemly repeated copies, 
stretching from either side of the centromere to ensure the proper centromeric 
assembly55. Uncontrolled transcription from these loci is thought to interfere with the 
centromere assembly54,56. 
Other genes. In contrast to germline-specific genes, imprints or repetitive elements, the 
relationship between DNA methylation and most coding gene expression is not linear. 
Most coding gene promoters are in fact unmethylated. Conversely, the DNA methylation 
of active gene bodies is mediated through H3K36me3-dependent recruitment of de novo 
methyltransferases and thus positively correlates with gene expression18. Roles in 
inhibiting cryptic, intragenic promoters and instructing splicing have both been proposed 
for DNA methylation at gene bodies57,58. Also, a recent study analyzing the DNMT3B-
depleted cells found aberrant transcription initiation sites in subtelomeric regions59. 
These findings demonstrate that although DNA methylation is often associated with 
transcriptionally inert genomic regions, it has also roles in regulating actively transcribed 
genes. 
 
3.5 How DNA methylation exerts its function 
 
Several modes of action have been proposed to date. DNA methylation is recognized 
specifically by methylated DNA binding domain (MBD) family of proteins60. As MBD 
proteins are known to interact with histone deacetylase and chromatin remodeling 
complexes61, the transcriptionally repressive character of DNA methylation could be 
achieved by these 5mC-specific readers. High redundancy has obscured the studies of 
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the role of MBD proteins in gene silencing, as single knockouts do not exhibit severe 
phenotypes62. 
Recently, multiple lines of research have focused on how DNA methylation impacts the 
ability of TF to bind its cognate sequence in the DNA. Exhaustive studies of TF specificity 
revealed that the binding of over 170 transcription factors was impaired by DNA 
methylation63. Presence of DNA methylation at distal regulatory elements could, in 
principle, impede transcriptional activity even of unmethylated CGI-promoter genes64. 
Strikingly, there are transcription factors with preference for methylated DNA adding a 
further layer of complexity to the interpretation of the roles of DNA methylation in 
transcriptional regulation63.  
 
3.6 Methylated cytosine as a mutagen 
 
The high levels of DNA methylation on the TEs and other repeats in the mammalian 
genome not only confer the transcriptional silencing, but could also introduce to a 
permanent alteration in the underlying DNA sequence through the process of 
deamination65. Unmodified cytosines undergo spontaneous deamination, which results 
in a conversion of the base to uracil. Such mutation is identified by the cell and corrected 
by base excision repair (BER)66. However, when methylcytosine is deaminated, it is 
converted to thymine, therefore introducing mutation. There is a dedicated enzyme called 
thymine DNA glycosylase (TDG) that corrects the aberrant G:T pairing67. However, if the 
mismatch was not recognized and repaired, it can be passed on to the daughter cell. 
Alteration in the DNA sequence of regulatory elements could, for example, impair 
transcription. 
Recent study found that DNA methyltransferases introduced the toxic lesion 3-
methylcytosine at a low rate both in vitro and in vivo. Comparative studies of nematode 
species that possess or lost DNMTs demonstrated that DNA methylation co-evolved with 
Alpha-Ketoglutarate Dependent Dioxygenase (ALKB2), an enzyme which repairs 
alkylation DNA damage68. Altogether, mutations are a byproduct of DNA methylation. 
 
3.7 The removal of DNA methylation 
 
There are two ways in which DNA methylation can be removed from its locus.  
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First, emerging directly from the mechanism of DNA methylation, is the lack of the 
maintenance for example by disrupting its machinery. Then, DNA methylation will 
become diluted over consecutive replication cycles (passive demethylation). 
Alternatively, in the process of active demethylation, specialized enzymes from the ten 
to eleven transferase (TET) family can catalyze the hydroxylation of methylcytosine to 5-
hydroxymethylcytosine (5hmC)69, 5-formylcytosine (5fC) and 5-carboxylcytosine 
(5caC)70. Not only are these modifications not recognized by DNMT1 and are not 
maintained, they also engage thymine DNA glycosylase (TDG), which excises the base 
and the abasic site is repaired by downstream DNA damage repair71. TET dioxygenases 
and de novo DNMTs were found to competitively bind and regulate the level of DNA 
methylation in some loci72. This active demethylation acts independently of DNA 
replication and has more specificity than ablating DNA methylation maintenance. It is 
therefore well-suited for dynamically regulating the levels of this modification. In fact, 
TETs are indispensable for mouse embryonic development73. 
 
3.8 DNA methylation is dynamic in the early development 
 
Although, the CpG methylation reaches 60-80% in the mammalian somatic cells, the 
levels of global DNA methylation fluctuate throughout the early embryonic development 
(FIG 1)74. During the early embryonic development, the DNA methylation pattern is 
erased from specialized cells (the egg and the sperm) in the so-called first wave of global 
DNA demethylation75. A subsequent re-establishment of DNA methylation is essential 
for the development of the newly forming organism76,77.  
Both passive demethylation (by excluding DNMT1 from the nucleus) and active 
demethylation mediated by TET oxidases contribute to the demethylation wave that 
result overall in about 20% of DNA methylation being retained. This includes the maternal 
and paternal imprints, as well as DNA methylation at the evolutionarily young and more 
potent transposable elements78. During embryo implantation, the genome becomes re-
methylated to reach the ~80% DNA methylation maintained throughout the somatic 




Figure 1: Global DNA methylation dynamics during development. Adapted from80. 
 
The second demethylation wave occurs during the development of primordial germ cells 
(PGCs) in a two-step manner. First, passive demethylation by the exclusion of UHRF1 
from the nucleus occurs. In the second step81, TET dioxygenases (specifically TET1 and 
TET2) remove DNA methylation mostly from imprinted loci, preparing the germline for 
establishing ICRs anew82,83. After the passive and active demethylation, only about 7% 
of CpGs in the primordial germ cells remain methylated84. The global DNA methylation 
is re-established in a sex-specific manner, with sperm having a significantly higher levels 
of methylation than oocytes85,86. While both waves of global DNA demethylation result in 
cell types with very low levels of methylcytosine, the state of hypomethylation occurs 
only transiently and even then the methylation of several loci is strictly maintained.  
 
3.9 The impact of loss of DNMT on embryonic development 
 
Function of DNA methylation in regulating gene expression, as well as its high 
conservation throughout the tree of life implies that it may play an important role at 
organismal level. Indeed, the previous genetic studies of the knockouts of DNA 
methyltransferases DNMT1 and DNMT3B demonstrated their early embryonic lethality, 
while the mice devoid of DNMT3A died shortly after birth76,77. Mouse embryos deficient 
for DNMT1 show a number of pathologies that emphasize the role of DNA methylation 
in a developing organism. In these DNMT1-deficient embryos resorption occurs around 
the neurulation stage76. Also, the knockout embryos were distinguished from littermates 
by their stunted growth at the E9 stage of development. The specimens fail to close the 
neural tube with an incomplete somitogenesis76. Likewise, the development of limb buds 
is retarded as well as allantois structures were abnormal in most of these embryos. 
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Moreover, histological analysis of several knockout embryo-derived tissues showed an 
increase in apoptosis. Lastly, the embryos do not produce blood and no blood vessels 
have been observed in the developing yolk sac76.  
In order to bypass the embryonic lethality of DNMT1KO embryos, mice containing one 
copy of a hypomorphic DNMT1 allele were engineered to produce only ~10% of DNMT1 
protein compared to wild type (WT) cells87. Although these mice were viable, a marked 
loss of DNA methylation was observed on repetitive elements. These mice developed 
fatal T cell lymphomas87. 
The pleiotropic KO phenotype and link between DNA hypomethylation and cancer upon 
DNMT1 depletion prompted multiple in vitro studies to identify the exact cause of 
DNMT1KO embryo lethality and identify which of the functions of DNA methylation 
specifically is imperative for the survival of an organism.  
 
3.10 DNMT1 deficiency in embryonic stem cells 
 
In order to model the early embryonic development, cells from the inner cell mass of the 
blastocyst are cultured in vitro, as the so-called embryonic stem cells (ESCs). These 
cells retain their ability to self-renew and differentiate into the three germ layers that form 
the embryo: ecto-, meso- and endoderm88. Previous efforts established both mouse and 
human embryonic stem cells in cultures89,90. Interestingly, both cultures differ by their 
morphology, growth conditions and also molecular features such as gene expression 
and DNA methylation level. Comparative studies between the two cell types 
characterized mouse ESCs (mESCs) as closely resembling the inner cell mass91. In 
contrast, the human ESCs (hESCs) display the molecular markers of the epiblast stage 
of development, which proceeds the blastocyst implantation92. Reflective of these 
developmental differences, hESCs have higher levels of DNA methylation than 
mESCs93.  
Genetic studies depleting the DNA methyltransferases in hESCs and mESCs were vastly 
different. While the knockout of de novo methyltransferases (DNMT3A and 3B) was 
tolerated in both cell types94,95, the removal of the maintenance methyltransferase 
(DNMT1) resulted in a loss of fitness in hESCs exclusively, although global DNA 
hypomethylation was observed in both mouse and human cells. The removal of Dnmt1 
alone or in combination of Dnmt3A and 3B led to a complete loss of DNA methylation in 
mESCs without affecting their self-renewal capability94. However, the differentiation of 
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Dnmt1-deficient mouse ESCs was impaired96. For example, in methylcellulose 
hematopoietic progenitor assay (used to assess the potential of ES cells to differentiate 
into hematopoietic lineage cells) had a low level of erythroid cell differentiation and no 
myeloid cells were formed96.  
 
3.11 DNMT1 deficiency in somatic stem cells 
 
Because (1) a direct differentiation of Dnmt1KO mESCs to cell type of interest is 
impossible and (2) knockout embryos do not develop to the point to form many of the 
tissues of interest, alternative means were used to obtain somatic cells deficient for 
Dnmt1.  
The commonly used Cre recombinase-based system for inducing gene knockout is 
bases on the ability of the CRE protein to guide recombination between small DNA 
sequences called loxP97. When two loxP sites are inserted into the genome in the same 
orientation, the recombination will result in the removal of the sequence between them, 
which is a potent way to engineer knockouts. Crosses between Dnmt1fl/fl (loxP flanked 
exons 4 and 5)98 mice and ones that expressed CRE in a tissue-specific manner (usually 
by placing it under the control of a tissue-specific gene promoter) enabled studies of 
Dnmt1KO cells in embryonic fibroblasts98, pancreas99, developing intestine100, 
myoblasts101, hematopoietic stem cells (HSCs)102, neural progenitor cells (NPCs)103 and 
both post-mitotic neurons and neuronal precursors104. The results of these tissue-specific 
knockouts of DNMT1 are confounding and often mutually exclusive, therefore only a few 
general, common themes emerge that will be described below. 
Cell cycle arrest followed by apoptosis. Mouse embryonic fibroblasts (MEFs) were 
reported to undergo cell cycle arrest and apoptosis in culture98. Furthermore, this loss of 
fitness phenotype was accompanied by gene expression deregulation and activation of 
transposable elements.  
Biased differentiation. In contrast, DNMT1 knockout in the more committed myoblasts 
(progenitors of muscle cells) in mice resulted in the preferential transdifferentiation of 
these somatic stem cells into osteocyte-like cells (progenitors of bone cells), both in vivo 
and in vitro. Trowbridge and colleagues examined the effect of the Dnmt1 ablation on 
hematopoiesis, by crossing the Dnmt1fl/fl and the Mx-Cre mice102. Interestingly, using 
the Mx-Cre system lead to a knockout in both HSCs and their bone marrow 
microenvironment, however, no defect in lineage composition or cellularity of the bone 
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marrow was observed. Hematopoietic stem cell knockout of Dnmt1 followed by 
transplantation into irradiated wild-type host (normal microenvironment) resulted in a 
preferential differentiation down the lymphoid lineage instead of myeloid lineage. At the 
same time, the overall number of HSCs was reduced upon transplantation. This event 
was not caused by apoptosis, but rather an increased rate of cell division and terminal 
differentiation. Of note, transcriptional analysis reported the expression of the same 
transposable elements as those observed in MEFs98,102.  
An analogous situation was observed in neural progenitor cells, which also had a biased 
differentiation potential and preferentially formed glial, rather than neuronal cells103. A 
more detailed analysis of Dnmt1 knockout in the neural lineage was performed by Fan 
and colleagues104. In agreement with the role of Dnmt1 as a maintenance 
methyltransferase acting during DNA replication, the depletion of this enzyme in the 
postmitotic neurons did not have a detrimental effect either in vitro or in vivo. Using the 
Nestin-Cre system to specifically knock out Dnmt1 in the brain resulted in either the 
embryonic lethality or the postnatal death, depending on how efficient the Dnmt11 
knockout was performing (95% versus 30%, respectively)104. The differentiated neurons 
did not display apoptotic markers, however, in the mice that survived due to the Dnmt1-
KO mosaicism (Cre recombinase worked in only 30% of cells), the Dnmt1-deficient 
neurons were eliminated from the postnatal brain within 3 weeks of birth104.  
Failure in differentiation. In contrast to the reports from HSC and NPC-specific 
knockouts, pancreatic progenitor cells fail to differentiate, rather than differentiating 
precociously. The p53-dependent apoptosis was attributed to the loss of progenitors and 
haploinsufficiency of trp53 rescued the ability of the cells to form an organ, albeit of a 
smaller size than in the wild-type littermates99. Both premature differentiation and 
apoptosis were the cause of reduced proliferation of the perinatal intestinal epithelium 
and consequently the death of most pups before weaning. The surviving crypt cells 
exhibited differences in the transcriptional program, notably upregulating DNA damage 
response and cell cycle checkpoint genes100.  
DNMT1 knockdown approach was in turn used to study the effect of maintenance 
methyltransferase depletion on the keratinocyte proliferation105. By expressing a short 
hairpin (sh)RNA with the sequence complementary to the DNMT1 mRNA, RNA 
interference (RNAi) machinery is directed to the targeted mRNA for its subsequent 
degradation that eventually leads to either partial or complete absence of a protein 
product. This strategy was employed to deplete DNMT1 in human keratinocytes (skin 
progenitors), followed by engraftment into immunodeficient mice105. Loss of the 
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maintenance methyltransferase resulted in premature differentiation of these progenitors 
and eventual tissue loss, similarly to what was reported for intestinal cells.  
 
3.12 DNMT1 deficiency in cancer cells 
 
Cancer cells divide rapidly and thus were utilized as a model to study the consequences 
of DNMT1 depletion. With the RNAi-based methods, previous studies generated cancer 
cell lines106,107 displaying higher or lower reduction of DNMT1 protein. These 
knockdowns were reported to trigger replication stress checkpoint106, or mismatch repair 
(MMR) deficiency-like phenotype107. A complete knockout of DNMT1 in HCT116 colon 
cancer cell line resulted in G2/M phase arrest108.  
Overall, these results present a complex repertoire of in vivo phenotypes that have been 
associated with the loss of DNMT1. Molecular mechanism of how a cell responds to and 
tolerates the deficiency in DNA methylation would likely dissect the underlying causes of 



















4. AIMS OF THE STUDY 
 
The aim of this study is to consolidate our understanding of how loss-of-function of the 
DNA maintenance methyltransferase affects cell homeostasis. Through a combination 
of next generation sequencing and molecular biology methods, we aim to characterize 
the general mechanisms of response to the absence of DNMT1. We concentrate on 
verifying phenotypes reported in the previous studies of DNMT1KO cell lines – both 
cancer and non-transformed. 
Specifically, we aim to address the following: 
(1) Characterize how DNMT1-deficiency affects cell growth, by assessing the 
number of growing cells, the cell cycle length and potential checkpoints, as well 
as the number of apoptotic cells;  
 
(2) Describe the effect of DNMT1-deficiency on genomic stability, by investigating 
DNA damage markers, expression of transposable elements and possible 
defects occurring during mitosis; 
 
(3) Investigate the effects of DNMT1 depletion on the level of DNA methylation and 
its distribution across the genome and how it affects the transcriptional output of 















5. MATERIALS AND METHODS 
 
Cell culture 
Human Embryonic Stem Cells HUES64109 or Human Induced Pluripotent Stem Cells 
ZIP13K2110 were cultured in a 5% CO2, 37°C incubator. The medium consisted of 
mTeSR1 (STEMCELL Technologies), with a 1:100 supplementation of Revitacell 
(Thermo scientific) during passaging and the first 24h after plating. The cells were plated 
on Geltrex (Thermo Scientific) basement membrane matrix-coated plates. The Geltrex 
stock was diluted 1/10 in Dulbecco Phosphate Buffered Saline (DPBS; Thermo 
Scientific) and the plates were stored in the incubator for 1h for coating.  
The media was changed daily and the cultures were passaged once every 4 days. For 
passaging, the cells were washed once with DPBS, followed by 3-5minute incubation in 
0.5nM EDTA in DPBS solution in the incubator. Cells were collected and washed once 
with mTeSR1 media and re-plated in small clumps at a 1:8 dilution. For freezing, cells 
were collected in the same way, re-suspended in mTeSR1, 1:100 Revitacell, 10% 
dimethyl sulfoxide (DMSO; Sigma-Aldrich), transferred to cryo vials (Thermo scientific) 
and stored overnight at -80°C in a Mr. Frosty (Thermo) ispopropanol freezing box. The 
vials were stored in liquid nitrogen tank. 
 
Cell counting 
For cell count experiments, the cells were collected using Accutase (STEMCELL 
Technologies), according to manufacturer’s instructions. Single cells were plated at 
40 000/well in a 12-well plate in triplicates and collected daily with the same method and 
for subsequent passage, another 40 000cells/well in a 12well plate were seeded. For 
counting, 10µL of cell suspension was mixed with Countess Trypan Blue Stain (0.4%, 
Thermo Scientific), loaded onto countess slides (Thermo Scientific) and counted on a 
Countess Automated Cell counter. The number of living cells was noted. 
The number of cells were plotted as “surviving cells with respect to control”, where at 
each time point the percentage of cells was calculated according to the formula: 
 𝑠𝑢𝑟𝑣𝑖𝑣𝑖𝑛𝑔 𝑐𝑒𝑙𝑙𝑠(𝑦) =
#𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛×100%








Nuclear protein extraction protocol was performed on live cells, briefly, we rinsed a 
confluent 10cm plate 2x with PBS and scraped into a 15mL Falcon. Spun @1200rpm for 
3min. Re-suspended in 7mL ice cold buffer A (+fresh PI and DTT). Spun @1500rpm for 
5min. Re-suspended the pellet in 500µL ice cold buffer C (+fresh PI and DTT). Spun 
@3000g for 5min. For WB re-suspended in 500µL RIPA (+PI and DTT, also DNase I and 
RNase A). Vortex 20min @4°C. Spun @max speed for 15min, moved the supernatant 
to a new tube and discarded the pellet. Added 83.3uL 4x LDS sample buffer (Thermo) 
to the supernatant. Denatured the samples @70°C for 10min and stored them at -20 to 
-80°C, or used immediately. If frozen, we first thawed the sample and heated it up to 
40°C. Vortexed briefly before running on a NuPAGE gel (Thermo). For immunoblotting, 
we resolved 7.5 – 15uL sample in the XCell SureLock Mini-Cell (Thermo) using 4-12% 
BisTris gels (Thermo) and MOPS buffer (Thermo) according to the manufacturer’s 
instructions. The protein was then transferred into nitrocellulose membrane using the 
iBlot 2 blotting system with pre-made transfer sandwiches (Thermo). The membrane was 
then blocked in 5% blotting grade blocker (Biorad) w/v solution in 1x Tris Buffered Saline 
– Tween-20 (TBS-T, Thermo). The same solution was used for staining with antibodies 
(overnight at 4°C): anti-DNMT1 (Chromotek E8; 1:500), anti-tubulin (Hybridoma bank 
12G10; 1:10 000). The blots were washed 5 times with TBS-T and then incubated with 
secondary antibodies: anti-Rat Horse-Raddish Peroxidase (HRP; Thermo 1:10 000) and 
anti-mouse HRP (Thermo; 1:10 000). The blots were visualized using SuperSignal kit as 
per manufacturer’s instructions (BioRad), followed by imaging in BioRad ChemiDoc on 
automatic settings. HiMark Protein standard (Thermo) was used to estimate the height 
of the bands.
Buffers used consisted of: 
 
Buffer A 






















Table 1. Nuclear extraction buffer composition. 
The ready buffers were filtered through 0.2µm filter and stored at 4°C 
Added to all buffers right before use: 1xRoche PI (25x stock in dH2O; Sigma), 1mM DTT 
(1M stock in dH2O; Sigma) and optionally 1mM PMSF (100mM stock in isopropanol; 
Sigma). Added to RIPA buffer right before use: 1:1000 DNaseI (NEB, optional), 1uL 
RNase A (Qiagen). 
 
Genomic DNA extraction 
Genomic DNA was extracted using the Qiagen blood and tissue sample kit (Qiagen), 
according to manufacturer’s instructions. 
 
5mC ELISA 
Purified genomic DNA was diluted to 20ng/µL and 100µL of each sample was used per 
replicate in 5mC ELISA (Zymo). The procedure was performed according to 
manufacturer’s instructions, with one modification: the DNA was denatured for 20 




The cells were stained using the Click-iT EdU Stain Kit, (protocol for attached cells; 
Thermo) according to manufacturer’s instructions, with modifications: the growing cells 
were incubated with half of the recommended EdU dose dissolved in basal DMEM 
(Gibco) medium for 30 minutes, followed by immediate fixation with 4% 
Paraformaldehyde (PFA; Thermo) in PBS. Stained cells were imaged using Cell 
 
RIPA 
50mM Tris pH 8 
200mM NaCl 
5% Glycerol 
0.5% Triton X-100 
0.1% Sodium Deoxycholate 
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Discoverer (Zeiss) microscope and the number of EdU positive and total cells were 
automatically counted using ZEN software (Zeiss). 
 
TUNEL stain 
The cells were stained using the In Situ Cell Death Detection Kit, Fluorescein (Sigma), 
according to manufacturer’s instructions. Stained cells were imaged using Cell 
Discoverer (Zeiss) microscope and the number of TUNEL-positive and total cells were 
automatically counted using ZEN software (Zeiss). 
 
CFSE stain 
The cells were detached using Accutase (described above) and incubated for 30 minutes 
with the CellTrace CFSE reagent dissolved in basal DMEM medium in the incubator, 
according to manufacturer’s instructions. The cells were then washed and plated 
normally, followed by detachment using Accutase and fixation with RNAprotect Cell 
Reagent (Qiagen). The cells were stored in the fridge until all the samples were collected. 
The cells were then stained with Hoechst 33342. The green and blue fluorescent cells 
were gated for and counted. The absolute fluorescence of CFSE was plotted using 
FlowJo software (FlowJo LLC).  
 
Hoechst 33342/DAPI stain  
Either DAPI (1mg/mL; Thermo) or Hoechst solution (10mg/mL; Thermo) were dissolved 
at 1:10 000 in PBS. A 10-minute incubation on a rotating platform in the darkness was 
followed by FACS analysis on FACS Aria II (BD Biosciences); or a single DPBS wash 
and fluorescence microscopy. 
 
Immunofluorescence staining 
The cells were imaged on the plates they were grown in. For confocal microscopy, we 
used ibidi polymer coated 60mm thin bottom dishes (Ibidi). The cells were fixed with 4% 
PFA, followed by 2 washes in DPBS. The cells were then permeabilized using 0.5% 
Triton X in PBS solution for 10 minutes, followed by blocking in a 5% Bovine Serum 
Albumin (BSA; Sigma), 0.2% Triton X in PBS for 30 minutes on a rotating platform, at 
room temperature. The same blocking solution was used to immunostain the cells with 





Antigen Concentration Company Catalog number 
Mre11 1:500 NOVUS NB100-1425s 
BLM 1:250 Santa Cruz 365753 
53BP1 1:250 Bethyl A300-272A 
T 1:500 R&D AF2085 
SOX17 1:500 R&D MAB1924 
Nestin 1:1000 R&D MAB1259 
tubulin 1:500 Sigma T9026 
 Table 2. Primary antibodies used in immunofluorescence microscopy. 
The samples were washed using 5% Bovine Serum Albumin (BSA; Sigma), 0.2% Triton 
X in PBS, 3 times each. The same buffer was used to incubate the cells with secondary 
antibodies: 
Antigen Concentration Company 
Mouse IgG; Alexa488 
conjugated 
1:1000 Thermo 
Rabbit IgG; Alexa488 
conjugated 
1:1000 Thermo 
Goat IgG; Alexa488 
conjugated 
1:1000 Thermo 




Table 3. Secondary antibodies used in the study. 
After 3 additional washed, the cells were stained with DAPI (described above) and 
imaged using CellDiscoverer microscope (Zeiss) for fluorescence microscopy or 
LSM800 with Airyscan (Zeiss) for confocal microscopy. Representative images were 
pseudocolored, merged and cropped using ImageJ (NIH). 




G-band karyotyping was performed by Cell Line Genetics (CLG). 20 cells per line were 







Plasmids were constructed by restriction enzyme digestion of a donor plasmid. 10nM 
each forward and reverse primers were used for PCR-amplifying desired DNA fragments 
(Phusion High-fidelity Master Mix GC, NEB), purifying both DNA fragments in Tris-
Acetate-EDTA (TAE) agarose gel. Bands of the desired size were excised from the gel 
and purified using Qiagen Gel extraction kit (Qiagen). The fragments were recombined 
together using Infusion cloning kit (Takara) according to manufacturer’s instructions. 
Stellar competent bacteria (Takara) were used for plasmid transformation, according to 
manufacturer’s instructions. In order to confirm correct insertion of the fragments, the 
transformed bacteria were plated on agarose plates consisting of LB and Ampicillin 
(100ng/mL). Resistant colonies were incubated in LB broth overnight on a bacteria 
shaker at 37°C and subsequently purified using Qiagen Miniprep kit. Purified 
recombinant plasmids were Sanger-sequenced by Eurofins genomics. The correct 
sequence of the plasmid was verified using Benchling. 
For transfection-quality purification, 50mL cultures of bacteria were grown overnight on 
a bacterial shaker at 37°C and purified using the Midiprep kit (Qiagen) according to 
manufacturer’s instructions.  
The knockout lines presented in this study were performed using CRISPR/Cas9 
technology111. Guide RNAs: lentiCRISPRv2 was a gift from Feng Zhang (Addgene 
plasmid # 52961 ; http://n2t.net/addgene:52961 ; RRID:Addgene_52961)112. We 
modified the plasmid by substituting Puromycin resistance gene with a Blasticidin 
resistance gene (BLA) sequence ordered from IDT.  
The design of guide RNAs used in this study was performed in Benchling 
(www.benchling.com) and the cloning was performed according to the instructions from 
the GeCKO protocol (http://genome-engineering.org/gecko/wp-
content/uploads/2013/12/lentiCRISPRv2-and-lentiGuide-oligo-cloning-protocol.pdf)112.  
Target gRNA sequence 
TP53 GGATGATTTGATGCTGTCCC 
LEFTY1 CTGTGGCTCTGCTGGGCACTC 
Table 4. Guide RNAs used in this study. 
The pLV-TRE3G-UCOE-GFP-WPRE plasmid was a kind gift from the Lindquist lab. 
NODAL or LEFTY1 cDNA sequences were ordered from IDT and inserted into the 





HEK 293T cells were grown in a Dulbecco's Modified Eagle Medium/Nutrient Mixture F-
12 (DMEM/F12) basal medium (Gibco), supplemented with 10% Fetal Bovine Serum 
(FBS; Gibco), 1x Penicillin-Streptomycin (STEMCELL Technologies) and 1x GlutaMax 
(Thermo). To make lentiviruses, these HEK cells were plated at 3.2x106 cells in a 10cm 
dish, and next day transfected with 30µL Mirus LT1 reagent (Mirus), 5µg donor plasmid, 
3.75µg psPAX2 plasmid (psPAX2 was a gift from Didier Trono (Addgene plasmid # 
12260 ; http://n2t.net/addgene:12260 ; RRID:Addgene_12260), 1.5µg VSV-G (pCMV-
VSV-G was a gift from Bob Weinberg (Addgene plasmid # 8454 ; 
http://n2t.net/addgene:8454 ; RRID:Addgene_8454) in 1mL DMEM basal medium.  
The next day the cells were fed 20% FBS medium (otherwise the same recipe as above) 
and incubated for 48-72h. The medium from the cells was harvested, centrifuged to get 
rid of the pellet of dead cells and mixed with LentiX concentrator (Takara) in a 3:1 ratio. 
The mix was incubated at 4°C overnight and centrifuged for 45min at 1500g in cooled 
centrifuge. The pellet containing lentivirus was re-suspended in 2mL DMEM, aliquoted 
and either used immediately or stored at -80°C. 
For transduction, hESCs were seeded in 6well plates at a regular density. On the 
following day they were incubated with 1mL mTeSR1, followed by the addition of 5µg/mL 
Polybrene (Santa Cruz Biotechnology), between 5 and 25µL concentrated virus re-
suspended in another 1mL of mTeSR1. After 24h of incubation with the virus mix, the 
media was changed to regular mTeSR and, following 2-4days of recovery, the cells were 
selected for virus integration. 
 
Antibiotic selection 
Cells recovered after viral transduction were plated sparsely on 10cm dishes in the 
presence of 4µg/mL Blasticidin. The drug was supplied until a control plate of WT cells 
treated in the same way has perished (usually within 4 days). Surviving colonies were 
grown for 10 days and manually scraped off and moved to a well in a 96well plate with a 
P200 pipette. The content of each well was then divided into two 96-well plates and 




Confluent cells were lysed using Direct PCR Lysis Reagent (Viagen) according to 
manufacturer’s instructions. 1µL of lysate was used for a genotyping PCR ran with the 
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Phusion GC master mix (NEB), the PCR products were resolved on a 1% TAE agarose 
gel, excised and purified using Qiagen gel extraction kit and cloned into TOPO vector 
using a Blunt-end TOPO kit (Thermo), according to manufacturer’s instructions. The 
bacteria were selected and genotyped as described above.  





Table 5. Genotyping primers used in this study. 
 
RNA extraction 
One well of a 6well plate was used per extraction. The cells were lysed in 1mL TRIzol 
reagent (Thermo), each milliliter of Trizol was mixed with 200µL of Chloroform (Sigma) 
and transferred into a heavy phase lock tube (VWR). After 15 seconds shaking, the 
mixture was incubated for 5min at room temperature to allow phase separation. The 
tubes were centrifuged at 12000g 4°C centrifuge for 15 minutes. The top aqueous phase 
was mixed with 1mL isopropanol, incubated at -20°C for an hour and centrifuged at 
maximum speed in a 4°C centrifuge for 30min. The supernatant was discarded and the 
pellet was washed once with 75% ethanol, followed by a wash with pure ethanol. After 
air-drying the pellet, the RNA was re-suspended in pure water (RNase free) and the 
concentration was measured using Nanodrop (Thermo).  
 
Reverse transcription 
1µg RNA was first subjected to a DNaseI digest using amplification grade DNaseI 
(Invitrogen), according to the manufacturer’s instructions. The reaction was then used 
directly for first strand synthesis using RevertAid kit (Thermo), according to the 
manufacturer’s instructions. Random hexamers were used for non-exon spanning 
primers (such as repeats), or oligo dT for exon-spanning primers (coding genes). The 
lack of DNA product was confirmed with a –RT (no reverse transcriptase enzyme) 





1µL RT reaction was mixed with 10nM each forward and reverse primer, 2x SYBR Green 
Master Mix (Thermo) and water, up to a total volume of 11µL. The reactions were 
pipetted into 384-well qPCR plates and ran on a ViiA 7 System machine (Thermo), using 
default settings. The results were analyzed in Excel normalized to the internal 
housekeeping gene control 𝑥 = 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑣𝑎𝑙𝑢𝑒 𝑜𝑓 
2∧(−𝐶𝑡 𝑠𝑎𝑚𝑝𝑙𝑒)
2∧(−𝐶𝑡 ℎ𝑜𝑢𝑠𝑒𝑘𝑒𝑒𝑝𝑖𝑛𝑔)





GAPDH GCACCGTCAAGGCTGAGAAC 113 
 AGGGATCTCGCTCCTGGAA  
NODAL agacatcatccgcagccta 114 
 caaaagcaaacgtccagttct  




LEFTY2 cctggacctcagggactatg 114 
 atcccctgcaggtcaatgta  
CER1 gccatgaagtacattgggaga 114 
 cacagccttcgtgggttatag  
NEUROG2 GAC ATT CCC GGA CAC ACA C 115 








 CTGCCCCCCTCTGGCAAG  
GFAP GGTTGAGAGGGACAATCTGGCACA 116 
 CTATAGGCAGCCAGGTTGTTCTCGG  
18S RRNA GTAACCCGTTGAACCCCATT 117 




 CAACGAAGGCCACAAGATGTC  
L1 GCTGGATATGAAATTCTGGGTTGA 118 
 AGGAAATACAGAGAACGCCACAA  
HERVK AAATAAGACCCAACCGCCAGTAGC 117 
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 GAATTGCCATGCCTCAGTATCTCC  
Table 6. qRT-PCR primers used in this study. 
 
ScoreCard 
The Scorecard (Thermo) experiment was performed as per manufacturer’s instructions, 
with modifications in the Reverse Transcription stage. We used 1.5µg RNA reverse-
transcribed according to the RevertAid kit (Thermo) instructions, in double the 
recommended volume. The reactions were then diluted with miliQ water and processed 
according to the ScoreCard manual. The score was calculated by the SCORE web 
browser app (Thermo).  
 
NPC differentiation 
80% confluent hESCs were detached from the plate using Dispase (Thermo) for about 
20min. The colonies were washed in DMEM/F12 basal medium and carefully transferred 
to a low attachment 6-well plate (Corning) and cultured in media containing N2 
supplement (Thermo), B-27-RA (no retinoic acid) supplement (Thermo) in DMEM/F12 
medium, supplemented freshly with 100nM LDN193189 (Sigma) and 10µM SB431542. 
Cells were cultured in suspension to form Embryoid Bodies and their media was carefully 
changed every second day. After 7 days, the EBs were plated on regular culture plates 
coated for 3h with matrix consisting of Poly-ornithine (20µg/mL; Sigma) and Laminin 
(5µg/mL; Thermo) and cultured in the same medium for another 7-10 days until neural 
rosettes formed. These were collected with neural rosette medium (STEMCELL 
Technologies). The rosettes were seeded again on Polyornithine-Laminin coated plates 
in NPC medium: the same DMEM/F12; N2; B27-RA base, supplemented with 20ng/mL 
basal FGF (STEMCELL) and 1µg/mL laminin. After a week, the cells differentiated into 
NPCs and were grown in the NPC medium on 83.3µg/mL Matrigel (Corning) re-
suspended in ice cold DMEM/F12 matrix (coating 1h, double washing before re-plating 
cells). The NPCs were passaged every week at a 1:3 ratio.  
 
Small molecules, antibiotics, cytokines and morphogens 
The cells were incubated with the following chemicals, which were diluted as per 
manufacturer’s instructions to make stock solutions stored at -20 to -80°C (the dose and 
























Figures were generated and assembled using GraphPad Prism 7 (Graphpad), Adobe 
Illustrator 2017 (Adobe) and ImageJ (NIH). The tables were generated in Excel 
(Microsoft). 
 
Dual protocol scRNAseq+RRBS 
The protocol was designed by Hongcang Gu, Andreas Gnirke and Arman Mohammad, 
who also prepared the libraries. It is based on G&Tseq with minor modifications119. Full 
protocol can be found in supplementary material, along with expression and methylation 
data. Briefly: 
The cells were detached from the plate using accutase, followed by fixation in RNA 
Protect buffer (Qiagen). The cells were then stored in the fridge and FACS sorted 
together into 96well plates containing 15 μl of RLT plus buffer (Qiagen) and 1 U μl−1 of 
SUPERase·In RNase inhibitor (Thermo). After sorting and freezing β-mercaptoethanol 
(Sigma), was added to the sample and the suspension was transferred into 96-well DNA 
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LoBind plate (Eppendorf). M-280 streptavidin beads conjugated to oligo dT reverse 
transcription primer were added to each sample, followed by incubation at 72 °C for 3 min 
and at room temperature for 25 min on a rotating platform. The mRNA was separated by 
a DynaMag-96 Side Magnet (Thermo) and to reverse transcribed as described in the 
Smart-seq2 protocol119. The genomic DNA was stored in a fresh LoBind plate. Following 
reverse transcription, the cDNA was amplified and an RNA-seq library was generated as 
described before120. The libraries were pooled and sequenced by an Illumina Hiseq2500 
sequencer. 
Agencourt AMPure beads (Beckman Coulter) were used to purify genomic DNA, which 
was eluted with 15 μl of low Tris–EDTA buffer. For the RRBS library generation, we used 
the CutSmart buffer (NEB) for the enzymatic reactions: MspI digestion, end-repair/A-
tailing and DNA ligation using T4 DNA ligase (NEB), without changing the solution 
between steps to avoid sample loss.  
The genomic DNA was set up for an 80min digestion reaction using 16U MspI (New 
England Biolabs) at 37 °C, followed by incubation at 65 °C for 15 min to inactivate the 
enzyme. The DNA ends were repaired and A-tailed using Klenow fragment (3’ to 5’ 
exonuclease) (New England Biolabs) reaction, supplemented with 0.3 mM dATP and 
0.03 mM each dCTP and dGTP at 30 °C for 25 min, followed by incubation at 37 °C for 
25 min, and heat inactivation at 70 °C for 10 min.  
The A-tailed DNA fragments were then ligated with 7nM indexed adapters overnight at 
16 °C, using T4 DNA ligase, followed by heat inactivation at 65 °C for 15 min. The 
libraries were pooled, and the adaptor dimers were removed using AMPure beads. The 
tagged DNA was eluted in 30μl of low Tris-EDTA buffer.  
Qiagen EpiTect Fast Bisulfite Conversion Kit was used according to manufacturer’s 
instructions (protocol marked with *), with a minor modification. We extended the bisulfite 
conversion time to 2 cycles of 20 min each, maximize the bisulfite conversion rates to 
over 99%. The bisulfite-converted DNA fragments were PCR amplified and the library 
DNA was purified using AMPure beads. The RRBS libraries were sequenced for 2 × 100 







The QC and read alignment were performed by Ayush Raman, Caleb Laureau and 
Martin Aryee. The scRNAseq data was processed as described before120. The scRRBS 
data was processed using a cloud-based computational pipeline121. Briefly, the quality of 
raw reads was assessed using FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc ; Andrews, 2010). The 
average per-base quality score across the sequencing samples was satisfactory to pass 
the QC. Trim galore (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) 
was used to trim low-quality bases from the ends of the reads. The reads were aligned 
to the human hg38 reference genome using Bismark2122. Duplicated reads were 
removed, and subsequently the number of covered CpGs was calculated.  
The estimate of methylation from the ratio between methylated and unmethylated alleles 
calculated across all the CpGs in the genome was summarized in a so-called ß-matrix. 
In this method, a ß-value per CpG is between 0 (unmethylated) and 1 (fully methylated).  
 
The data set was then tested for biases using scmeth package in R environment121. Low-
quality samples were identified based on alignment and discarded, average methylation 
per base across the reads (M-bias, Citation: Vermunt et al. Cell Reports 2014) was 
estimated, followed by calculating CpG and mean methylation across samples. Sufficient 
sequencing depth was ensured by plotting the downsampling saturation curve (number 
of CpGs as a function of read number), indicating that the probability of sequencing a 
new CpG plateaued with the number of reads we covered. 
 
The replicates of the cells from the same time point (i.e., same day) were pooled together 
by taking the mean of the ß-values. Next, the genome was divided into 1-kb non-
overlapping tiles and averaged ß-value per tile was calculated. All the tiles with no signal 
(i.e., ß-value and coverage equal to 0) were removed.  
 
scRRBS data was analysed by Dr Jocelyn Charlton using R studio and Bioconductor 
packages123, while the scRNAseq and combined analyses were performed by Dr Sudhir 
Thakurela using R studio and Seurat package124. The DEG analysis, GO term 
analysis125,126, gene pools overlap analysis (using Venny: 
https://bioinfogp.cnb.csic.es/tools/venny/) and plotting the expression of particular genes 





The libraries were prepared by the MPI-MG Berlin sequencing facility, briefly: RNA 
libraries were prepared using the TrueSeq RNA Sample Prep v2 HS Protocol (Illumina), 
followed by 50 bp paired-end sequencing on the NextSeq500 Sequencing System 
(Illumina). The QC and alignment were performed by Dr Jocelyn Charlton. FastQ raw 
reads were trimmed using Cutadapt127. The reads were then aligned using STAR 
aligner128 (to the hg19 human genome assembly) and Stringtie v1.3129 was used for 






























6.1 Genetic approach to study the consequences of the disruption of 
the maintenance of DNA methylation. 
 
We set out to study DNMT1 using a genetic approach considering the following criteria: 
1. As DNMT1 acts alongside replication, its loss-of-function phenotype was almost 
exclusively reported in mitotic cells. We thus reasoned that the culture needed to 
be replicating to allow the passive loss of methylation from the DNA, to 
recapitulate the most severe phenotypes of DNMT1KO studied before. In fact, 
many of the cases of DNMT1-deficiency published up to date resulted in a loss 
of fitness76,98,102,106.  
2. To study the precise cause for this, we would also employ a model with a strong 
and penetrant phenotype arising from the depletion of DNMT1.  
3. Lastly, we were interested in cells that are genetically stable. Previous, molecular 
biology studies often utilize cancer cell lines, such as U2OS or HCT116, due to 
their easy culturing, rapid growth and suitability for nucleic acid delivery, which 
renders them permissive for genetic manipulation130. However, due to their 
genomic instability and abnormal global DNA methylation pattern, cancer cell 
lines could potentially yield confounding results in our study. Therefore, we 
decided to utilize a non-tumor-derived line instead. This will enable the distinction 
between an intrinsic cell line instability and the consequences of DNMT1 absence 
as has been reported for some of the cases of DNMT1 depletion in 
vitro87,106,108,131. 
Given the listed criteria, an attractive alternative to cancer cells were embryonic stem 
cells (ESCs). This cell type, derived from the inner cell mass (ICM) of a developing 
mammalian embryo, is characterized by a virtually indefinite self-renewal potential. 
Importantly for our studies, ESCs remain genetically stable and euploid in cell culture 
conditions over multiple passages. Previous studies demonstrated that mouse ESCs 
sustain normal cell proliferation in the absence of DNMT1 and de novo 
methyltransferases DNMT3A and 3B94. Unlike the mouse model, DNMT1 is essential for 
the proliferation of human ESCs95. Although both cell lines were derived from the 
blastocyst inner cell mass of the respective species, human ESCs are believed to 
represent a later stage of development called the epiblast, based on their growth 
condition requirements, X chromosome inactivation and gene expression pattern91,132,133. 
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Because of these differences, we chose human embryonic stem cells as a suitable model 
for studying DNMT1. 
Since the growth of hESCs is incompatible with the absence of DNMT195, we employed 
an inducible depletion strategy instead of conventional knockout strategies. In this study, 
we used two complementary approaches to dissect the consequences of DNMT1. Either 
strategy eliminated technical biases that were confounding factors in previous studies. 
In order to ensure consistency in our methodology, we have cultured the both cell lines 
in identical conditions in a complete human pluripotent stem cell medium (mTeSR) on 
membrane matrix (Geltrex). 
 
CHAPTER 1. Characterization of tools to acutely remove DNMT1. 
 
6.2 DNMT1 depletion on the transcript level with tetracycline-
inducible system  
The generation of the cell line has been described in ref. 7, where our group employed 
a Tet-off system134 to control the expression of DNMT1. Briefly, the cell line was created 
using lentiviruses to ectopically integrate a wild-type DNMT1 cDNA under the control of 
Tet-response element (TRE) and a tetracycline transactivatior (tTA). The binding of tTA 
to TRE allows for the expression of DNMT1 from a separately delivered exogenous allele 
in the absence of tetracycline analog doxycycline (dox). The endogenous alleles of 
DNMT1 were subsequently knocked out (Fig. 2A). The resulting cell line expresses a 
functional DNMT1 only from the transgenic allele, which is not transcribed in the 
presence of doxycycline (Fig. 2B). We will further refer to this line as “TetOFF DNMT1”. 
To independently validate the system for this study, we first assayed its performance. To 
this end, we checked the kinetics of the DNMT1 protein depletion using western blot (Fig 
4A, left panel). We extracted the nuclear proteins from the control and DNMT1-depleted 
cells. The protein lysates were separated on an SDS-polyacrylamide gel, transferred 
onto a nitrocellulose membrane and incubated with a monoclonal antibody specific to 
human DNMT1. We observed a nearly complete depletion of DNMT1 already after 48h 
post transcriptional inhibition and the protein is not detectable after 72h (FIG 4A). 
Due to the differences in bioethics regulations between the USA and Germany, the 
originally used HUES64-based line had to be substituted with a human induced 
pluripotent cell (hiPSC) line. These cells are derived by reprogramming of human 
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fibroblasts135 and were found nearly identical to hESCs in terms of morphology, gene 
expression, DNA methylation and histone modification landscape136,137(Fig 4B). 
 
 
Figure 2. TetOFF DNMT1 inducible depletion system. A. In the absence of endogenous 
DNMT1 (crossed out green bar), the source of functional DNMT1 transcript (black lines) 
in the cells is an exogenous allele (DNMT1 cDNA – blue box), under the control of TRE 
promoter (grey bar). It is activated by tTA (red shape), the product of exogenous tTA 
gene (orange bar). B. In the presence of doxycycline (yellow circle), tTA is unable to the 






6.3 DNMT1 depletion on the protein level with PROteolysis TArgeting 
Chimera (PROTAC)  
 
In the final stages of this work, we switched to using a hiPSC cell line (created by Simon 
Lauer), which utilizes an alternative approach to deplete DNMT1 at the protein level (FIG 
3). We employed a proteolysis targeting chimera (PROTAC) based technology138, 
whereby a heterofunctional, small molecule is used to recruit the ubiquitin ligase complex 
to the protein of interest. The resulting ubiquitinated product is subjected to proteasomal 
degradation. Because there was no molecule that targets DNMT1 specifically, we used 
a strategy described by Nabet et al139. Briefly, the gene of interest is endogenously 
tagged with a variant of a chaperone protein (mutFKBP), which is recognized by a highly 
specific PROTAC molecule called dTAG-13. In the absence of dTAG-13, the stability of 
the mutFKBP-tagged protein is not affected. However, upon addition of dTAG-13 to the 
media, both mutFKBP and the Cereblon (CRBN) E3 ligase complex directly bind, thereby 
facilitating ubiquitination of the tagged protein. Due to its high specificity for mutFKBP 
(and not the ubiquitously expressed wild-type FKBP), the system does not have off-target 
effects and has been validated for a variety of targets139,140. 
In our study, this protocol was further modified to knock in the mutFKBP linked to 
mCerulean fluorescent protein into both endogenous DNMT1 alleles. In our study, this 
protocol was further modified to knock in the cDNA encoding the mutFKBP linked to 
mCerulean into the both alleles of the DNMT1 gene. 
By default, the TetOFF DNMT1 was used for the majority of the expreiments presented 





Figure 3. PROTAC-based DNMT1 inducible depletion system. A. XY plot summarizing 
a bioinformatic analysis of the DNMT1 protein predicted structural organization using two 
programs: IUpred2 (red line) and ANCHOR (blue line). Higher score represents less 
intrinsic structure. B. Schematic representation of donor sequence used to 
endogenously target the DNMT1 gene for the creation of the degDNMT1 fusion gene. 
mCerulean (blue), GS linker (yellow), mutFKBP (dark green), endogenous DNMT1 (light 
green). C. The DNMT1 protein (light green) has been endogenously tagged with 
mutFKBP (dark green) and mCerulean (blue). The domains are linked by a flexible GS 
linker (yellow). The addition of dTAG-13 small molecule (red) facilitates the recruitment 
of Cereblon E3 ligase complex (scaffold shown in grey) by directly binding CRBN 
(orange).  The E2 ligase (violet) ligates ubiquitin (purple) to the DNMT1 chimeric protein, 
thus targeting it for proteasomal degradation. 
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Bioinformatic analysis of amino acid sequence composition of DNMT1. In order to 
choose a suitable terminus to tag DNMT1, we performed a bioinformatic analysis of the 
amino acids composition and the domain organization of the DNMT1 protein (FIG 3A), 
to ensure that the tag does not impair its function. The most suitable place for the tag on 
a protein is at the terminus which is intrinsically unstructured with no functionally 
important fold or domain in its vicinity. Our analysis using the Prediction of Intrinsically 
Unstructured Proteins tool141,142 revealed that these criteria are met for the N terminus of 
DNMT1 (FIG 3A). 
Indeed, based on previous studies, which tagged either the endogenous wild-type or 
ectopically expressed DNMT1 with GFP, the N-terminal fusions do not affect DNMT1 
stability or localization143. This is consistent with the structure of DNMT1 protein, which 
is highly organized towards the C-terminal end, due to the presence of the structured 
methyltransferase domain. 
Validation of the PROTAC-based strategy. Our N-terminal tagging approach resulted 
in the transcription of a fusion mutFKBP-mCerulean-DNMT1 protein referred to here as 
“degDNMT1” (FIG 3A,B). Such mutFKBP-mCerulean-DNMT1 chimeric protein enables 
depletion at the protein level after the addition of small molecule ligand dTAG-13. We 
validated the depletion system by monitoring protein level using a western blot assay. In 
contrast to the TetOFF system, the PROTAC-based depletion cell line underwent a rapid 
DNMT1 degradation within 24h post 125nM dTAG-13 addition and the protein was not 
detectable after 48h (Fig 4A, right panel). Consistent with our expectations, the direct 
degradation of DNMT1 at the protein level elicited faster depletion of the protein than 




Figure 4. Molecular characterization of the inducible DNMT1 depletion systems. A. 
Western blot showing the presence of DNMT1 under normal and long exposure. TetOFF 
DNMT1 (left panel) and degDNMT1 (right panel) were treated with doxycycline (2 µg/mL) 
and dTAG-13 (125 nM), respectively, until DNMT1 protein was no longer detectable. B. 
Representative brightfield images of the control (top panels) and small molecule treated 
(bottom panels) TetOFF DNMT1 and degDNMT1 cell lines. DNMT1 was depleted in 
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each of the lines for 5days. Scale bar: 100 µm. C. 5mC ELISA results depicting the DNA 
methylation retained by doxycycline-treated TetOFF DNMT1 (red, top panel) or dTAG-
13 treated degDNMT1 (blue, bottom panel) cell lines. The value is expressed as the 
proportion of 5mC compared to the untreated, control line. Error bars: SD. N=3 D. XY 
plot depicting the survival of small-molecule treated depletion cell lines, calculated as the 
percentage of live cells with respect to the untreated controls. TetOFF DNMT1 is 
represented by red line and degDNMT1 by blue line. Passages are indicated by vertical 
dashed lines.  Error bars: SD. N=3. 
 
6.4 Systematic analysis of downstream effects caused by the loss of 
DNMT1. 
 
After successful validation of the DNMT1 depletion systems, we turned to study the 
downstream consequences triggered by the lack of DNMT1. Because of DNMT1’s 
function and mode of action, we focused on DNA methylation levels, cell cycle and cell 
fitness. 
Global levels of DNA methylation. Given that DNMT1 maintains DNA methylation 
throughout replication, as expected, the depletion of this enzyme in hESCs leads to a 
decrease in global levels of DNA methylation3. We validated these observations in our 
study using an ELISA assay that provides a quantitative measure of 5-methylcytosine 
(5mC) abundance (FIG 4C). Briefly, we purified the genomic DNA and hybridized it to 
the assay plates for a subsequent incubation with a 5mC-specific antibody. After rigorous 
washing of the unbound antibody, we detected the specific signal, which reports on the 
amount of the 5mC in the sample. Depleting DNMT1 on the transcriptional or protein 
level led to a 75% reduction in global DNA methylation as compared to the control cells 
with intact DNMT1. In agreement with the technical differences between the TetOFF and 
degron systems, the loss of global levels of DNA methylation in the two varies, yet shows 
the consistent downtrend. In the TetOFF system the methylation is gradually lost over 
the course of 5 days (equal to 5 cell doublings) post dox addition. This DNMT1 depletion 
leaves the cells with only a quarter of their initial DNA methylation content. This is in line 
with our western blot results showing complete protein depletion after 3 days. In contrast, 
the degDNMT1 cells reach 50% of wild-type global DNA methylation levels already 24h 
after depletion of DNMT1, followed by modest losses of methylation over the course of 
the next few days. Neither of the cell lines lost 100% of DNA methylation, despite the 
absence of DNMT1. The incomplete demethylation regardless of the DNMT1 depletion 
strategy could be explained by the activity of remaining DNA methyltransferases 




Cell growth. Since DNMT1 is essential for the survival of hESC95, we assessed the 
fitness of the DNMT1-deficient cells and primarily focused on the viability of the 
population. To this end, we adapted the hESCs and hiPSCs to single-cell growth. Next, 
we plated the DNMT1-deficient and non-induced control cells in equal numbers and 
counted them during each passage to assay their proliferation potential. The alive cells 
were subsequently plated in equal numbers for the next passage until no live cells were 
present. The cells deficient for DNMT1 grew slower than their respective control lines 
(FIG 4D). The absence of DNMT1 led to a progressive reduction in the number of live 
cells in three to four passages. Regardless of the method used and its efficiency in 
depleting DNMT1, we observed the most striking effect on population growth during the 
second passage of the experiment. Between days 4 and 8 of the experiment, the 
proportion of live cells decreased the most, concurrently to the changes in cell 
morphology and the reduction in global DNA methylation level (FIG 4A and C). 
Therefore, we concluded that the ability to proliferate is inversely correlated with the 
number of passages following DNMT1 depletion. 
 
6.5 Cell cycle progression  
 
The reduction in cell proliferation prompted us to investigate the cell cycle of the DNMT1-
depleted cells. Since DNMT1 acts concurrent to replication, we hypothesized that their 
attenuated growth could be attributed to a cell cycle arrest, specifically the S-phase 
disruption.  
EdU incorporation. To measure the proportion of dividing cells, we employed a thymine 
homolog 5-Ethynyl-2´-deoxyuridine (EdU) incorporation followed by fluorescent 
microscopy. EdU is integrated into the newly synthesized DNA and can be fluorescently 
stained using click chemistry144 allowed us to mark cells actively undergoing 
replication145. The proportion of EdU positive cells did not change immediately after 
DNMT1 was depleted, however, the proportion of cells actively undergoing S-phase was 
reduced after the first passage (Fig. 4A). Furthermore, although DNA replication 
occurred in around 20% of cells even after 3 passages, it was significantly diminished 
with 40% of EdU positive cells, compared to the control population. The loss of DNA 
methylation may therefore affect the ability of cells to undergo DNA replication. We have 
a few explanations for this observation. First, we noted that not all cells behaved 
uniformly (i.e. some remained replicating while others did not), which might be explained 
by the amount of retained DNA methylation that could affect the severity of the phenotype 
between cells. Alternatively, the DNMT1-deficiency could lead to terminal differentiation 
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in a fraction of cells, which in turn decreases the proportion of cells entering the S-phase. 
Also, we cannot exclude that the DNMT1-depleted cells have a defect in the 
incorporation of the EdU during replication. The cell cycle and the EdU result specifically 
will be discussed later in this thesis. 
 
Figure 5. Characterization of the cell cycle progression in the TetOFF DNMT1 cell line. 
A. Bar graphs summarizing the proportion EdU-. DNMT1-depleted cells (red bars) and 
control cells (grey bars) were stained with respective stains and imaged using Zeiss Cell 
Discoverer. Positive cells in the images, as well as total number of cells counterstained 
with DAPI, were automatically counted by Zeiss ZEN software. Error bars: SD. * 
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pval≤0.05; ** pval≤0.005; *** pval≤0.0005; n.s. – not significant. N=3 B. Bar plot 
summarizing the results of FACS analysis on Hoechst-stained cells. N=2 C. Histograms 
of CFSE-positive cells in control (top panel) and DNMT1-depleted (bottom panel) cells. 
Histogram colors represent time-matched cells, defined in the legend. Light blue – freshly 
stained positive control. Grey – unstained negative control. N=2 D Bar graph 
summarizing the number of TUNEL- positive cells. N=3 The imaging, counting and 
plotting strategy employed are described in A.  
 
Cell cycle arrest. Next, we checked if the proportion of cells in respective phases of the 
cell cycle was perturbed by the loss of DNA methylation. To this end, we stained the cells 
with DNA-binding chemical Hoechst 33342, which provides an estimate the total amount 
of DNA in the cells146. 
We used fluorescence-activated cell sorting (FACS) approach to estimate the 
abundance of cells in G1 (2n DNA), G2/M (4n DNA) and S phase (2-4n DNA). In order 
to avoid technical bias in the staining efficiency, we have fixed TetOFF DNMT1 cells at 
several time points (Fig 5B) and stained them together. We observed an enrichment of 
cells in the G2/M phase after 2 days of DNMT1 depletion, but did not detect other 
signatures of cell cycle arrest at any other time points. 
The length of the cell cycle. The decreased proportion of actively replicating cells could 
result from the prolongation of the entire cell cycle that would have been missed when 
applying the previous methods. In order to examine whether the cells in the critical time 
point between day 4 and day 8 of DNMT1 depletion divide slower than their wild type 
counterparts, we employed Carboxyfluorescein succinimidyl ester (CFSE) staining with 
the cell-penetrable dye that covalently attaches to lysine residues, thus fluorescently tags 
all cellular proteins and becomes progressively diluted over cell divisions147. After a pulse 
stain with the dye followed by a wash out, we quantified the fluorescence of protein-
incorporated dye by FACS (Fig 5C). Comparing the DNMT1-deficient line to untreated 
control demonstrated no changes in the rate of dye dilution indicating no change in the 
duration of the cell cycle. Taken together, we did not observe any defect in the length of 
or an arrest in the cell cycle in DNMT1-deficient hESCs despite a defect in proliferation. 
Although the EdU staining showed fewer DNA hypomethylated cells underwent DNA 
replication, we did not observe arrest at any of the cell cycle phases or decreased rate 
of the cell cycle progression in the TetOFF DNMT1-depleted cells compared to control. 
We thus hypothesized that the DNMT1 absence could trigger apoptosis, rather than cell 




Apoptosis. Programmed cell death can result from a failure to respond to stress 
subsequently leading to loss of fitness of cultured cells148. As DNA fragmentation is the 
final step and a hallmark of cell death, we used Terminal deoxynucleotidyl transferase 
dUTP Nick End Labeling (TUNEL), a method to stain the free DNA ends resulting from 
genome fragmentation in the cells undergoing apoptosis149. We observed an increase in 
the number of TUNEL-positive DNMT1-deficient cells (compared to control) in the 
second passage, which was elevated further in the third passage (Fig 5D). However, we 
find that this minor difference in the apoptotic cells cannot explain the strong defect in 
cell proliferation at the corresponding time point (passage 2; FIG 4D). We speculate that 
a different mechanism of cell death, such as necrosis, could be responsible for the loss 
of fitness in the DNMT1-deficient cells. Further work will be required to dissect this mode 
of death.  
 
6.6 Uncoupling DNA hypomethylation from the presence of DNMT1 
 
Although the three main catalytically active DNA methyltransferases DNMT1, DNMT3A 
and DNMT3B are essential for development and survival of mouse pups, the double 
knockout of de novo methyltransferases (DNMT3A-/-; DNMT3B-/-), hence referred to as 
the DKO line, is compatible with human ESC survival95. The reason for that could be that 
DKO cells retain more global DNA methylation than DNMT1-depleted cells. Overall, this 
may suggest a limit to how DNA hypomethylated a viable hESC can become. 
 
 
Figure 6. Global DNA hypomethylation using 5-azacytydine. 5mC ELISA results 
depicting the global cytosine methylation amount in the control 3A/B double knockout 
cells and 5-AzaC treated counterparts. Error bars: SD. * pval≤0.05; ** pval≤0.005; *** 




Small molecule-induced DNA hypomethylation. In order to assess whether the total 
amount of DNA methylation is correlated with cell viability, we induced global DNA 
demethylation in a DNMT1-independent way with a small molecule. Cytosine homolog, 
5-azacytydine (AzaC), is incorporated into the DNA and mimics a substrate for DNA 
methylation. However, unlike the regular cytosine, it entraps the methyltransferases 
covalently linked to the DNA. Because the DNMTs are no longer able to catalyze methyl 
group transfer, this results in a global DNA hypomethylation. In addition, the crosslinking 
of DNMTs to the DNA across the entire genome leads to DNA damage150. In order to 
reduce the global DNA methylation levels while avoiding cytotoxicity caused by AzaC, 
we utilized the DKO line. We reasoned that any methylation lost in the DKO cells by 
trapping the remaining DNMT1 enzyme would be permanently lost, thus the DNA 
methylation can no longer be fully replenished. Therefore, we considered to treat DKO 
cells with AzaC for over two cell divisions (3 days). This would deplete DNA methylation 
so we would then stop treatment to allow recovery from any DNA damage while 
maintaining the new, less methylated state. The cycle of AzaC treatment and recovery 
could be repeated in consecutive passages, until a minimal level of DNA methylation 
compatible with cell survival is reached. In this experiment (performed by Toshiyuki 
Ushijima), the DKO cells were treated with low doses (1 or 10nM) of AzaC for 3 days, 
followed by a day of recovery, passaging (in the absence of AzaC) and resumed 
treatment two days after attachment. We assayed the amount of methylated DNA after 
each treatment using 5mC ELISA (Fig 5). While 1nM AzaC did not change level of DNA 
methylation, 10nM AzaC treatment reduced the DNA methylation to 41%. The treatments 
in the two following passages rendered cell populations retained a surprisingly high 35% 
global DNA methylation level. Higher concentrations of the drug or subsequent 
treatments resulted in cell death. Notably, the retained DNA methylation level is higher 
than in the TetOFF DNMT1-depleted cell line. Although we cannot completely rule out 
the impact of DNA damage on the survival of the AzaC-treated DKO cells, we note that 
the cells were still able to proliferate between the second and third treatment, but the 
drug no longer reduced their DNA methylation levels. It is therefore likely, that complete 
DNA demethylation is incompatible with hESC survival. The level of 35% DNA 








In this chapter, we confirmed that the depletion of DNMT1 in hESCs results in diminished 
levels of DNA methylation and a perturbed cell fitness. Specifically, we observed a 
reduction in cell number during consecutive passaging, accompanied by alterations in 
cell morphology. Even though we did not detect changes in the overall duration of the 
cell cycle or the cell cycle profiles, loss of DNMT1 correlated with a decrease in EdU-
incorporating cells. Moreover, the loss of cell fitness correlated with an increased number 
of apoptotic cells after each consecutive passage. Interestingly, we noticed that the  DNA 
methylation level is reduced and maintained at the low level (about 25% of the control 
line methylation in the TetOFF system and about 35% in degDNMT1 cells), but not 
directly after the loss of DNMT1 protein. Furthermore, when using AzaC to reduce the 
global levels of DNA methylation in hESCs, we also observed a retention of a similar 
level of global DNA methylation, despite repetitive attempts with prolonged treatment. 
We conclude that the loss of methylated DNA, rather than the absence of DNMT1 is the 
cause of the loss-of-fitness phenotype described in this chapter. In fact, our group 
previously showed that DNMT1KO-associated cell death cannot be rescued with a 
catalytically inactive DNMT195. 
The lethality phenotype we observed appears fundamentally different than what was 
reported in cancer lines or mouse embryonic fibroblasts devoid of DNMT198. For 
example, we did not observe an accumulation of G2/M arrested cells, as was shown by 
Chen and colleagues for DNMT1KO HCT116 cells108. Altogether, the DNMT1-deficient 














CHAPTER 2. The impact of global DNA hypomethylation on 
genome stability. 
 
Because ablation of DNMT1 from cells elicits a vast reduction in the methylated 
cytosines, we wondered if this effect has consequences on genomic integrity, as 
previously suggested  
6.8 DNA damage  
Could then the hypomethylation cause a damage in the DNA? In fact, multiple studies 
have put forward this hypothesis studying various systems. For example, the DNMT1KO 
cancer model cell lines106,108, non-transformed cells106 and a tissue-specific DNMT1KO 
in mouse liver151. 
All in all, the conclusions drawn from depleting DNMT1 from cancer cells are not 
coherent and depend on the specific design of a study, therefore considered 
controversial. For example, DNMT1-deficient hepatocytes were reported to present 
markers of DNA damage that in turn induced the hepatocyte senescence; measured by 
the G1 phase arrest and an upregulation of a senescence marker, p21151. Another study 
found that the DNMT1KO in HCT116 cells resulted in the G2/M phase arrest, due to the 
accumulated DNA damage and mitotic defects108. Lastly, Unterberger and colleagues 
reported DNMT1 knockdown with siRNA to cause ataxia telangiectasia and Rad3-related 
(ATR)-dependent activation of DNA damage signaling in human bladder transitional 
carcinoma-derived cells and also in untransformed human fibroblasts. The authors 
proposed that the DNMT1 deficiency triggered an activation of the S-phase checkpoint 
that stopped further progression through the cell cycle106. If these inconsistencies stem 
from technical differences or heterogeneity of cancers remains a burning question in the 
field.  
Because our system for depleting DNMT1 from cells has proven efficient and tight, and 
presents a technological advance over the previously used approaches, we explored if 
DNMT1-deficient iPSCs show hallmarks of genomic instability. Notably, our cells do not 
show defects in all aspects of the cell cycle studied, such as length and arrest, therefore 
we do not anticipate an excessive DNA damage that would perturb these parameters. 
We set out to confirm the observation with another technique and asses the signature of 
DNA damage in a more direct way. To this end, we employed fluorescence microscopy 
to monitor a highly conserved sensor for DNA double-stranded breaks (DSB) called 
Mre11152. As a part of the MRN complex, Mre11 binds the sites of damage and 
orchestrates the response to the insult153. Importantly, Mre11 is present at the sites of 
DNA damage occurring due to an error, such as replication fork collapse154 or exposure 
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to genotoxic agents, but also when DNA damage is caused by sister chromatid exchange 
(SCE)155. It promotes both the repair via homologous recombination156 and non-
homologous end joining157. We, therefore, anticipated that regardless of the mechanism 
leading to double-strand break formation, MRE11 foci accumulation will be a reliable 
readout. Furthermore, it marks the DSBs very specifically, without creating a wide 
domain around the damage site158. 
 
Figure 7. DNMT1 depletion does not cause Mre11 foci formation. Fluorescent 
microscopy images of degDNMT1 cell line stained with antibody against Mre11 (green) 
and counterstained with DAPI (blue). Cells in white dashed-line squares are shown 
enlarged in the last column. Top row: control degDNMT1 cells. Middle row: 
hypomethylated degDNMT1 cells, treated with dTAG13 for 5 days. Bottom row: control 
positive for DNA damage – cells treated with 50µg/ml zeocin. Scale bars: 10µm. 
 
We stained the hypomethylated degDNMT1 hiPSC line with an antibody specifically 
recognizing Mre11 and found that while Mre11 accumulated in nuclear foci after 
treatment with a genotoxic agent zeocin159 (positive control, FIG 7). After 5 days of 
continuous DNMT1 depletion, we did not observe any accumulation of Mre11 in the 
DNMT1-depleted cells as compared to controls (FIG 7). We attempted to corroborate 
these results with an alternative method, that relies on monitoring DNA damage-
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dependent phosphorylation of histone H2A.X, which is a widely used marked of DNA 
damage160. To this end, we employed fluorescence microscopy with all commercially 
available antibodies. However, we found that none of them succeeded in reporting a 
specific signal in our positive control samples (data not shown), unlike the staining with 
the antibody against Mre11. 
Altogether, we concluded that the depletion of DNMT1 and the subsequent DNA 
hypomethylation does not lead to the Mre11 foci accumulation, and therefore likely not 
causing double strand DNA breaks in human pluripotent stem cells. 
 
6.9 Chromosomal instability 
 
The link between DNA methylation and chromosomal integrity is an area of active 
research. One of the reasons is a rare, autosomal recessive disease called the 
Immunodeficiency, Chromosomal instability and Facial anomaly (ICF) syndrome161 
caused primarily by mutations in de novo methyltransferase DNMT3B162. On the 
molecular level, the defect is characterized by the loss of DNA methylation on classical 
satellites of chromosomes 1, 9 and 16 and decondensation of juxtacentromeric 
regions163. This leads to the formation of abnormally condensed chromosomes 
characterized by multiradial shape. If global hypomethylation of DNA elicits similar 
abnormalities has not yet been studied. Similarly, there is no known mechanism that 
would link the loss of DNMT1 to increased genomic instability.  
Karyotyping of DNMT1-deficient cells. To address if the DNA hypomethylation 
impacts centromere stability, we employed a widely-used method, Giemsa (G-band) 
karyotyping of TetOFF DNMT1 cells. We looked for hallmarks of ICF such as centromere 
decondensation, however, we did not observe differences between cells with a normal 
DNA methylation level and the cells affected by the loss of DNMT1 for 5 consecutive 
doublings (Representative karyotypying results for two genotypes; FIG 8). Unexpectedly, 
3 out of 20 karyotyped, deficient for DNMT1 cells exhibited loss of chromosomes 3, 15 
or Y, respectively. Because of that, the cells have undergone loss of heterozygosity 
(LOH) on these chromosomes.   
A similar observation was previously made in the hypomethylated mouse lymphomas87. 
Because DNMT1 is a haplosufficient gene, the Jaenisch lab created a “chip” 
hypomorphic allele of DNMT1, which led to a decreased expression of DNMT1 in the 
derived from it mESCs164. Mice bearing only the chip DNMT1 allele (the so-called chip/- 
mice87) expressed about 10% of the wild-type DNMT1 levels, which resulted in DNA 
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hypomethylation of the tested IAP retrotransposable elements and centromeric repeats. 
These specimens developed aggressive T-cell lymphomas that led to death by reaching 
8 months old in 80% of the pups. While retrotransposable elements were not upregulated 
in the chip/- mice, the lymphomas exhibited gains or partial losses of chromosomes. 
However, no karyotype analysis was performed in other mouse tissues in this study. The 
genomic rearrangements in the T-cells (such as gain of chromosome 15) are well-known 
to result in a growth advantage and frequently occur in lymphomas87 suggesting that this 
particular mutation could show a selective advantage in the course of the disease 
development. Despite the reduction of DNA methylation and accumulation of 
chromosomal abnormalities, both ICF syndrome patients and model chip/- mice undergo 
complete embryonic development. Therefore, it is highly unlikely, that the occasional 
chromosomal loss in DNMT1-depleted hESCs directly leads to the dramatic loss of 




Figure 8. Representative karyotypes of control and DNMT1-deficient cells. 
Representative images of G-band karyotyping in control TetOFF DNMT1 cell line A. and 





6.10 Mitotic defects 
 
Anaphase bridges. We wondered if the LOH observed in a few cells depleted for 
DNMT1 could point to a defect in mitosis. Interestingly, a previous study demonstrated 
that the knockdown of DNMT3B in HCT116 cells yielded accumulation of anaphase 
bridges and misaligned metaphase chromosomes165 that are prime examples of 
abnormal mitosis166. Therefore, we investigated similar phenotypes in the TetOFF 
DNMT1 cells in the control and after the DNMT1-depletion (FIG 9). We utilized 4′,6-
diamidino-2-phenylindole (DAPI) to image mitotic chromosomes during the anaphase of 
mitosis. Regardless of the presence or absence of DNMT1 (5 cell doublings - minimal 
time required to hypomethylate the genome), we observed identical early anaphase 
bridges and resolved late anaphases without lagging chromosomes (FIG 9). 
 
Figure 9.  Anaphase bridge formation occurs in early anaphases during hESC mitosis. 
Representative pictures of anaphases stained with DAPI in control (top row) and 
DNMT1-deficient (bottom row) hESCs. Early (<10µm distance between daughter cells’ 
chromosomes) and late (>10µm distance between daughter cells’ chromosomes) 
anaphases are shown in left and right column, respectively. Red arrow – anaphase 




Figure 10. Ultra-fine BLM bridges are resolved during anaphase. Fluorescent 
microscopy images depicting early (first row; <3µm distance between daughter cells’ 
chromosomes), intermediate (second row; <10µm distance between daughter cells’ 
chromosomes) and late (third row; >10µm distance between daughter cells’ 
chromosomes) anaphases in HUES64 hESCs, stained with antibodies against BLM 
(white) and counterstained with DAPI (blue). Bottom row: positive control for BLM bridge 
formation depicting anaphase in cells treated with topoisomerase inhibitor camptothecin. 




Chromosome decatenation. Next, we further examined alternative anaphase-related 
phenotypes and focused on chromosome decatenation, which is a mechanism to 
untangle sister chromatids for faithful chromosome segregation167. This process is 
performed on anaphase DNA structures called PICH-bridges, also known as Ultra-Fine 
Bridges (UFBs)168, proposed to be the remnants of centromeric chromatin catenates that 
hold sister chromatids together and provide tension between the kinetochores to clear 
the spindle assembly checkpoint (SAC). PICH and BLM DNA-dependent ATPases 
resolve such catenates with topoisomerase, Topo IIα169. Due to these DNA bridges being 
very thin, they do not accumulate enough DAPI signal to be visible under a fluorescent 
microscope unlike the intact chromosomes; however, the thin DNA bridges accumulate 
the Bloom helicase that could be stained with an antibody to indirectly monitor them. 
Consistently with previous studies168, we observed a decline in the number of UFBs over 
the course of anaphase in wild-type cells (FIG 10). Cells in early anaphase, with mitotic 
chromosomes of daughter cells only beginning separate, display multiple BLM-positive 
bridges. The bridges are stretched out in intermediate anaphase (less than 10µm 
distance between chromosomes of daughter cells) and are completely resolved before 
late anaphase (over 10µm distance between chromosomes of daughter cells). The wild-
type cells treated with a topoisomerase inhibitor, camptothecin170 (positive control) 
display an increased formation of the DNA bridges (FIG 10). When we examined cells 
deficient for DNMT1 (for 2, 4, 6 or 8 doublings, respectively), we observed no difference 
as compared to wild-type cells; the vast majority of observed anaphases were completely 
resolved before or during intermediate anaphase, regardless of condition (Fig 11). These 
results indicate that the hypomethylated cells are capable of decatenating UFBs. 
Therefore, we concluded that DNMT1-deficient cells do not display decatenation defects 




Figure 11. DNMT1-depleted cells are able to resolve anaphase UFBs. . Fluorescent 
microscopy images depicting late anaphase with bridge resolution in TetOFF DNMT1 
cells stained with antibodies against BLM (white) and counterstained with DAPI (blue). 
Top row: control cells; subsequent rows: cells treated with dox for 2, 4, 6 or 8 days, 
respectively. Scale bars: 10 µm. 
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Because DNMT1 acts co-replicatively, we hypothesized that its depletion could lead to 
a defect in the S-phase of the cell cycle. However, this type of defect would not manifest 
itself by arresting the cells in S-phase, as we did not observe any accumulation of the S-
phase-arrested cells after removal of DNMT1 (FIG 5B). In such case, we considered an 
accumulation of under-replicated DNA as a possible mechanism. Discrete regions in the 
genome called Chromosomal Fragile Sites (CFS) are difficult to replicate due to, for 
example, their repetitive nature171. Thus, if replication of these regions is incomplete, the 
partially synthesized DNA can be carried on through the cell cycle172. Previous studies 
identified 53BP1 as a protein that creates protective foci around the under-replicated 
DNA in the subsequent G1 phase to prevent further damage and was used as a sensitive 
marker of such loci173. In order to elucidate whether the under-replication phenomenon 
occurs in the hypomethylated hESCs, we quantified the 53BP1 foci. Lukas and 
colleagues found that wild type cells accumulate fewer than 6 foci per nucleus173, 
whereas a challenge with doxorubicin (a drug that intercalates in the DNA causing 
damage) vastly increased the number of foci (FIG 12A). 
In the cells depleted for DNMT1 (for 2, 4, 6 or 8 days, respectively) we observed a minor, 
but not statistically significant increase in the 53BP1 foci (day 4, 6 and 8), as compared 
to matched, untreated controls (FIG 12B). This is an interesting observation given the 
hypomethylated hESCs incorporate less EdU during replication, which may implicate a 
change in kinetics or fidelity of DNA synthesis (FIG 5A). Future experiments will be 
required to address this discrepancy with alternative approaches, such as DNA combing, 
and also examine, for example, if the cells depleted for DNMT1 do not display a 




Figure 12. Loss of DNMT1 does not promote the accumulation of 53BP1 foci. A. 
Representative pictures of fluorescence microscopy imaging of TetOFF DNMT1 cells 
stained with an antibody against 53BP1. Top row: positive control of cells treated with 
10nM doxorubicin. Middle row: TetOFF DNMT1 cells. Bottom row: DNMT1-deficient 
65 
 
TetOFF DNMT1 line treated with doxycycline for four days. Right column: enlarged view 
of cells shown in the red dotted line squares. Scale bar: 50 µm. 100 cells were screened 
per condition. B. Quantification of 53BP1 staining in TetOFF DNMT1 cells. Bars 
represent the percentage of cells with 6 or more 53BP1 foci.  
 
Mechanisms masking mitotic defects. Although our data demonstrates only 
occasional loss of chromosomes in a very few cells, we considered the possibility that 
the major defects could have already caused a cell death and, because of that, were 
missed in our analysis. Alternatively, the potential deleterious effect of global 
hypomethylation of DNA could be masked by a cellular buffering system that 
compensates for the insults to genomic stability. In fact, a very thorough study of cell-
cycle regulators demonstrated that a single knockout of genes involved in replication, 
such as CDT1 or ORC1, did not impact the mitosis in these cells, however a double 
knockout with the TP53 gene had a synergistic effect, with nearly all mitoses being 
erroneous174. Therefore, the product of the TP53 gene, the p53 protein may have a 
modulatory effect on several knockouts and buffer their loss. p53 is a tumor suppressor 
transcription factor, often referred to as “the guardian of the genome” due to its central 
role in responding to cellular stress. Some of its many roles include integrating signals 
from DNA damage or triggered cell cycle checkpoints and regulates genes involved in 
DNA repair, senescence and apoptosis to elicit a suitable response175. Interestingly, 
knockout of the trp53 gene in mouse embryonic fibroblasts was shown to partially rescue 
the DNMT1KO-associated growth defect98. We sought to test these findings in the 
DNMT1-deficient hESCs. To this end, we knocked out the TP53 gene in the TetOFF 
DNMT1 cell line using lentivirally-delivered Cas9 together with a guide RNA that targets 
the TP53 genomic locus (FIG 13). To select the most efficient gRNA with the lowest 
number of off-targets, directing the Cas9 enzyme to an exon shared by all TP53 
transcript isoforms, we used an integrated gRNA prediction platform provided by 
Benchling. We confirmed homozygous knockout in clonally derived cell line using a PCR-
based genotyping strategy followed by Sanger sequencing. The selected clone 
contained an out-of-frame deletion in one allele and an in-frame insertion of 51 
nucleotides containing three in-frame stop codons that would result in the loss of protein 
product. The resulting TetOFF DNMT1; TP53-/- line was characterized by significantly 
increased growth rate compared to the parent line (FIG 14A). We then compared the cell 
number of DNMT1- and DNMT1;TP53-depleted cells after one passage. In line with the 
findings of Jackson-Grusby and colleagues98, the hypomethylated cells devoid of TP53 
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show an increased survival as compared to the hypomethylated cells (FIG 14B). Next, 
we monitored the kinetics of the loss of fitness for both cell lines.  
 
Figure 13. The creation of TetOFF DNMT1; TP53KO cell line. A. Parental TetOFF 
DNMT1 was transduced with a lentiviral vector containing wild-type Cas9 cDNA, a guide 
against human TP53 and a drug resistance cassette. The untransduced cells were 
selected against with blasticidin. Clonal colonies of surviving cells were picked and 
genotyped. B. Chromatogram results of genotyping of the TP53-exon 4 in WT hESCs 
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(top panel) and the TetOFF DNMT1; TP53KO line. Consensus sequence is shown on 
top of each panel as a grey bar. Green arrows: guide sequence. Chromatograms: 
sequences of the alleles of TP53. 
 
 
Interestingly, the TP53KO suppressed the cell death of DNMT1KO cells at passage 2, 
hence delaying severe loss of cells by one passage. However, the TP53KO was not able 
to rescue the initial drop in cell viability      within the first passage (4 doublings) of DNMT1 
depletion (FIG 14C). These results suggest that the DNMT1-deficiency-associated 
growth phenotype in hESCs is at least partially dependent on TP53.  
To check if the presence of p53 in the hypomethylated cells masks otherwise-occurring 
genomic instability, we have employed confocal microscopy to score metaphase defects. 
Previous study174 employed DAPI and tubulin staining to image mitotic chromosomes 
and the mitotic spindle and distinguished three abnormal metaphase phenotypes. We 
used the same method to score the mitotic abnormalities occurring in the DNMT1-
deficient hESCs. Representative examples of each defect are shown in (FIG 15A). Off-
axis chromosomes (FIG 15 A, white arrow) do not assemble with the other chromosomes 
in the mitotic plate. Spindle multipolarity results from more than two centrosomes 
creating additional mitotic poles. Major plate defects manifest themselves by the lack of 




Figure 14. TP53 knockout impacts the growth of control and DNMT1-deficient hESCs. 
A. and B. Bar graphs depicting the number of cells grown one passage (4days) after 
single-cell plating of TetOFF DNMT1 control cells (black bar) in comparison to TetOFF 
DNMT1; TP53KO lineage (A), or TetOFF DNMT1-depleted cells compared to cells 
deficient in both DNMT1 and TP53 (B). C. Scatter plot depicting the DNMT1-deficient 
TetOFF DNMT1 or TetOFF DNMT1; TP53KO cells that survived each passage. The 
values are expressed as a fraction of cell number achieved by control dox untreated cells 
of respective lineage. Vertical dashed lines represent re-plating for a new passage. * 
pval < 0.05; ** pval < 0.005; *** pval < 0.0005. Error bars: SD. 
 
 
We scored the mitoses in DNMT1-depleted cells and observed whether the absence of 
p53 can modulate the phenotype (FIG 15B). While DNMT1-depleted cells displayed a 
minor increase in the proportion of off-axis chromosomes, we observed similar ratios of 
unaffected mitoses in the control and DNMT1-depleted cells (87% versus 86%, 
respectively). In stark contrast, TP53 deletion resulted in an increase in all mitotic defects 
compared to control cells, with only 70% normal mitoses. Lastly, depletion of both 
DNMT1 and p53 further exacerbated the number of mitotic defects seen in the TP53KO 
cell line. For example, a major increase in off-axis chromosome defect cell arose from 
69 
 
19% in TP53KO to 31% in the double knockout. Our data suggests a synergistic effect 
between DNMT1 and TP53 with respect to mitotic defects, thus the double knockout 
presents an additive phenotype that is stronger than each of them separately Therefore, 
this genetic experiment implies that DNMT1 and TP53 act in separate pathways in 
regards to mitosis defects. Interestingly, despite the accumulated genomic insults in the 
double knockout line, these cells show a growth advantage over the DNA 
hypomethylated cells. If this is due to the impaired checkpoints in the TP53 knockout or 
whether genomic instability does not affect the fitness of DNMT1-depleted cells will be 
an exciting area of further research. Future studies will be required to address the 
mechanism behind the increased survival of the DNMT1KO-TP53KO cells. In addition, 
to examine specificity of TP53, it will be interesting to examine if a deletion of any other 




Figure 15. TP53KO does not act synergistically with DNMT1-depletion in causing 
metaphase errors. A. Representative images of cells undergoing normal (first column) 
or erroneous metaphases (second to fourth columns). Cells were stained with an 
antibody against tubulin (green), counterstained with DAPI (blue) and imaged using 
confocal microscopy. White arrows – off-axis chromosomes. Scale bars: 5 µm. B. Pie 
charts depicting the quantification of the proportion of metaphases scored according to 
the key shown in A. Each genotype is presented in a separate circle; colors represent 
mitotic phenotypes. 20<N<40 metaphases per condition. 
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6.11 Expression of transposable elements 
 
Repetitive sequences such as transposable elements (TEs) typically bear highly 
methylated DNA at their genomic loci. This was proposed to be a mechanism by which 
the cells prevent the expression and transposition of these elements. Multiple studies 
reported the demethylation of transposable elements in DNMT1 knockout cell lines and 
embryos87,98,102,176. The global loss of DNA methylation resulted in transcriptional 
activation of TEs98,102. Jackson-Grusby and colleagues hypothesized that such 
expression of transposable elements, which belonged to the intracisternal A particle 
(IAP) family, could cause of DNMT1KO MEF cell death via increased transposition and 
resulting DNA damage98.  
Although transposons make up nearly half of the human genome80, very few are able to 
transpose. This is ascribed to the degeneration of TE sequences, caused by 
accumulation of mutations or truncations due to an incomplete transposition. DNA 
transposons are believed to be virtually extinct in the context of the human genome177. 
RNA transposons, however, contain transposition-competent elements. Human LINE 
elements, which occupy the most of the human genome out of all the TE classes, only 
an estimated 60-100 are capable of transposition178. Another transposition-competent 
class, analogous to the mouse IAP, are human endogenous retroviruses (HERVs). 
Particularly the HERVk subtype has been shown to transpose into new locations in the 
human genome179. 
Although the expression of different classes of transposons has resulted in mutations180, 
however, it also occurs during normal embryonic development and transition from primed 
to naïve state in hESC117. We decided to investigate if the transcription of transposable 
elements occurs in the TetOFF DNMT1-deficient hESCs. To this end we used 
quantitative reverse transcription polymerase chain reaction (qRT-PCR) to directly 
compare the level of TE transcripts between control and the globally hypomethylated 
cells (FIG 16). Specifically, we chose primers amplifying the HERVk gag sequence117 
and to the consensus sequence among all L1 transposons, including the most recent 
L1_Hs class181. 
No significant upregulation of the L1 transcript level accompanied the loss of DNMT1 
(FIG 16A). In contrast, HERVk elements were increased 4 fold (FIG 16B). This is 
comparable to HERVk upregulation during in vitro reprogramming of primed hESCs to 
naïve state, a process that does not lead to cell death117 We therefore conclude that 
minor upregulation of the TEs is not likely the underlying cause of the DNMT1 depletion-





Figure 16. The effect of DNMT1 depletion on repetitive element expression. Bar graphs 
depicting the expression level of A. L1, B. HERVk, C. Alpha satellite repetitive elements. 
* pval < 0.05; ** pval < 0.005; *** pval < 0.0005. n.s – not significant. Error bars: SD. N=3. 
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Centromeric repeats. Centromeric DNA hypomethylation following the mutations in 
DNMT3B is one of the hallmarks of ICF syndrome161,162. Although we did not find any 
evidence for chromosome decondensation in our TetOFF DNMT1-depletion cell line, we 
explored whether global DNA hypomethylation could impact the transcription of 
centromeric repeats.  
The change in transcription level of satellite repeats has been observed in various cancer 
types. For example, pancreatic cancer cells upregulated alpha satellites over 40-fold, 
compared to healthy tissue182. Nevertheless, its role in disease or genomic instability is 
not well understood. 
We performed qRT-PCR in the TetOFF DNMT1-deficient hESCs using primers mapping 
to the consensus sequence of human alpha satellite 171bp repeats, which are present 
in the higher order repeats in centromeres of all the human chromosomes183. 
Interestingly, we only observed a modest, less than 2-fold upregulation of ALRs following 
DNMT1 depletion (FIG 16C). This result indicates that the hypomethylated DNA in 




We have employed fluorescence and confocal microscopy approaches to investigate if 
a hypomethylated genomic DNA poses an insult to genomic stability. We showed that 
the DNA damage markers were not enriched in the acutely hypomethylated human 
ESCs compared to control, even though the DNA damage was previously reported in 
other types of DNMT1-deficient cells. If this is due to the unique biology of embryonic 
stem cells as compared to cancer cells or simply an indirect effect remains to be 
studied. Even though the hypomethylated ESCs lack the known DNA damage markers, 
we detected a loss of single chromosomes in a few cells. In the future, it will be interesting 
to track chromosomal aberrations in hESCs, examine how these affect the cell survival 
and when they occur with respect to the loss of DNA methylation.  
We also considered if the hypomethylated hESCs would display markers of genomic 
instability more prominently in the absence of p53. While loss of TP53 increased the 
survival of DNMT1-deficient cells, it also increased the occurrence of mitotic 
abnormalities. This observation uncouples the impaired proliferation from the presence 
of mitotic defects, therefore suggesting that both processes are rather independent. 
Whether the absence of p53 uncovered genomic insults posed by the hypomethylated 
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genome or if it creates a sensitive, genetic background more prone to defects, remains 
to be studied in the future and likely will bring new mechanistic insights.  
Our results demonstrated that global DNA hypomethylation did not significantly impact 
the expression of transposition-competent elements or the major satellite repeat 
sequences. Although DNA methylation levels are significantly downregulated in the 
absence of DNMT1, DNMT-independent mechanisms in the cells work to repress 
transposable elements. Notably, the KRAB-associated protein (KAP1), directed by Zinc 
Finger Proteins, is able to recruit the H3K9 methyltransferase SET domain bifurcated 1 
(SETDB1) to the transposon loci and thus facilitate their silencing even after the depletion 
of DNMT1176.  
Other non-coding sequences in the genome, such as microsatellites, are too repetitive 
to be examined using qRT-PCR or conventional RNA sequencing techniques. Further 
studies using nanopore sequencing methods, which are adapted for long reads, could 
be applied to elucidate the changes in expression of these sequences in DNMT1-
deficient cells. Although demethylated transposable elements were found to be 
recombination hotspots in testis49, our DNA damage staining and karyotyping results 
argue against the recombination or chromosomal translocation events occurring in the 
DNMT1-deficient hPSCs. 
Taken together, we conclude that hypomethylation of DNA does not likely trigger a 
genomic instability directly, albeit we cannot exclude the presence of DNA abnormalities 
as secondary, indirect consequence. These observations prompted us to consider and 
investigate other mechanisms that are responsible for the loss of fitness observed upon 









CHAPTER 3. Simultaneous profiling of cytosine methylation and 
transcripts levels in individual cells. 
 
Our 5mC ELISA-based measurements in the DNMT1-depleted hESCs highlighted that 
about 30% of DNA methylation was retained in the cell population. This result could be 
achieved in two ways: (1) either the majority of cells retain a similar low levels of the 
global DNA methylation or (2) the population consists of a heterogeneous mixture of cells 
containing both high and low levels of DNA methylation. In order to elucidate which 
possibility is correct, we employed a technique that would allow us to quantify the 
methylation level and genome-wide distribution of this epigenetic mark in individual cells. 
Bisulfite conversion. Sequencing-based methods assaying DNA methylation rely on 
bisulfite conversion9 reaction, in which unmethylated cytosines are deaminated and 
thereby converted to uracil. The methylation status of each cytosine is monitored by the 
subsequent DNA sequencing, where deaminated cytosines pair with adenines and are 
thus interpreted as thymines, while methylated cytosines are not. By comparing the DNA 
sequence of a reference human genome with the sequencing results after bisulfite 
conversion, the converted cytosines (previously methylated) are distinguished from 
endogenous thymines. Because of the introduced nucleotide alteration, the sequencing 
reads carry the information about the DNA methylation status and can be subjected to 
quantitative and qualitative analyses. 
Genome-wide profiling of DNA methylation. Due to the large information content and 
complexity of genomes, mapping DNA methylation sites across the entire genome 
requires next generation sequencing (NGS) approaches.  Several methods 
implementing bisulfite conversion have been developed to date. For example, the Whole-
Genome Bisulfite Sequencing (WGBS)184, can be used for quantifying the cytosine 
methylation level across all the CpGs in the genome. Because CpGs are 
underrepresented and unevenly distributed across the human genome, sequencing of 
the entire genome is cost inefficient. Therefore, several strategies have been developed 
to enrich for the reads of interest. One of such approaches is an immunoprecipitation of 
methylated DNA (MeDIP), which uses an antibody against 5-methylcytosine to enrich for 
DNA fragments containing methylated cytosines185. Another strategy, called Reduced 
Representation Bisulfite Sequencing (RRBS), focuses sequencing on the relevant, CpG-
containing loci, enriching for the gene-proximal regions and lowering the coverage of 
numerous repetitive sequences or gene deserts 186. RRBS utilizes the DNA restriction 
enzymes that contain the CG dinucleotide in their recognition sites to fragment the DNA, 
producing fragments containing CpG-enriched sequences.   
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Single-cell sequencing. We recognized that the RRBS technology presents an 
attractive and powerful approach to assess the cytosine methylation status in our studies 
on the DNMT1-dependent DNA methylation. Therefore, we leveraged the power of DNA 
methylation analysis and combined it with the sequencing of single cells. Single cell 
sequencing methods are the state-of-the-art approach to address heterogeneity in a cell 
population. For example, single cell sequencing of transcriptomes facilitated the 
identification of cell subpopulations in complex tissues, such as the brain187 and 
characterization of dynamically changing processes, such as gastrulation188. Protocols 
assaying transcription, DNA methylation, chromatin accessibility, histone modifications 
or combinations of several readouts have been developed and implemented in a number 
of recent studies189–191.  
Because the amount of DNA material for all single cell analyses is the limiting factor, we 
considered the variant of RRBS, the single-cell reduced representation bisulfite 
sequencing (sc-RRBS)192 approach as the most suitable for our studies.  The protocol 
for the sc-RRBS includes all the steps of a regular RRBS in a single tube to minimize 
loss of DNA material from the single cell. This technique succeeded at quantifying the 
demethylation of maternal and paternal pronuclei in mouse zygotes, as well as, providing 
qualitative data on the regions that were losing DNA methylation with a different kinetics 
than others192.  
DNA methylation profiling combined with transcriptome profiling in individual 
cells. Because one of the roles of methylated cytosines is to restrict transcription193, 
ideally one would combine information of the cytosine methylation status together with 
transcript profiles in every cell. Therefore, we decided to combine the sc-RRBS with 
another technique: single cell RNA sequencing (scRNAseq)120. RNA sequencing is a 
method for assaying the mRNA transcripts level of all the genes; and its single cells 
version has been broadly used recently.  
The development of a new technology (FIG X) that combines single-cell methylome and 
transcriptome analysis was performed by Hongcang Gu, Arman Mohammad and 
Andreas Gnirke of the Broad Institute. To obtain single-cell libraries, the polyadenylated 
RNA was first isolated by hybridysation of biotinylated oligo(dT) followed by 
immunopurification of poly(A)-containing mRNAs with streptavidin beads. After the 
subsequent reverse-transcription reaction, the cDNA was converted into SMART-Seq2 
sequencing library and processed as described before120. Concomitantly, the genomic 
DNA of each sample was purified, digested with enzymes, ligated to adapters and 
bisulfite-converted. Our collaborators Caleb Laureau, Ayush Raman and Martin Aryee 
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have processed the raw sequencing data and aligned the reads to the human genome 
using a custom firecloud-based pipeline for scRRBS121. The DNA methylation and 
transcription data were analyzed by Jocelyn Charlton and Sudhir Thakurela, 
respectively. Altogether, the resulting technology of dual sequencing - scRNAseq+RRBS 
(described in more details in the Methods section) empowered us to simultaneously 
study the distribution of DNA methylation and the transcriptional output originating from 
each individual cell.  
 
6.13 The combined scRNAseq and RRBS dual protocol dataset  
 
We followed the decay of DNA methylation and its impact on the steady state RNA 
abundance after transcriptional shutoff of DNMT1 in the TetOFF DNMT1 hESCs. Our 
study included 9 timepoints (day 0 to day 8 with or without the transcriptional shutoff of 
the DNMT1 transgene) where cells were fixed daily and FACS-sorted simultaneously. 
The libraries were prepared as described and sequenced on the Illumina HiSeq 4000 
machine. With 78% read mapping to the human genome a median of 1,031,026 CpGs 
were covered at least once, which is very similar to the efficiency obtained by Guo and 
colleagues in their sc-RRBS protocol194. By comparison, an alternative sc-WGBS195 
protocol yielded more CpGs mapped (3.7x106 on average), however, (1) it covers fewer 
CpGs than the RRBS methods and (2) there are fewer matched regions covered 
between cells, which would make that method less optimal for our purposes. 
The scRNAseq protocol yielded a median of 963,842 transcripts uniquely mapping to the 
genome. This covers a median of 5,626 genes expressed per cell with an expression 
level of at least 0.1 transcripts per million (TPM).  Overall, these statistics from the both 
sc-RRBS and sc-RNAseq indicate that the experiment and the general approach were 
technically successful and thus will be suitable for further analyses. 
In order to avoid biases and false data, we filtered out cells where the protocol yielded 
suboptimal results, for example, we excluded cells with low number of mapped reads in 
either protocol. In the analysis of scRNAseq, we also excluded the cells with read number 
higher than 1 standard deviation from the average, as these were highly likely to 
represent cell doublets. 96% and 76% of the cells passed the scRBBS and RNAseq, 
respectively. Taken together, 72% of the cells passed both the RRBS and RNAseq 
criteria and were used in our analysis.  
While mapping the cells to the genome, we noticed that cells collected after day 4 show 
expression profiles enriched in ribosomal RNAs (rRNAs). Because the transcript capture 
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method used in our protocol is based on purifying the polyadenylated RNAs and rRNAs 
are not polyadenylated, we suspected that this scRNAseq library was contaminated with 
the genomic DNA. Thus, the samples representing this time point were excluded from 
the transcriptome analyses.  
 
 




6.14 Quantitative and qualitative study of DNA methylation in the 
individual DNMT1-depleted cells  
 
We used the resulting data sets to analyze the amount and distribution of the methylated 
cytosines in the individual cells, as well as in the pools of cells from the matching time 
point with the goal of finding a common characteristic for the regions retaining DNA 
methylation in the DNMT1-deficient cells. To this end, we investigate the methylation on 
the scale of chromosomes, as well as at specific sets of loci, stratified by their function. 
First, we plotted the mean DNA methylation of cells at each time point, as well as the 
methylation average of individual cells (FIG 18). Consistently with our 5mC ELISA results 
(FIG 4C), the global levels of methylated cytosines decrease gradually over time and 
plateau in samples collected five days after the transcriptional shutdown of DNMT1. 
Interestingly, the DNA methylation profile shows highly variable patterns between the 
cells before this time point (for example, at day 3) and thus, after averaging, gives an 
intermediate value. This variability could stem from (1) a technical reason, the 
heterogeneous response to blocking transcription in the TET-OFF system; (2) a 
biological reason, intrinsically heterogeneous response to the reduction of the DNMT1 
protein levels; or (3) the number of cell division the cells went through since the reduction 




Figure 18. DNMT1 depletion results in loss of DNA methylation. Violin plot representing 
the mean methylation (indicated on top) across hESCs depleted for DNMT1 for the 
indicated amount of time. Each dot represents the mean DNA methylation of a single 
cell. 
 
Interestingly, even at the final time point (after 8 days of DNMT1 depletion), we did not 
find cells that would retain less than 10% global methylation, suggesting that further 
reduction in global DNA methylation could be incompatible with survival. On the contrary, 
only a few cells retained the methylation levels above 60% beyond day 5, which could 
be a result of their early, spontaneous terminal differentiation into a non-mitotically 
engaged cell type that would prevent dilution of the methylated cytosines in the genome 
even in the absence of the maintenance DNA methyltransferase, DNMT1.  
 
6.15 Investigating the DNA methylation on chromosomal level 
 
We wondered if any retention of methylated cytosines could occur by the virtue of 
inheriting highly methylated chromosomes from the parental cell. Therefore, we sought 
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to characterize the global DNA methylation decay on the chromosomal level in more 
details. 
Even though cytosine in the CpG dinucleotide is the substrate for DNA methylation, there 
are specific sequence contexts that are preferably unmethylated. These are the CpG-
dense regions of high guanine-cytosine richness called the CpG islands (CGIs)36, 
genomic features overlapping with 70% of gene promoters in the human genome37. 
In contrast, in the other parts of the genome, CpG dinucleotides are typically 
underrepresented (averages at less than 1% while expected is 4.4%)38. The sequence 
of the human chromosome 19 is enriched for the CpGs, as it contains high gene density. 
In fact, its total cytosine methylation content is reduced 3-6% as compared to the average 
in the human genome. The same trend was maintained in the DNMT1-depleted cells 




Figure 19. Mean chromosome CpG density does not predict DNA methylation retention 
in DNMT1-depleted hESCs. A. Plot depicting the CpG density of each of the human 
autosomes. B. Plot depicting the deviation of DNA methylation from the average of all 





We plotted the mean methylation of each chromosome in each individual cells (FIG 20). 
The control cells (day 0) display a high level of DNA methylation across all chromosomes 
(60-80% of CpGs). We suspect that this variation is likely due to some cells actively 
undergoing replication. In the control cells, the DNA methylation of any given 
chromosome closely correlates with the mean DNA methylation level of the cell. 
As the cells lose DNMT1, the pattern of mean DNA methylation on chromosomes 
changes profoundly. After three days of DNMT1 depletion, the cells retain a consistent 
methylation average on their chromosomes, however, we observed variability between 
cells (FIG 20). In contrast, the cells collected at day 4 consisted of both highly and lowly 
methylated chromosomes, despite their similar methylation means. We hypothesize that 
these variable patterns at day 3 could likely result from a kinetics of DNMT1 protein 
depletion, for example the cells could retain DNA methylation across the genome thanks 
to the residual DNMT1 (that would be below the western-blot detection limit; see FIG 
5A). At day 4, however, the DNMT1 protein is no longer present, thus the retained 
methylation level will depend solely on how much DNA methylation was inherited from 
the parental cell. At the latest time point, day 8 after the transcriptional shutoff of DNMT1, 
the analyzed cells show a homogenous and consistently low DNA methylation pattern 
on chromosomes. We did not find evidence of specific retention of DNA methylation on 
any particular chromosome.  The DNA methylation level we found in the cells at day 8 
likely marks the minimal level of DNA methylation compatible with survival.  
Overall, our results indicate that the survival of the DNMT1-deficient cells is not linked to 
the DNA methylation level at any particular chromosome, but rather the retention of this 
epigenetic mark across the entire genome. We hypothesize that the retained DNA 
methylation reflects the level of the mark required for survival. It remains to be studied if, 
in the absence of DNMT1, the de novo methylation obtained through overexpressing 
DNMT3A/B could substitute it. 
Next, we asked if the position of CpGs along the chromosome determines their 
maintenance in the absence of DNMT1. FIG 21 shows a representative plot of CpG 
methylation at chromosome 5 in 30 randomly chosen cells at day 0, 5 and 8 (due to the 
limiting number of reads, these CpGs were not matched). We found the DNA methylation 
seems to be scattered across the chromosome length and does not show any 





Figure 20. Mean chromosome methylation of globally DNA hypomethylated DNMT1-
deficient hESCs. Heatmap representing the mean DNA methylation of each 




Figure 21. Distrubution of DNA methylation across the chromosome in DNMT1-depleted 
cells. Heatmap of DNA methylation of each CpG mapped across the short (p) and long 
(q) arms of chromosome 1 in 30 randomly selected cells and day 0, 3 and 8. Red bar 




6.16 Qualitative analysis of DNA methylation 
 
Because downstream in-depth analyses required a more substantial read coverage, we 
pooled the scRRBS reads from the cells belonging to a single time point. For the 
subsequent analysis, we stratified the human genome based on the function of each 
region. Our features of interest were gene promoters, introns, exons, enhancers, CpG 
islands and transposable elements. Intrinsically, these different regions vary in the DNA 
methylation level. The CGIs had the lowest average methylation level, averaging at less 
than 15% methylation. As these coincide with most of gene promoters in human genome, 
the promoter regions showed lower DNA methylation than the genome average (FIG 
22A). In contrast, gene bodies are methylated, evident from the mean methylation levels 
of both introns and exons. We identified intermediate levels of DNA methylation at 
annotated enhancers. The DNA methylation level of transposable elements, such as 
LINEs, was about 10% higher than the genome average (FIG 22B). This is consistent 
with the conserved role of DNA methylation in transcriptional silencing of these 
regions196. Again, once we analyzed the genome DNA methylation profile of DNMT1-
depleted cells, the genomic features showed neither preferential depletion nor 
preferential retention of the mark. Therefore, we considered to stratify the genome based 
on histone modifications and monitored the methylation level at regions enriched in 
specific histone marks based on the ENCODE ChIP-seq data197. Of our interest were 
marks found at enhancers (H3K27ac, H3K4me3), promoters (H3K4me3) and active 
genes (H3K36me3) as well as the repressive mark H3K9me3198 (FIG 22C). Similarly to 
genomic features, none of the histone marks was associated with preferential retention 
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of DNA methylation. For example, H3K9 trimethylation, a histone mark associated with 
heterochromatin was enriched with high DNA methylation, as previously observed199. 
Similar to the pattern in the entire genome, the loss of DNMT1 elicits a progressive 
reduction in DNA methylation in the H3K9me3-associated regions.  
 
Figure 22. DNA methylation is lost proportionally across genomic features in DNMT1 
deficient cells. A., B., and C. Mean DNA methylation level from pooled scRRBS data for 
each time point for listed genomic features, repetitive elements and DNA underlying 
chromatin marks, respectively. D. Representative snapshot of DNA methylation plotted 
across 200kb of the human genome (location listed above), including POU5F1 locus. 
The data was captured in WGBS200 (in gray) or scRRBS (cells from each time point were 
pooled together). Each dot represents a single cytosine. Red box encircles an enhancer 
element, while the green box encircled the promoter.  
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We used the pooled the scRRBS data to visualize the extend of the global DNA 
methylation decay (FIG 22D). A representative snapshot of POU5F1 locus shows the 
high global levels of DNA methylation in wild-type hESCs (gray; published WGBS 
data200) and untreated TetOFF DNMT1 line, punctuated by loci of low DNA methylation 
(promoter). Upon the depletion of DNMT1, previously highly methylated regions become 
intermediately methylated. Sharp dip in enhancer methylation (red box) became wider 
due to the methylation around being lost. The POU5F1 promoter (green box) maintained 
its unmethylated state (FIG 22D).  
Altogether, consistent with previously published results95, we observed that DNA 
methylation was lost proportionally at all the listed features, following the trend line of the 
bulk genome average. While the features with low DNA methylation lost less of the mark 
as compared to transposons, all of them retained the methylated cytosines at about 50% 
their respective initial levels. Indeed, only 22% of the autosomal CpGs are dynamically 
regulated throughout normal development200, suggesting that the remaining CpG 
methylation could likely be maintained by DNMT1. This agrees with the DNMT1 role as 
a global maintenance methyltransferase201. 
Gene promoters. Subsequently, we studied the DNA methylation decay in the 
promoters of coding genes (FIG 23A). We hypothesized that since the very few 
promoters are highly methylated in hESCs202, they could preferentially retain DNA 
methylation, but not be well-represented when plotting the average methylation of all 
promoters. Instead, we plotted the frequency of promoters bearing certain DNA 
methylation levels at each time point of the experiment. As previously reported, the 
majority of promoters were unmethylated, with very few promoters methylated above 
80% in control cells (red line). Contrary to our hypothesis, the highly methylated 
promoters did not retain their methylation when DNMT1 was absent. Instead, the 
population of highly methylated promoters (>80%) was gradually reduced after day 5 
(<20%; FIG 23A).  
Because the majority of promoters for coding gene consist of CpG Islands, they display 
low levels of DNA methylation. In fact, the difference is so striking that they create dips 
of a local hypomethylation in the otherwise highly methylated genome200. The edges of 
these CpG Islands were named CGI shores and these are thought to be dynamically 
methylated by competition between de novo DNA methyltransferases (DNMT3A/B) and 
TET demethylases 72. In order to examine if the distribution of DNA methylation within 
the promoter region was altered, we performed a metagene analysis centered around 
the transcriptional start sites (TSS) of all genes surrounded by 5kb upstream and 5kb 
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downstream sequences (FIG 23B). We found that the DNA methylation in TetOFF 
DNMT1 cells was reduced evenly throughout the experiment. We observed no 
preferential retention of the epigenetic mark up- or downstream of the TSS. A similar 
metagene analysis of all the exons and their surrounding regions displayed the identical 
trend of a gradual loss of DNA methylation with no qualitative change in its pattern (FIG 
23C).  
 
Figure 23. The distribution of DNA methylation across promoters and exons in DNMT1-
deficient hESCs. A. Density plot depicting DNA methylation across the promoters  
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(± 1kb from the TSS, with at least 5 CpGs covered; n = 22,555) in pooled cells from each 
time point. B. and C. Metagene analysis of DNA methylation of all promoters and all 
exons, respectively, including ±5kb region around.  
 
Overall, our in-depth analysis demonstrates the DNMT1-depleted cells did not 
preferentially maintain DNA methylation at any genomic features. It is possible, however, 
that there are certain genomic regions that are (1) not annotated or (2) covered by 
multiple annotations. To gain an unbiased view on the genome, we tested if DNA 
methylation was retained at any loci using a differential analysis. To this end we divided 
the human genome into 500bp tiles and kept only the tiles with five or more CpGs present 
(FIG 24A). Next, we asked if any of the tiles contained over 50% DNA methylation at the 
given time point. As expected, the number of such tiles decreased over time, but there 
were still some present even at late time points, between days 6 and 8 of DNMT1-
depletion (FIG 24A). We asked if any of these methylated tiles are present in multiple 
final time points (FIG 24B). We have found 4,237 regions maintained (0.7% of all tiles) 
at days 6, 7 and 8, and 19,956 (3.5% of all tiles) that were maintained in at least 2 out of 
3 time points. We asked what genomic features the overlapping tiles belonged to (FIG 
24C). The majority of tiles was located in introns and they were mostly mapped to repeat 
elements (75%). The main repeat element was assigned to short interspersed nuclear 
elements (SINEs) (over 50% of tiles). Closer inspection revealed that most of these 
SINEs were Alu elements, the most abundant class of SINEs in the human genome(FIG 
24D)80. Curiously, both evolutionary young Alu elements203 (such as AluY) and more 
conserved (AluSx) were found with high DNA methylation levels despite the loss of 
DNMT1 (FIG 24E). Of note, our analysis used reads uniquely mapped to the human 
genome to assign their identity and genomic coordinates with high confidence. As most 
of the repeat elements are present in multiple copies in the human genome, we might 
only capture a fraction of highly methylated Alu elements. Future analysis using the 
newest sequencing technologies applying long sequencing reads for long single DNA 












Figure 24. Preferential retention of CpG methylation in DNMT1-deficient hESCs. A. 
Density plot depicting the methylation of the genome divided into 500bp tiles (n = 571,303 
500bp tiles with at least 5 CpGs covered) in cells pooled from each time point of the 
scRRBS experiment. Bray dotted line represents 50% DNA methylation cutoff. B. Venn 
diagram depicting the overlap of 500bp genomic tiles from A., which retained at least 
50% methylation at designated time points. Number of overlapping tiles is listed. Overlap 
significance pval ≤10-270 C. The identity of genomic features that include the 50%≤ DNA 
methylated tiles overlapping at time points 6, 7 and 8. SE – super enhancers, CGI – CpG 
islands, TSS – transcriptional start site. D. Table depicting the frequency of top 5 classes 
of transposable elements overlapping with the DNA methylation-retaining tiles in the 
experiment (left side) and in the genome (right side). E. Table depicting the identity of 
top10 SINE elements most frequently overlapping with the tiles preferentially retaining 
DNA methylation. 
 
Why is the DNA methylation retained at these elements? One possible explanation could 
be that these particular elements were recognized by the TRIM28/ZFP machinery 
specialized in silencing transposons51. The TRIM28-based silencing system facilitates 
specific recruitment of de novo DNA methyltransferases. The odds of these elements 
being actively methylated could be affected by the fact that they lie mostly in the 
intragenic regions. Alternative a TRIM28-independent mechanism would involve a 
chromatin marker of transcribed genes, a histone modification H3K36me3, which is 
recognized by PWWP domain-containing proteins204. It was shown that DNMT3A and B 
both contain the PWWP domain that are necessary and sufficient to recruit the enzymes 
to DNA for its subsequent action18. Further experiment will need to be conducted to 
address the role of TRIM28 and the transcription process in the DNMT1-independent 




In this study, we employed a single-cell sequencing method to measure the abundance 
and genomic distribution of DNA methylation in the DNMT1-deficient hESCs. In 
agreement with our previous 5mC ELISA results, we found that depletion of DNMT1 on 
the transcriptional level leads to a gradual, but not complete, loss of DNA methylation. 
By examining methylation levels in individual cells, we demonstrated that in the final time 
point of the experiment the low average levels (around 25%) of this mark in DNMT1-
depleted cells are maintained across the population. The DNMT1-depletion phenotype 
is therefore robust, as we did not see cells that would retain their DNA methylation 
despite the absence of the maintenance methyltransferase. 
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Curiously, we have not captured any cell that would retain less than 10% of global DNA 
methylation, suggesting that, unlike mESCs, a complete demethylation of hESCs is 
deleterious. The alternative explanation could be that de novo methyltransferases 
DNMT3A/B are able to maintain this level of DNA methylation on their own. Single-cell 
sequencing data of even later time points than examined here (such as the day 12th), 
could further corroborate this hypothesis.  
Through the analyses of (1) chromosomes, (2) regions or (3) tile-level DNA methylation, 
we were able to demonstrate that the distribution of retained DNA methylation was 
largely stochastic. The only exception was a small subset of elements, mostly belonging 
to the Alu TE family, which remained highly methylated (over 50% mean methylation), 
even up to 8 days post DNMT1 depletion. These regions were continuously methylated 
across examined time points suggesting the ongoing maintenance process in a DNMT1-
independent manner. In such case, the maintenance could only be performed by the de 
novo methyltransferase enzymes DNMT3A and DNMT3B.  
Our lab demonstrated that DNMT3A and 3B maintain DNA methylation on a set of 
genomic loci95. However, we did not observe changes on these loci in the absence of 
DNMT1. Our data could indicate that DNMT3A and 3B are only preferentially recruited 
to a few of their substrate loci for methylation, while the rest of their targets are the 
genomic regions maintained by DNMT1. In the absence of DNMT1, de novo DNA 
methyltransferases are presented with thousands of new substrate loci for DNA 
methylation, nevertheless the DNA methylation drops to low levels. We hypothesize that 
the de novo DNMTs abundance could be the limiting factor for maintaining global DNA 
methylation in the absence of DNMT1. An alternative explanation could be a lack of 
additional factor, which would be needed to recruit DNMT3A or 3B to the hypomethylated 
loci. Finally, the loss of DNA methylation could be followed by transcriptional activation 
which, in turn, prevents the establishment of de novo DNA methylation. Further studies 
will offer some other possible interpretations of this paradigm. Indeed, the 
overexpression of DNMT3B in mouse cells was found to cause DNA hypermethylation205, 
reinforcing the hypothesis that the abundance of de novo methyltransferases in a cell 
could be a mechanism to maintain global DNA methylation in the absence of DNMT1. It 
would be interesting to study, whether overexpression of DNMT3B could substitute for 





6.18 Single-cell transcriptome  
 
The transcriptional state determines the identity of the cell and reacts to intracellular and 
extracellular signals. Because of the role of DNA methylation in repressing transcription, 
we hypothesized that a genome-wide loss of DNA methylation will impact the 
transcriptome of the cells. Previous studies of the expression changes in DNMT1KO 
cells98,102,176 reported different extent to which the transcriptomes were affected by the 
global DNA hypomethylation. This could be ascribed to many factors, such as differences 
between cell types and sequencing methods used. With our dual-sequencing protocol, 
we analyzed the transcriptome of single cells, as well as the relationship between gene 
methylation and expression. We have also pooled scRNA-seq data from cells to compare 
changes in gene expression across time points. 
With our dual-sequencing protocol, we had the unique ability to analyze not only DNA 
methylation but also the transcriptome of single cells that gave us a relationship between 
the gene methylation and expression. Therefore, we have the pooled scRNA-seq data 
from cells to compare changes in gene expression across time points. 
 
The tSNE clustering. In order to visualize the differences between transcriptional states 
of single cells, we utilized tSNE clustering, which is an analysis method that groups cells 
based on the similarities between their transcriptomes (FIG 25).  While, in this method 
the composition of the transcriptomes is the most relevant to assign single cells into 
clusters, the distances between clusters is less crucial. We then colored the plot based 
on different criteria, such as the time point of collection (FIG 25, 26), number of mapped 
reads, number of expressed genes or mean DNA methylation. We did not observe 
technical bias introduced by these variables that could affect the clustering. 
Next, we examined how biological factors, such as the time point of collection post-
DNMT1 depletion or the mean level of DNA methylation correlate with the clustering. We 
observed distinct clustering of cells from time points 0 and 3, which formed one cluster. 
The cells from time points 1 and 2 formed a separate cluster. In contrast, the cells from 
later time points (5 through 8) formed three distinct clusters. These results suggest that 
later time point hypomethylated cells are more similar to one another than to the cells at 
earlier time points (days 1 and 2), or the control. We did not observe clustering of cells 
according to the mean level of DNA methylation (FIG 25B). For example, cells from the 
highly methylated time point 0 cluster with the cells from time point 3, which exhibit a 
variable amount of DNA methylation. These results suggest that the length of DNMT1 
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deficiency period is a better predictor of transcriptional cell-to-cell similarity than the 
amount of methylation retained by the individual cells.  
 
Figure 25. tSNE clustering of DNMT1-deficient hESCs based on their transcriptomes. 
A. Unsupervised clustering of TetOFF DNMT1 hESCs collected in the scRNAseq 
experiment. B. tSNE clustering colored by mean DNA methylation of each cell. C. tSNE 







Figure 26. tSNE clustering of DNMT1-deficient hESCs does not depend on technical 
variability. A. Unsupervised clustering of TetOFF DNMT1 hESCs collected in the 
scRNAseq experiment. B. tSNE clustering colored by library run in which the cells were 
prepared and sequenced. C. tSNE clustering colored by number of genes expressed 







6.19 Identifying transcriptional changes occurring in response to the 
loss of DNMT1 
 
In order to identify any DNA methylation level-driven changes, we analyzed differentially 
expressed genes between the highly and lowly methylated cells from time points 5-8. 
We compared the transcriptomes of cells retaining the highest mean DNA methylation 
(more than 35%) to the least methylated ones (less than 20% average DNA methylation; 
FIG 27). Interestingly, no genes differed significantly in their expression between the two 
groups (representative examples shown in FIG 27B). We then concentrated on the 
transcriptomic differences between time points to define their possible effect on cell 
fitness. To this end, we explored the differences between the transcriptomes of pooled 
cells at each time point of the experiment (1-8) to the control cells (time point 0). The 
number of differentially expressed genes (DEGs; at least 2-fold difference in the average 
expression between the time points and a qval≤0.05) is shown in FIG 28. We observed 
that the number of upregulated genes is higher than the number of genes that become 
downregulated for each of the time points. Both day 1 and day 2 exhibited around 300 
DEGs each. While we only saw 24 DEGs at day 3, consistent with cells from that time 
point clustering closely with control cells, cells at day 5 again exhibited an increased 
transcriptional deregulation. Moreover, the longer the cells were hypomethylated, as 
seen in the case of time points 5 through 8, the more DEGs were identified. The lists of 




Figure 27. Expression in most and least DNA methylated cells from DNA hypomethylated 
time points. A. Violin plot depicting mean DNA methylation of cells at the experimental 
time points post DNMT1 depletion. Pink rectangle encircles the top highly methylated 
cells (mean methylation >0.35). Blue rectangle encircles the most hypomethylated cells 
(mean methylation <0.2). The number of cells and cells also covered in the scRNAseq 
analysis is listed. B. Violin plots depicting representative examples of differentially 
expressed genes. 
 
In order to explore the function of the differentially expressed genes, we sub-divided 
them into classes of functionally related genes. To this end, we performed gene ontology 
(GO) analysis125,126,206 on the separated groups of up- and downregulated genes at each 
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time point. Top 10 GO terms with the lowest FDR for the gene sets are shown in Table 
9. Since day 3 only presented 24 DEG in total, it was not significantly enriched for any of 
the terms and is not represented in the figure. 
 
 
Figure 28. Differentially expressed genes. Bar graph representing the number of 
differentially expressed genes between pooled scRNAseq data from control cells and 
each experimental time point. Up- and downregulated genes are colored in orange and 
blue, respectively. 
 
Transcriptional downregulation in the DNMT1-deficient cells. We first focused on 
the analysis of downregulated genes that came out unexpectedly given the negative 
regulator role of DNA methylation. We found the analyzed time points were enriched in 
several categories, such as Signal Recognition Particle (SRP)-dependent co-
translational protein targeting to membrane, viral process, or nonsense-mediated decay 
(NMD). It turned out that all these processes were actually significantly enriched because 
of the same group of genes ascribed to multiple categories. The inspected genes 
belonged to Ribosomal Protein Genes (RPGs), a family of highly conserved proteins 
that, together with ribosomal RNAs (rRNA), make up the ribosome. There are nearly 80 
RPGs in the human genome207 and a recent publication has sub-divided RPGs based 
on profiles of expression in different tissues and in cancer cells, suggesting that subsets 
of the ribosomal protein genes have a common regulatory mechanism208. We have 
compared the RPGs downregulated across early (days 1 and 2) and late (days 6 – 8) 
time points with the published RPG classification. The RPGs downregulated in our 
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experiment did not belong to tissue-specific or cancer-downregulated classes defined in 
the previous study208 (FIG 29). 
 
 
Figure 29. Downregulated Ribosomal Protein Genes do not belong to a single expression 
group. A. Heat map representing the expression of downregulated RPGs. B. and C. 
Venn diagrams depicting the overlap between previously distinguished208 subgroups of 
ribosomal protein genes (in blue and pink) and RPGs downregulated at day 2 (B.) or day 




Upon the removal of RPGs from the downregulated gene lists, a few general metabolic 
terms were found to be statistically significant. We investigated the roles of these genes 
in metabolism and found several housekeeping genes209 that became downregulated, 
however, they did not belong to a single metabolic pathway. For example, we observed 
a downregulation of PGK1 (a glycolytic enzyme), tubulin (TUBA1B, which codes for a 
component of microtubules) or PPIA, a peptidyl prolyl cis/trans isomerase, a chaperone. 
It is worth noting that none of the housekeeping genes was completely silenced, 
however, they underwent a statistically significant 2- to 3-fold reduction in their 
expression.  
 
6.20 Transcriptional upregulation following depletion of DNMT1.  
 
Pro-apoptotic BAX gene. We next moved to study the genes upregulated in the 
DNMT1-deficient cells that are conceptually in line with the repressive role of DNA 
methylation in transcription. This pro-apoptotic protein is able to dimerize, open channels 
in the mitochondrial membrane to cause cytochrome C release into the cytosol and, in 
consequence, trigger the canonical apoptosis pathway210. The process is dependent on 
BH3-only family of proteins, which activate BAX. Another mitochondrial membrane 
protein called Bcl-2 acts as a safeguard. Upon BAX activation, Bcl-2 can inhibit 
mitochondrial membrane perforation by directly binding BAX211. Only after Bcl-2 is 
completely bound, excess of active BAX can lead to the activation of apoptosis212. BH3-
only family of proteins are activated by p53213. In the previous chapter we were able to 
demonstrate that TP53 knockout is able to partially rescue the DNMT1 absence-caused 
loss of fitness (FIG 14). If spontaneous BAX activation occurred in the DNMT1-depleted 
hESCs, the knockout of upstream factor (p53) would not confer rescue. 
The common upregulated genes in DNA hypomethylated cells. We continued the 
analysis of upregulated genes at other time points, again relying on the gene ontology 
analysis. Both day 1 and day 2 upregulated genes were enriched for GO terms related 
to metabolism. The fact that the transcriptome at day 3 was again more resembling the 
control argues against a differentiation program being triggered in response to the loss 
of DNMT1 protein. We hypothesize that this transient gene deregulation could be a 
response to the addition of doxycycline to medium or the cell plating conditions which, in 
order to maintain good attachment efficiency and survival, included treatment with Rho 
kinase inhibitor (ROCKi) for 24h after plating. Ideally, a second control consisting of dox-
untreated cells plated in the same way as the treated cells could confirm this hypothesis. 
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We then compared the differentially expressed genes conserved across the time points 
and asked what were the constantly upregulated genes. Out of 151, 144, 357 and 707 
genes upregulated with respect to control for days 5,6,7 and 8; 64 were upregulated in 
all time points (FIG 30). 
  
 
Figure 30. Overlap of Differentially Expressed Genes in globally DNA hypomethylated 
hESCs. Venn diagram depicting the overlap between DEGs from time point 5 (green), 6 
(blue), 7 (purple) and 8 (pink). The number of genes in each overlap is indicated. 
 
We have also explored genes upregulated at earlier time points (d5 and d6) and later 
time points (d7 and d8). The lists of top 100 upregulated genes common for designated 
time points can be found in Table 10. The upregulated genes common for all time points 
between day 5 and 8 included transcripts present only in a variety highly specialized 
tissues, such as MYL7 – myosin light chain specifically expressed only in the heart 
muscle. Another example is the upregulation of neurotensin (NTS) that encodes for a 
neurotransmitter. A different category found in the upregulated genes included metabolic 
genes which are highly expressed in most tissues, such as the carbonyl reductase 1 
(CBR1), an NADH-dependent enzyme with wide substrate specificity. Interestingly, a 
common group of genes significantly upregulated in the examined time points were 
morphogens that belong to the Activin/Nodal signal transduction pathway – LEFTY1, 
CER1 and FST. The expression of LEFTY1 lies downstream of NODAL-mediated signal 
transduction and we were able to confirm NODAL upregulation at day 3, preceding 
LEFTY1 upregulation. The analysis of genes upregulated at only at the earlier time points 
(day 5 and day 6) showed similar upregulation of a few widely expressed and specialized 
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tissue genes, such as leucine tRNA synthetase (LARS1) and cranio-facial E3 ubiquitin 
ligase NOSIP, respectively. The latest time points (day 7 and day 8) were also enriched 
in metabolic and specialized tissue-specific genes, like cystatin (CST; a protease 
inhibitor present in saliva and other secretions). We also observed an upregulation of 
gonad-specific genes, such as the transposon silencer MAEL or a meiotic protein, called 
SYCP3. In line with the germline-specific coding genes becoming upregulated, we 
observed an upregulation of germline-specific long, non-coding RNAs (lncRNAs) from 
the XAGE, MAGE and GAGE families. Although numerous germline genes were 
derepressed, we did not observe the expression of the canonical germline markers (such 
as DPPA3 or DDX4), which suggests that the cells did not undergo differentiation into 
the germline lineage.  
Previous studies conducted in diverse cell types reported that DNMT1KO leads to the 
deregulation of germline-specific genes, since the expression of some gonad-specific 
genes is inversely correlated with the promoter DNA methylation, which is a negative 
regulator of gene expression91. We aimed to find out if more genes in the DNMT1-
deficient hESCs display similar expression dynamics. To explore this possibility, we 
identified genes, which lose DNA methylation at their promoter regions (d0 methylation 
is higher than d8 methylation by at least 40%) and belong to the genes upregulated at 
the d8 category. Both mean methylation and expression of such genes is plotted in FIG 
31. Indeed, for most germline-specific genes (including MAEL and SYCP3) the 
expression increases after promoter methylation has decreased. The upregulation of a 
few specialized tissue-specific genes (such as MYL7) also correlated with loss of the 
repressive DNA methylation from their promoter region. Nevertheless, less than 70 
genes identified in our analysis exhibited the trend of transcriptional upregulation 
following promoter hypomethylation. This is consistent with the idea that not only the 
absence of the repressive chromatin mark but also a positive signal, such as the 





Figure 31. Genes in which promoter methylation negatively correlates with expression. 
Heat maps representing the expression of indicated gene in all cells in the designated 




We purified polyadenylated RNA from the single cell-sorted hESCs and processed it 
concurrently to the genomic DNA to obtain both transcriptome and DNA methylome 
information from single cells. We clustered the cells based on their gene expression 
profiles and found out that our cells clustered into three main groups: (1) Day 3 cells 
showed few genes that were differentially expressed with regards to control cells and 
thus clustered with time point 0. (2) Co-clustering of day 1 and day 2 cells, which was 
most likely caused by a response to passaging, ROCK inhibitor and doxycycline common 
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to these time points. (3) Cells collected at day 5 and onwards clustered separately and 
showed a most severe difference in gene expression compared to the control cells out 
of all the experimental time points. 
We analyzed the differentially expressed genes between cells belonging to different time 
points and control cells to identify how the loss of DNMT1 affects the transcriptional 
output of the cells. The DNA hypomethylated cells from time points 5- 8 demonstrated a 
progressively increased number of DEGs, suggesting that even when the DNA 
methylation is brought down to a minimum (a mean of about 25%), the changes in 
transcriptome are progressing. Upon investigation of the upregulated gene lists, we were 
able to identify certain gene expression patterns. The upregulated genes in DNA 
hypomethylated cells (time points 5-8) could generally be assigned to one of the three 
categories: (1) widely expressed metabolic genes; (2) specialized tissue-specific genes, 
which belong to diverse lineages; (3) gonad-specific transcripts. The deregulation of a 
large number of genes seemed to be mostly stochastic; the loss of DNA methylation at 
the promoter region directly preceded the activation of only a few genes.  
Taken together, our scRNAseq results identified some of the known genes upregulated 
in response to DNA hypomethylation, as well as other genes, the upregulation of which 
could be a hESC-specific response to global DNA hypomethylation. In the next chapter, 
we follow up on the changes in a few of these newly-identified DEGs, which belong to 
the Activin/Nodal signal transduction pathway. 
 
CHAPTER 4. Loss of DNMT1 increases sensitivity to the 
stimulus-dependent activation of transcription. 
 
Our transcriptomic analysis revealed that DNMT1 deficiency resulted in deregulation of 
gene expression. Furthermore, each consecutive day after ablation of DNMT1 yielded 
more differentially expressed genes with respect to controls. Among the upregulated 
genes, we found the Activin/Nodal signal transduction pathway. Since the activity of this 
pathway is essential for the pluripotency of hESCs214,215, we decided to explore how the 
imbalance in the expression of the Activin/Nodal pathway impacts the growth of hESC, 




6.22 Characterization of the TGFβ superfamily Activin/Nodal signal 
transduction pathway. 
 
Morphogens are molecules which act proximally and distally to orchestrate embryo 
patterning216. Because of their mode of action, they are typically secreted and act through 
binding to an extracellular receptor. Some of the most studied morphogens belong to the 
Transforming Growth Factor Beta (TGFβ) superfamily, which includes the Activin/Nodal, 
BMP and GDF signal transduction pathways217.  
In mammals, the TGFβ/Activin/Nodal signal transduction pathway is activated by the 
following morphogens: TGFβ, Activin A, Activin B or NODAL. Activin A/B are recognized 
by heterotetrameric receptors consisting of two subunits of each ActRIIB and Alk4218. 
NODAL requires a co-receptor CRIPTO to enable signal transduction via ActRIIB and 
Alk4219. Therefore, both Activin A/B and NODAL converge on the same ActRIIB and Alk4 
receptors. On the other hand, TGFβ is recognized by a distinct heterotetrameric receptor 
consisting of TβRII and Alk5220.  
The binding of morphogens to their respective receptors results in the phosphorylation 
of receptor-associated Small Mothers Against Decapentaplegic (SMAD) proteins 
SMAD2 and SMAD3221. Upon phosphorylation, these factors bind a common mediator-
SMAD (co-SMAD), called SMAD4, and translocate to the nucleus to activate 
downstream target genes222. The target specificity is confined by distinct DNA sequence-
specific transcription factors modulating the binding of SMADs, such as p53, FoxH1 or 
OTX2223,224. In this way, the Activin/Nodal signal transduction pathway activates gene 
expression in a cell non-autonomous manner. One of the downstream targets of the 
pathway is the Nodal gene itself, which creates a positive feedback loop to amplify the 
initial input signal in this signaling pathway. This mechanism exists in the early embryo 
to maintain the high levels of NODAL protein in the epiblast and sustain its growth and 
identity225. Other genes activated downstream in a response to the NODAL stimulus are 
genes, the protein products of which act as direct inhibitors of NODAL: Lefty homologs 
(LEFTYA and B)226,227 and Cerberus (CER1). CER1 functions as a broader inhibitor of 
Nodal, BMP and Wnt228 signal transduction pathways. This creates a negative feedback 
loop, which in turn restricts the spatial activity of NODAL. 
In response to TGFβ/Activin/Nodal stimuli, a wide range of genes change their 
expression pattern. This transcriptional response downstream of the stimuli controls the 
viability of the epiblast cells and primitive streak formation (in vivo), or hESCs survival 
and meso- and endoderm differentiation (in vitro)229–231. We therefore explored if the 
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perturbations in morphogen expression could contribute to the loss of fitness phenotype 
in the DNMT1-deficient cells.  
 
6.23 Nodal signal transduction pathway components in cells 
deficient for DNMT1 
 
We re-visited our results of scRNAseq to investigate the expression of genes acting in 
the Activin/Nodal signal transduction pathway. We observed that loss of DNA 
methylation coincided with the deregulation of nearly all the morphogens in the Nodal 
signal transduction pathway (NODAL, FST, LEFTY1, LEFTY2, CER1) at different time 
points of the scRNAseq analysis. The only factor not deregulated was the gene encoding 
for Activin A, which is not expressed in hESCs (Fig 32A). The expression level of 
Follistatin (FST), a direct inhibitor of Activin232, increased as soon as day 1 after the 
transcriptional shut off of DNMT1 and remained upregulated throughout the experiment 
(FIG 32A). In contrast, NODAL was upregulated as soon as day 3 post DNMT1 depletion. 
Indeed, NODAL was one of the few differentially expressed genes between control and 
day 3 cells (Table 8). In agreement with LEFTY1 being a direct target of the NODAL-
induced signal transduction, the expression level LEFTY1 increased at day 5 and 




Figure 32. scRNAseq expression of Activin/Nodal signal transduction pathway 
morphogens. A. Heat map representing the expression value [TPM] of chosen genes 
of the Activin/Nodal signal transduction pathway. INHBA – Activin A. B. tSNE clustering 
of cells used in the DNMT1-depletion scRNAseq colored by time point, for reference to 
C. tSNE plot of scRNAseq results colored by the expression of chosen morphogens. 




To elucidate if the changes in expression were present in the most DNA hypomethylated 
cells, or if a small number of cells highly upregulated these factors, we examined the 
expression of NODAL inhibitors in the individual cells (FIG 32B and C). While nearly all 
cells from time points 5-8 expressed LEFTY1, the two remaining inhibitors of NODAL - 
LEFTY2 and CER1 became expressed as late as at days 7 and 8 and in smaller subset 
of cells. Nevertheless, the upregulation in these few cells significantly raised the average 
expression for the respective time point (Fig 32C and 33A).  
 
Figure 33. Expression of chosen morphogenes in DNMT1-deficient hESCs. A. Heat 
map representing the fold change in expression of NODAL, LEFTY1 and CER1 in 
scRNAseq hESC, B. bulk RNAseq and C. qRT-PCR (N=3). 
 
In order to corroborate these observations and gain further insights in gene expression, 
we performed RNAseq on the bulk population of DNMT1-deficient hESCs at the crucial 
time points of day 3, day 5 and day8 post DNMT1 depletion. To avoid naming confusion 
with the single-cell study, this will be referred to as “bulk RNAseq” (FIG 33B). 
We observed a similar trend of changes in the two sequencing analyses, when looking 
at the expression patterns of NODAL and LEFTY1. For example, we found ~2-fold 
NODAL upregulation at day 3, followed by subsequent increase in the expression of 
LEFTY1 at day 5, which was elevated further (5-6 fold) at day 8. Conversely to our 
scRNAseq results, which showed a 25-fold upregulation of CER1 at day 8, we observed 
a twofold upregulation of that gene in the bulk RNAseq study (FIG 33B). This analysis 
was further confirmed by qPCR measuring the transcription of the morphogens of 
interest (FIG 33C). As CER1 was highly expressed in a small subset of cells in 
scRNAseq, it could have been underrepresented in the bulk sequencing. Alternatively, 
the variation between the two approaches could stem from normalization methods during 
data processing. Nevertheless, both data sets agree on the trend of the change. 
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Altogether, our analyses show that the upregulation of NODAL is followed by the 
upregulation of LEFTY1 after depletion of DNMT1 in hESCs. 
 
6.24 Morphogen deregulation in the absence of Activin/Nodal signal 
transduction 
 
We next examined, whether the global DNA hypomethylation is (1) sufficient for the 
deregulation of NODAL and its antagonists and (2) if the signaling via SMADs is 
necessary in this process. Since hESCs rely on the SMAD2/3-mediated signaling for 
survival215, we genetically engineered the degron into the DNMT1 locus in Human 
Embryonic Kidney (HEK293T) cells, (developed by Simon Lauer); and utilized the 
PROTAC-based degDNMT1 strategy to induce small-molecule mediated depletion of 
DNMT1 (Described in chapter 2.2; further referred to as HEKdegDNMT1 line).  Addition 
of dTAG13 small molecule to these engineered HEKdegDNMT1 cells resulted in 




Figure 34. Absence of Activin/Nodal morphogen upregulation in response to DNMT1 
depletion in HEK263T cells. A. Western blot results depicting the degDNMT1 HEK cell 
line inducible depletion of DNMT1 in the presence of dTAG13. Loading control – tubulin. 
Clone #3 was used in the subsequent analysis. Performed by Simon Lauer. B. qRT-PCR 
analysis of the expression of chosen morphogens (normalized to GAPDH) in cells 
deficient in DNMT1 and treated for 48h with 2µM SB421543 (TGFβ/Activin/Nodal 
receptor inhibitor). Error bars: SD. * pval≤0.05; ** pval≤0.005; *** pval≤0.0005; no 




To confirm if the SMAD2/3 phosphorylation does not occur in the DNMT1-depleted cells, 
we used a small molecule inhibitor of Alk4/5/7 receptor, called SB431542233. Next, we 
performed a qPCR analysis of the expression of genes that function in the Nodal 
signaling pathway in the control- and DNMT1-depleted HEKdegDNMT1cells, as well as 
the SB431542-treated cells (FIG 34B). As expected, none of the studied targets 
(NODAL, LEFTY1, LEFTY2 or CER1) was expressed in the HEK293T cells in the 
presence or absence of SB431542. Depleting DNMT1 using the degron system also did 
not lead to any significant changes in the expression of the examined morphogens (FIG 
34B; note very low expression levels). The result did not change upon the depletion of 
DNMT1 combined with SMAD2/3 inhibition by SB431542 (FIG 34B). The result did not 
change upon the depletion of DNMT1 combined with SMAD2/3 inhibition (FIG 34B). This 
is consistent with previous studies demonstrating that the expression of NODAL and its 
antagonists dependents on the Activin/Nodal signal transduction pathway activity227. 
Inducing the DNA hypomethylation is therefore insufficient to activate the expression of 
NODAL, LEFTY1/2 and CER1 in HEK293T cells probably due to the absence of 
TGFβ/Activin/Nodal receptor stimulation.  
While these results suggest that changes in the expression of Activin/Nodal morphogens 
are not a universal response to global DNA hypomethylation, we reasoned that it could 
contribute to the loss-of-fitness phenotype we observe in the DNMT1-deficient hESCs. 
For example, LEFTY1 could negatively impact the fitness of the DNMT1-deficient hESCs 
if NODAL-dependent signal transduction is required for hESC growth. In fact, 
corroborating observations were reported recently234. In the study by Fiorenzano and 
colleagues, a CRIPTO-blocking peptide was used to treat hESCs, which specifically 
disrupted the interaction between NODAL and its receptor (without affecting TGFβ1 
binding to TβRII and Alk5)235. Despite culturing in TGFβ-supplemented medium, the cells 
performed poorly in proliferation assay compared to control controls. Moreover, reducing 
the amount of CRIPTO protein using shRNAs led to lower growth rate and a spontaneous 
differentiation in the CRIPTO knock-down hESC lines234. Inspired by previous studies, 
we perturbed the NODAL-induced receptor stimulation in hESCs by ectopic expression 






Figure 35. LEFTY1 is a negative regulator of hESC growth. A. XY graph depicting the 
growth curve of TetOFF DNMT1 hESCs (black), treated with 5ng/mL recombinant 
LEFTYB (green), 5ng/mL recombinant NODAL (purple) or DNMT1-deficient TetOFF 
DNMT1 cells, counted at passage 2, days 5-8 post DNMT1 depletion (red). N=2. B. 
Schematic representation of lentiviral vector construct used for NODAL or LEFTY1 
overexpression in hESCs. LTR – Long Terminal Repeats, UCOE – Ubiquitous 
Chromatin Opening Element, TRE – Tet Response Element, rtTA – recombinant Tet 
transactivator. C. Representative images of NODALoe and LEFTY1oe cell lines 
exposed to varying concentrations of doxycycline for 24h. Phase view of live colonies 
(gray) is overlaid with morphogen expression visualized via GFP fusion (green). D. Bar 
graph representing cell counts to compare growth of NODALoe and LEFTY1oe lines 
exposed to indicated amount of doxycycline for a single passage (4 days). Error bars: 
SD. * pval≤0.05; ** pval≤0.005; *** pval≤0.0005; n.s. – not significant. N=3 
 
6.25 LEFTY1 impacting the proliferation of hESC  
 
Gain of function assessment. To examine whether LEFTYB (the protein product of the 
gene LEFTY1) could affect the growth of hESCs, we compared the growth of DNMT1-
deficient cells in passage 2 (day 5-day 8 after DNMT1 depletion) with the growth of 
control cells treated with recombinant NODAL and LEFTYB proteins (Fig 35A). 
Treatment with a recombinant NODAL resulted in a similar growth as the control cells, 
despite an initial lag (FIG 35A). In contrast, treatment with LEFTYB inhibited the growth 
of hESCs. We thus concluded that LEFTYB, but not NODAL, negatively impacts 
proliferation of hESCs in a manner comparable to the depletion of DNMT1 (FIG 35A). 
Supplementation of a recombinant protein does not recapitulate the steps of processing 
and secretion that naturally follow the expression of a signaling molecule. In order to 
examine the impact of ectopic expression of NODAL and LEFTY1 on hESC growth, we 
engineered a lentiviral delivery system that would enable an inducible expression of a 
gene in wild-type HUES64 cell line (FIG 35B). Briefly, the expression cassette sequence 
was flanked by LTR repeats236 to mediate random integration into the genome. Next, an 
upstream chromatin element opening sequence (UCOE) was introduced to prevent 
silencing of a TRE promoter237. We PCR-amplify the cDNA of either NODAL or LEFTY1 
and cloned them into the donor vector. Each gene was C-terminally fused to super-folded 
GFP (sfGFP) to provide reliable readout of the doxycycline-induced transgene 
expression. The second transgene consisted of an rtTA transactivator linked by 
cleavable liner (P2A)238 to the blasticidin-resistance cassette. In the presence of 
doxycycline, the rtTA binds the TRE promoter and activates the transcription of the 
NODAL or LEFTY1 gene. The blasticidin resistance gene served as a selection method 
for donor integration and activity. The clonal picking of the blasticidin-resistant colonies 
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led to the generation of the morphogen-overexpression hESC lines call thereafter: 
NODALoe and LEFTY1oe. After doxycycline supplementation (24h), the respective 
transgenes were activated in hESCs in a dose-dependent manner (FIG 35C). To 
measure the effect of morphogen overexpression on cell growth, we performed a cell 
count on the NODALoe/LEFTY1oe lines induced with 0.1µg/ml doxycycline (FIG 35D). 
Again, the results demonstrated a deleterious effect of LEFTY1, but not NODAL, 
expression on the hESC growth. Taken together, we concluded that the ectopic 
expression of LEFTY1 has a negative effect on the growth of hESCs. We suspect that 
this is linked to its role as an inhibitor of the Activin/Nodal signal transduction pathway.  
 
Loss of function. If the increased expression of LEFTY1 negatively affects the hESC 
growth, we hypothesized that knockout of LEFTY1 could alleviate the DNMT1-deficient 
cell growth defect. In order to explore this possibility, we turned to lentiviral strategy 
presented in FIG 13. to deliver the Cas9 protein and an sgRNA against LEFTY1 to disrupt 
the gene in the TetOFF DNMT1-inducible depletion cell line. After transduction with such 
virus and subsequent selection for its expression, we individually collected single cell-
derived colonies and genotyped the LEFTY1 locus to identify a LEFTY1 heterozygote 
(+/-) and a LEFTY1 homozygous knockout (-/-) clones (FIG 36A and B). We noted that 
while the LEFTY1+/- cell line did not affect the growth of hESCs, the complete LEFTY1 
knockout cell line had a significant growth advantage over wild-type cells, consistent with 
our observations of LEFTY1 being a negative regulator of hESC growth (FIG 36C).  
We next compared the growth of the TetOFF DNMT1-depleted parental line with TetOFF 
DNMT1; LEFTY1+/- and TetOFF DNMT1; LEFTY1-/- lines (FIG 36D). We observed that 
the initial loss of fitness of the DNMT1-deficient cells in the first passage was not affected 
by of the absence of LEFTY1. This is consistent with our RNA sequencing data, which 
demonstrated that LEFTY1 is not significantly upregulated immediately after DNA 
methylation loss (FIG 33). In contrast, the proportion of surviving cells at day 8 was 
significantly higher in the TetOFF; LEFTY1-/- compared to just the DNMT1-depleted cells. 
On average, the growth of DNMT1-depleted; LEFTY1-/- double-deficient line was a 
quarter of that of reached by the TetOFF; LEFTY1-/- single knockout line. In contrast, 
after two passages the growth of DNMT1-deficient cells was 10% of that reached by 
control cells. The heterozygous cell line TetOFF; LEFTY1+/- did not show a statistically 




Figure 36. LEFTY1 knockout can partially rescue DNMT1 depletion-induced growth 
defect. A. and B. Sanger sequencing results visualizing the mutations in LEFTY1 exon 
1 (yellow bar) in TetOFF DNMT1; LEFTY1+/- cell line and TetOFF DNMT1; LEFTY1-/- line, 
respectively. The sequence of guide RNA used is shown in gray. C. Bar graph depicting 
the number of cells of the respective TetOFF DNMT1 cell lines after a single passage (4 
days) in the absence of doxycycline. D. XY graph representing the cell growth of DNMT1-
deficient cell lines as a proportion of live cells with respect to DNMT1-present controls, 
calculated after every passage. Error bars: SD. * pval≤0.05; ** pval≤0.005; *** 





We conclude that LEFTY1 upregulation is one of the consequences of global loss of 
DNA methylation in hESCs, which negatively impacts the growth of the cells. Since the 
rescue provided by LEFTY1 knockout was partial, additional mechanisms must be 
involved in reducing the fitness of the DNMT1-deficient cells. 
 
6.26 DNMT1-deficiency affects transcriptional response in hESC  
 
The pluripotency of hPSCs is maintained in the cell culture conditions by supplementing 
the medium with TGFβ1 and the Fibroblast Growth Factor (FGF)133. Balance between 
these two signal transduction pathways dictate the propensity of hPSCs to differentiate 
into ectoderm (FGF) versus meso- and endoderm (Activin/Nodal). This process is 
coordinated by the transcription factor NANOG215. Interestingly, NANOG is one of the 
direct downstream targets of the Activin/Nodal signal transduction, as well as a co-factor 
acting to fine-tune this pathway and restrict its endoderm-inducing potential. On the other 
hand, NANOG acts to inhibit the expression of the FGF2-mediated neuroectoderm 
factor. The multiple functions of NANOG are regulated by inputs from extracellular stimuli 




Figure 37. DNMT1 deficiency results in changes in expression of transcription factors. 
A. Bar graphs representing the bulk RNAseq results of expression of the pluripotency-
associated transcription factors (NANOG, SOX2 and POU5F1, respectively) in control 
cells and TetOFF DNMT1-depleted cells for 3, 5 or 8 days. B. Bar graph of bulk 
RNAseq expression of ectoderm-associated TFs. SOX1 has not been detected at any 
of the time points (RPKM<0.1). C. Bar graph representing the bulk RNAseq 
measurement of the expression of meso- and endoderm-associated transcription 
factors in TetOFF DNMT1 cells. Error bars: SD. * pval≤0.05; ** pval≤0.005; *** 
pval≤0.0005; n.s. – not significant. 
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Since DNA hypomethylation influences the expression of the Activin/Nodal signal 
transduction pathway morphogens, we hypothesized that this could influence the 
transcriptional balance maintained by NANOG and in turn lead to the differentiation of 
the DNMT1-deficient hESC. To test this hypothesis, we turned to our bulk RNAseq 
data to compare the expression level of transcription factors characteristic for either the 
pluripotent hESCs (NANOG, POU5F1, SOX2; FIG 37A), ectoderm (PAX6, SOX1; FIG 
37B) or combined meso- and endoderm stages of germ layer differentiation (EOMES, 
T, SOX17, FOXA2, GATA4; FIG 37C). Although we did not observe a transcriptional 
shut off of POU5F1 in the DNA hypomethylated cells, NANOG was significantly 
downregulated. The decrease in NANOG expression could further result in 
differentiation of hESCs in agreement with its role as a balance between Activin/Nodal 
and FGF signal transduction pathways. Our analysis showed the low level of PAX6 
expression at day 8 of DNMT1 depletion and the absence of SOX1 expression that 
overall indicate a lack of ectoderm differentiation. In contrast, the expression pattern of 
the meso- and endoderm markers after DNMT1 depletion gradually resembled the in 
vitro differentiation of hESCs towards mesendoderm and endoderm, respectively239. 
For example, we observed an initial upregulation of BRACHYURY (encoded by the T 
gene), which was subsequently downregulated, as well as upregulation of FOXA2 and 
SOX17 (FIG 38). In addition, we observed an upregulation of PRDM1, a transcription 
factor found in mesoderm-derived primordial germ cells, indicating that the hESCs are 
not strictly following endoderm differentiation program. 
 
Figure 38. Changes in expression of key TFs suggest mesendodermal differentiation of 
DNMT1-deficient hESCs. Heat map representing the expression (log2RPKM) of key 
TFs measured in bulk RNAseq in the presence (control) or absence of DNMT1 for 3, 5 




In order to validate these observations, we performed immunofluorescence microscopy 
on control and DNMT1-deficient hESCs to estimate the protein level of BRACHYURY 
and SOX17. Consistent with our RNAseq results, we noted higher amount of SOX17 
present in the DNMT1-deficient cells compared to control. The levels of BRACHYURY 
protein were also increased even at day 8 of DNMT1 depletion, despite lowered 










Figure 39. The expression of T and SOX17 changes in DNMT1-deficient hESCs over 
time. Representative images depicting the DNA staining using DAPI (top row) and 
immunofluorescent staining against T (second row) and SOX17 (third row). The images 





The differentiation genes are targets of SMADs. Since the mesendoderm 
differentiation program is induced in the presence of Activin in vitro240, we explored if the 
upregulation of genes in response to global DNA hypomethylation could be ascribed to 
the mesendodermal gene activation by SMAD2/3, the signal transducers of the 
TGFβ/Activin/Nodal receptors (FIG 40). We employed Genomic Regions Enrichment of 
Annotations Tool (GREAT)241 to identify genes with a TSS within 10kb of a SMAD2/3 
binding site in undifferentiated hESCs, or cells subjected to mesendoderm differentiation 
regimes. This approach identified 583 and 3326 SMAD2/3target genes in ESCs and 
mesendoderm, respectively. We then investigated the overlap between these targets 




Figure 40. DNMT1-deficient hESCs upregulate mesendodermal targets of SMAD2/3. 
A. Venn diagram depicting the overlap between genes upregulated at day 8 of DNMT1-
depletion (scRNAseq) and hESC SMAD2/3 binding target genes. B. Venn diagram 
depicting the overlap between genes upregulated at day 8 of DNMT1-depletion 
(scRNAseq) and human mesendoderm SMAD2/3 binding target genes. Significance of 
each overlap is listed beneath the graphs. 
 
Out of 583 hESC SMAD target genes, only 24 overlapped with the day 8 upregulated 
genes (FIG 40A). We expected this result, as the genes regulated by SMAD2/3 are likely 
already active in the control hESCs. Strikingly, 171 genes overlapped between the target 
genes of SMAD 2/3 binding and the day 8 upregulated genes (24% of day 8 upregulated 
genes), which bore high statistical significance (p <1.05x10-7; FIG 40B). As a control, we 
assessed the overlap between day 8 upregulated genes and a randomly generated 
3326-gene list. Only 84 genes were shared by the control lists, therefore, the overlap 
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between SMAD2/3 targets and day 8 upregulated genes is non-random. This suggests 
that the changes in the transcriptional program resulting from DNA hypomethylation 
could, to some extent, be caused by the abnormal engagement of the already active 
Activin/Nodal signal transduction pathway. Instead of being restricted to the pluripotency 
genes, this signaling pathway activates additionally the gene expression program of the 
mesendoderm. In agreement with these results, we observed an increased expression 
of meso- and endoderm marker transcription factors as early as 3 days post DNMT1 
depletion, followed by the upregulation of mesendoderm targets of the Activin/Nodal 
signal transduction pathway – of note, the mesendoderm-upregulated transcription factor 
genes, such as T and SOX17 also are the SMAD2/3 targets in this lineage (FIG 31; FIG 
38).  
We next examined the differentiation potential of the DNMT1-deficient hESCs using a 
Scorecard experiment (FIG 41). Scorecard is a qRT-PCR based assay, which uses an 
algorithm established based on differentiation profiles of differentiated hESC lines136,242 
to estimate the propensity of hESCs to differentiate into ecto-, meso- or endoderm. The 
result is presented as a “score” - an auxiliary unit summarizing the expression of key 
lineage markers, used to directly compare the “differentiation state” of cells within one 
line or across different experiments. Consistent with our observations of mesoderm 
program activation in the absence of DNMT1 in hESCs, the DNMT1-deficient cells have 
a higher mesoderm score than the control cell line. Our hypothesis was that the treatment 
with the meso- or endoderm differentiation-promoting signaling molecules will affect the 
score of the DNMT1-deficient and control cells. To this end, we cultured the cells for 6 
days in the absence of DNMT1 to induce DNA hypomethylation, followed by 2 days 
treatment with LIF (as a control, as this cytokine is not associated with hESC 
differentiation), WNT3A (endoderm-promoting factor) or BMP4 (mesoderm-promoting 
factor). Both the control and DNMT1-deficient cells responded transcriptionally to the 
treatment with each factor, as reported by the change in score. Curiously, although the 
response always displayed the same trend, i.e, both control and DNMT1-deficient hESCs 
had an increased endoderm or mesoderm score in response to WNMT3A and BMP4, 
respectively, the score was always higher for the DNMT1-deficient cells. These results 
suggest that the DNMT1-deficient hESCs are more receptive to respond when exposed 
to extracellular cues, compared to control cells. The implications of this finding will be 




Figure 41. hESC response to morphogen induction changes upon DNMT1 depletion. 
Heatmap depicting the score (auxiliary unit) of control and degDNMT1 hiPSCs, derived 
from their expression of a panel of Pluripotency, Ecto-, Meso- and Endoderm-
associated genes. Mock control untreated cells (8d – 2 passages culture), DNMT1-
deficient cells (degDNMT1; 8d of 125nM dTAG-13 – 2 passages culture) or either cell 
line grown for 6 days, followed by 2 days of treatment with 500U ml−1 LIF, 100 ng ml−1 
BMP4 or 50nM ml−1 WNT3A, respectively were used (total 8d – 2 passages growth). 
 
Whether the DNA methylation-dependent, spontaneous differentiation is a cause of loss 
of fitness is unclear. Prompted by the recent report that DNMT1KO hNPCs are viable243, 
we next investigated if alternative model using different stimulus such as differentiation 








Figure 42. DNMT1-deficient hESCs cannot undergo NPC-directed differentiation. A. 
Schematic of the hESC to NPC differentiation protocol steps, with representative 
images of each stage depicted below. First row – differentiation of control cells. Middle 
row – differentiation of cells depleted of DNMT1 at the beginning (time point 0) of the 
protocol. Bottom row – differentiation of cells depleted of DNMT1 after EB plating (time 
point 7). Scale bar 50µm. B. Representative image of phase microscopy of wild-type 
NPCs and fluorescent microscopy to visualize the immunofluorescence of the NPC 
marker Nestin (green). Scale bar 50µm. 
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6.27 Neural Progenitor Cell (NPC) differentiation of DNMT1-deficient hESCs 
 
We subjected the TetOFF DNMT1 cell line to a three-step differentiation regime towards 
NPC (FIG 42A). Briefly, the undifferentiated colonies were aggregated into Embryoid 
Bodies (EBs) and grown in the presence of inhibitors for the Activin/Nodal and BMP4 
signal transduction pathways to promote the ectoderm differentiation over the meso- and 
endoderm lineages. The EBs were then seeded on laminin-covered plated until they 
formed neural rosettes. Selectively passaging the rosettes into the bFGF-supplemented 
medium yielded the differentiation into NPCs, which show presence for the NPC marker 
Nestin over the course of 21 days (FIG 42B). First, we wanted to learn if the DNMT1 
depletion interferes with the ability of hESCs to undergo and complete this differentiation 
procedure. To this end, we induced the transcriptional shutdown of DNMT1 in our cells 
at the beginning of the NPC-derivation. While the DNMT1-depleted cells were able to 
form EBs, they failed in producing rosettes (FIG 42A; middle row). When DNMT1 was 
depleted later in the grown rosettes, the cells still failed to form NPCs when the conditions 
were switched from Nodal/BMP inhibition to bFGF (FIG 42A; bottom row). Altogether, 
these results demonstrated that global DNA hypomethylation interferes with 
differentiation of hESCs into NPCs. This is likely due to an interference of the global DNA 
hypomethylation with the ectoderm differentiation program or with coordinating the 
transcriptional shutdown of the pluripotency factors necessary to commit to a new 
lineage. 
As embryogenesis in mice deficient for DNMT1 does not progress to the NPC-
differentiation stage, we could not compare our results to the in vivo model. However, a 
study by Fan and colleagues engineered mice bearing the NPC-specific DNMT1 
knockouts to study the impact of DNA hypomethylation on NPC differentiation 
potential103. NPCs give rise to both neurons and glial cells (such as astrocytes), however, 
their propensity to differentiate into either lineage was affected without DNMT1. The 
DNMT1-depleted NPCs are more likely to differentiate towards the glial lineage, rather 
than neural lineage in vivo103. Furthermore, global DNA hypomethylation accelerated the 
differentiation towards glia in in vitro cultured DNMT1KO primary NPCs compared to 
controls, when both were exposed to the glia-inducing Leukemia Inhibitory Factor 
(LIF)103. LIF is a small a cytokine which activates the Janus Kinase – Signal Transducers 
and Activators of Transcription (JAK-STAT) signal transduction pathway244. This 
pathway is essential for neural progenitor cell differentiation into astrocytes. Fan and 
colleagues demonstrated that 2 days of LIF supplementation was sufficient to induce the 
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expression of Glial Fibrillary Acidic Protein (GFAP; an astrocyte marker) in DNMT1KO, 
but not in the control NPCs. 
Inspired by the previous findings, we tested them in our system. We depleted DNMT1 in 
the TetOFF DNMT1-derived NPCs and investigated the expression levels of GFAP, 
along with the transcription factors found to induce astrocyte differentiation (NF1b, 
SOX9)113 and, as a control, the master transcription factor regulating neural 
differentiation – Neurogenin2 (NEUROG2) (245; FIG 43A). Remarkably, we observed that 
the expression of SOX9 was elevated in the DNMT1-depleted NPCs compared to the 
control cells. Even though the expression levels of NEUROG2 changed in the DNA 
hypomethylated cells as well, the difference was not statistically significant. We did not 
detect the expression of GFAP in either condition, thus, DNMT1-depletion is insufficient 
to trigger and complete the entire glial differentiation in human NPCs in vitro (FIG 42A). 
When we induced the differentiation towards glia via the addition of LIF for 2 days, we 
saw that the expression levels of both SOX9 and NF1b increased in both wild-type and 
DNMT1-depleted NPCs, with regard to respective controls (FIG 43A). Despite the 
presence of these glia-specific transcription factor, we did not detect GFAP mRNA in 
either of the conditions (FIG 43A). We hypothesize that additional environmental stimuli 
might be required to trigger expression of this glial differentiation marker in hESCs, even 
in the DNMT1-deficient state. Indeed, a special astrocyte medium is used to differentiate 
human NPCs into astrocytes246. Similarly to the LIF treatment experiment, culturing the 
DNMT1-deficient NPCs in the astrocyte medium did not result in an increased expression 




Figure 43. DNMT1 depletion leads to an increase in SOX9 in the presence of JAK-
STAT agonist. A. Bar graph depicting qRT-PCR analysis of NPC expression of 
neuronal and glial genes. B. Bar graph of representative qRT-PCR analysis of the 
expression of SOX9, an astrocyte TF that is a known JAK-STAT signal transduction 
pathway target in TetOFF DNMT1 hESCs. N=5. C. Bar graph depicting qRT-PCR 
analysis of the expression of NF1b, a glial TF that is not a known JAK-STAT signaling 
pathway target, in TetOFF DNMT1 hESC line. Cells in A., B. and C underwent DNMT1-
depletion for a total of 8 days in the presence of 2µg/mL doxycycline. LIF treatment: 
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48h, 1000U. D. Bar graph representing the results of qRT-PCR analysis of SOX9 
depletion in degDNMT1 hiPSCs. The cells were DNMT1-depleted for a total of 8 days 
and the LIF treatment was 48h long in the presence of 500U LIF. Error bars: SD. * 
pval≤0.05; ** pval≤0.005; *** pval≤0.0005; n.s. – not significant. N=2. 
 
Taken together, the human NPC deficient for DNMT1 did not spontaneously differentiate 
into astrocytes, nor was the glial differentiation induced shortly after exposing cells to 
astrogenesis-promoting conditions, as this was the case for mouse DNMT1KO NPCs. 
This could be an inherent difference between mouse and human NPCs, or a technical 
difference in the propensity to differentiate between primary and in-vitro derived NPCs. 
Nevertheless, our results demonstrated that SOX9 – one of the main transcription factor 
driving glial development, was significantly upregulated in human DNMT1-deficient 
NPCs compared to controls. Furthermore, LIF treatment for two days was sufficient to 
increase SOX9 expression further in control and DNMT1-deficient NPCs. This is 
consistent with SOX9 being a direct target of JAK-STAT signal transduction pathway247 
We hypothesize that cells with the reduced levels of DNA methylation are more prone to 
mount an unrestricted response to a signaling cue.  
Strikingly, when instead of the NPCs, we repeated the experiment in the TetOFF DNMT1 
hESCs (where the cells were depleted of DNMT1 for 6 days, followed by 2 days of LIF 
treatment) we also saw a statistically significant increase in the expression of SOX9, but 
not the negative control NF1b in the DNA hypomethylated cells (FIG 43B and C). Next, 
we sought to reproduce these results in the degDNMT1 cell line (FIG 43D). Exposure to 
LIF elicited a statistically significant upregulation of this transcription factor in DNMT1-
deficient, but not control cells. Of note, unlike the TetOFF DNMT1, the degDNMT1 cells 
expressed a basal level of SOX9 in the control and the DNMT1-deficient state. 
Why was SOX9 upregulated in the presence of LIF in the DNMT1-deficient, but not 
control hESCs? We hypothesized that the global loss of DNA methylation could affect 
the chromatin accessibility of SOX9 enhancer regions and enable transcription of this 
gene exclusively in the DNA hypomethylated cells. To further explore this possibility, we 
investigated the changes in DNA methylation levels on the known SOX9 enhancers in 
control and the DNMT1-deficient hESCs using our scRRBS data (CHAPTER 3). 
SOX9 is a transcription factor important for the development and function of diverse 
tissues. Aside from glial differentiation, SOX9 is indispensable for chondrocyte and testis 
gene regulation248,249. Mutations in a single allele of SOX9 results in a severe 
developmental defect called campomelic dysplasia (CD)250, which results in a pleiotropic 
phenotype including skeletal malformations and sex reversal in male patients. Multiple 
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enhancers of SOX9 have been identified through studies of CD cases resulting from 
mutations in non-coding loci251 and mutagenesis approaches252. We sought to compare 
the DNA methylation status of SOX9 enhancer loci in the control and DNMT1-depleted 
cells. 
 
Figure 44 SOX9 enhancers lose DNA methylation in the absence of DNMT1. Heat map 
depicting scRRBS DNA methylation averages of three SOX9 enhancer regions in hESCs 
under control conditions or after DNMT1 depletion for indicated period of time. 
 
We identified three enhancer regions that were represented in our sequencing data with 
enough coverage for further analyses. Interestingly, these regions were all highly 
methylated in control cells (mean methylation of 82%, 75% and 99%, respectively.; FIG 
44) which is consistent with no detectable gene product. In turn, after 8 days of DNMT1 
depletion, their methylation was reduced to 35%, 0.4% and 17%, respectively. Further 
experiments will be required to identify the role of DNA methylation in indirectly 
controlling SOX9 expression. Deeper coverage of DNA methylation data combined with 
TF binding motif analysis, will be instrumental to elucidate the requirement for the JAK-
STAT signaling-dependent in the SOX9 activation in the normal development (such as 






Among genes upregulated in response to global DNA hypomethylation, the Activin/Nodal 
signaling pathway drew our attention in particular. Not only is that pathway essential for 
the survival of hESCs, but also the deregulation of its components (especially LEFTY1) 
was consistent across single-cell and bulk RNAseq measurements and further confirmed 
by qPCR.  We therefore examined the impact of their protein products, morphogens: 
NODAL and LEFTY1, on the hESCs proliferation. Both the addition of the recombinant 
LEFTYB, as well as its ectopic overexpression had a negative impact on the hESC 
growth. In contrast, the NODAL treatment or overexpression did not exert any visible 
effect on these stem cells. In order to directly probe the impact LEFTY1 upregulation 
could elicit on the loss of fitness of DNMT1-deficient hESCs, we knocked out either one 
or both alleles of LEFTY1 in the TetOFF DNMT1 background. The depletion of LEFTY1 
partially restored the stunted growth of the DNMT1-depleted cells in the late (passage 
2), but not the early (passage 1) time point, consistent with the timing of LEFTY1 
expression in the DNMT1-deficient hESCs. 
While LEFTY1 is a negative regulator of hESC growth, our study of NODAL and LEFTY1 
expression in HEK293 cells demonstrated that the loss of DNMT1 is not sufficient to 
cause the expression of these morphogens. NODAL and its inhibitors could have been 
upregulated in the hypomethylated hESCs by the virtue of being regulated by SMAD2/3, 
rather than directly orchestrating the expression of downstream genes. We therefore 
investigated if the global DNA hypomethylation-induced changes in gene expression 
could be explained by activity of the Activin/Nodal-stimulated signal transduction. Our 
bioinformatics analysis demonstrated that nearly a quarter of genes upregulated in 
response to DNA hypomethylation are previously described targets of the Activin/Nodal 
signal transduction pathway. Surprisingly, the targets were not specific to hESCs, but 
rather to mesendoderm, a lineage derived from pluripotent cells in response to the WNT 
and Activin signaling pathways, even though no WNT was supplemented in the medium. 
This change in expression could have been executed significant increase in the 
expression meso- and endodermal transcription factors, which followed the loss of 
DNMT1 in hESCs.  
Depletion of DNMT1 in hNPCs in the presence of LIF resulted in an increased expression 
of glial marker and JAK-STAT target SOX9. Strikingly, loss of DNMT1 facilitated the 
activation of SOX9 in the presence of LIF in hESCs as well. These results suggest that 
the changes in gene expression upon global DNA hypomethylation are influenced by the 
environment of the cells. Comparison of gene expression between hESCs and DNMT1-
deficient cells demonstrates necessity of DNA methylation as a licensing factor in 
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response to all the environmental cues that otherwise would be instructive to elicit an 
aberrant transcriptional program.  
The fact that the DNMT1-deficient hESCs did not uniformly differentiate into endoderm 
could be explained by multiple reasons: (1) the lack of WNT, another signal transduction 
pathway crucial for mesendodermal development, (2) the inhibitory effect of FGF present 
in the medium or (3) the inability of the DNA hypomethylated cells to inhibit the 
expression of pluripotency factors, which are incompatible with the new identity (such as 
POU5F1), which has been reported before96. 
The aberrant gene expression downstream of the Activin/Nodal signal transduction in 
the absence of DNMT1 prompted us to explore if changing the culture conditions to 
exclude extracellular signal cues could result in a rescue the loss of fitness of the 
DNMT1-depleted hESCs. Temporal ablation of signaling during NPC derivation did not 
improve the growth of DNA hypomethylated cells in comparison to controls under the 
same conditions, suggesting other, cell-autonomous mechanisms are responsible for the 























7.1 The epigenetic landscape 
 
Over the course of development, a totipotent cell undergoes differentiation into all the 
cell types of an organism. Totipotent cells give rise to pluripotent cells, which have a 
restricted potential, because they can become one of the three germ layers, and can no 
longer commit to the extraembryonic lineage. Each subsequent commitment to a new 
cell type restricts the number of possible cell states that can be achieved, until the cell 
commits to a final function, thus becoming terminally differentiated. 
Conrad Waddington described that process in the metaphor of a ball (representing a cell) 
rolling down a rugged hillside (FIG 45A)253. The ball falls into one of the valleys and 
continues down this specific route, until it meets an inflection in the landscape, where it 
can again roll in one of several possible directions. At the same time, the slope and the 
hills prevent the cells from rolling over to the neighboring valley. In the same way, cells 
cannot abruptly change their identity by switching to a parallel differentiation route. 
Altogether, the route taken by the cell determines where it eventually lands (which 
terminally differentiated cell fate it assumes).  
 
Figure 45. The Waddington landscape.Adapted from253. 
The topology of this landscape is underpinned by ropes anchored to the ground (FIG 
45B). Each anchor represents a gene exerting its influence on the shape of the 
landscape above through a set of interconnected ropes. Although genes are the ultimate 
anchor points, their action is modulated through the chemical properties of gene products 
(ropes), which can interact with one another and the environment, changing the ultimate 
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shape of the landscape above the genes – an epigenetic landscape (greek “epi”, 
meaning “above”)253.  
Decades of research identified a vast repertoire of complex processes that regulate gene 
expression in a DNA sequence-independent manner. This is orchestrated by chromatin 
– an entity composed of the DNA and nucleosomes, which carry posttranslational 
modifications, that can alter the binding capabilities of proteins initiating gene expression. 
Such modes of regulation offer a platform for genome interpretation.  
Transcription factors take advantage of permissive environment to bind their recognition 
motif. While the short binding motifs are found in multiple loci across the genome for 
each transcription factor, only a fraction are actually bound254. The specificity of 
transcription factors is also controlled by other means, such as combinatorial binding of 
two or more factors. Furthermore, DNA and chromatin modifications can act refractory 
to transcription factors by blocking the binding. For example, the methylation of cytosines 
in the DNA can inhibit DNA-binding proteins directly by altering their binding motif, or 
indirectly via recruiting methyl-binding proteins (MBDs), which occupy methylcytosine-
marked loci255.  
Chromatin modifications, DNA methylation and transcription factors can integrate 
extracellular cues and, altogether, these variables shape the Waddington epigenetic 
landscape. How exactly the cell-autonomous and non-cell-autonomous cues are 
reconciled and integrate at chromatin to instruct a cell for a lineage commitment has 
been an area of intensive research.   
 
7.2 What happens in the absence of instructive signals? 
 
Pluripotent stem cells can exit their self-renewing state to differentiate into ecto-, meso- 
or endoderm. In vivo genetic experiments elucidated multiple signal transduction 
pathways, which are essential for these differentiation processes216. However, can a cell 
autonomously commit down a differentiation pathway in the absence of environmental 
stimuli that supports either self-renewal or lineage commitment? Or, to put it in the 
metaphor of Waddington pathway, does a single “valley” constitute the preferred 
direction of differentiation for a cell? This concept of a “default pathway” was explored in 
elegant experiments by Tropepe and colleagues256. The culture of mouse embryonic 
stem cells in the absence of any signaling molecules resulted in a spontaneous 
differentiation towards the ectoderm. The explanation to this finding was proposed by 
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Argelaguet and colleagues, who found that the DNA methylation and chromatin 
accessibility profile of pluripotent and ectoderm cells are more similar to one another 
than to the primitive streak-derived meso- and endoderm191. Active remodeling of 
chromatin is, therefore, required to enable the differentiation towards the latter two germ 
layers. In line with these findings, active remodeling of the pattern of DNA methylation 
occurs during the gastrulation and is guided by the DNA demethylating TET enzymes. 
Perturbation of their function in the mouse embryo result in defects in gastrulation and 
the formation of mesoderm-derived tissues73.  
 
7.3 How can DNA methylation contribute to maintaining hESC 
pluripotency? 
 
The work presented here explored how the withdrawal of one factor controlling the shape 
of Waddington landscape, namely DNA methylation, affects the self-renewal of human 
embryonic stem cells. We found that, unlike the results presented in the “default 
pathway” model, cells with reduced levels of DNA methylation did not differentiate 
towards the ectoderm. We believe these results are consistent with the presence of 
TGFß in the hESC medium, as the early observations of the “default pathway” claimed 
that the TGFß-superfamily of signal transduction factors act refractory to the default 
commitment256. The human ESCs are cultured in a medium which contains TGFß and 
FGF - these signaling cues promote self-renewal, but can also induce a lineage 
commitment. These contradicting roles are reconciled through the action of NANOG, 
which imposes stasis on lineage commitment215.  
Could the withdrawal of the extracellular signaling cues permit the “default pathway” 
differentiation of the DNMT1-deficient hESCs? We tested this possibility during the hESC 
differentiation toward the neural progenitor cell lineage. We observed that these cells 
were not viable. Whether DNA methylation was necessary for the differentiation towards 
the ectoderm or for sustaining the ectoderm lineage is a topic for future studies.  
We describe how the depletion of DNMT1 in hESCs under normal culturing conditions 
resulted in an upregulation of the meso- and endoderm-specific transcription factors 
followed by the expression of the TGFß targets specific for these lineages. Together with 
our previous study, this work demonstrated that the DNMT1 depletion in hESCs led to 
the upregulation of genes associated with the embryo posterior fates (meso- and 
endoderm), such as NODAL or LEFTY1136,226,257. 
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Importantly, this effect is not a general response to the DNMT1 depletion, as it was not 
present in the DNMT1-deficient cells devoid of the TGFß signaling. We hypothesize that 
the global DNA hypomethylation led to a misinterpretation of the signaling cues – the 
TGFß mediated signal transduction prompted the incorrect activation of the 
mesendoderm-specific targets of the SMAD proteins (effectors of the TGFß signaling)258, 
instead of exclusively to loci promoting self-renewal. 
Can the loss of DNA methylation alter TF binding? In vitro and in vivo studies 
investigating the TF specificity to either methylated or unmethylated DNA reported that 
various TFs show preference to methylated or unmethylated DNA, or not exhibit a 
preference at all63,259,260. The answer is, therefore, highly context-specific. Whether the 
SMAD family of transcription factors are DNA methylation sensitive is not known. Due to 
the SMAD binding as obligate heterotrimers, they were not thoroughly characterized in 
systematic in vitro assays. Testing the specificity of the SMAD binding in response to the 
different signal transduction pathways and with different co-factors is, therefore, an 
interesting direction for future study.  
Curiously, when we introduced additional molecules capable of inducing meso- and 
endoderm lineage commitment, we observed a more robust transcriptional response in 
the DNMT1-deficient hESCs compared to control. We hypothesize that the loss of DNA 
methylation does not activate genes, but rather renders their loci permissive for TF 
binding, such that newly induced transcription factors (effectors of signal transduction 
pathways) can easily activate their targets in the more accessible chromatin 
environment. Investigating whether the global loss of DNA methylation changed the 
binding specificity of signal transduction pathway effectors or other transcription factors 
is necessary to better understand the transcriptional changes underlying the DNMT1 
depletion in hESCs. Combining our data on the DNA methylation level at the enhancer 
elements with the information on transcription factor binding and the nascent 
transcription (for example, after metabolic labelling of RNA with the SLAM-seq 
method261), could provide a comprehensive picture of the stepwise induction of 
differentiation by environmental factors in the presence and absence of DNA 
methylation. 
DNMT1 depletion has profound effects on the proliferation of hESC, which manifests 
itself shortly after DNA methylation is depleted throughout the genome. Transcriptional 
deregulation could be one of the factors that contributes to such loss of fitness. It could 
act both through the upregulation of negative regulators of the hESC growth, such as 
LEFTY1, and conflicting transcriptional programs being active simultaneously (for 
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example, the pluripotency program versus the mesendodermal program).  The rapid 
onset of the loss of fitness of the DNMT1-deficient hESCs could also result from a 
deregulation of other, transcription-independent mechanisms of maintaining cell 
homeostasis. Investigating the immediate consequences of DNMT1 depletion in more 
detail is another area open to future studies. 
 
7.4 DNMT1KO in mouse embryonic stem cells 
 
Reduction of the global level of DNA methylation is an essential step during early 
embryonic development in vivo. Both the cells of the inner cell mass of the blastocyst 
and the primordial germ cells contain significantly less DNA methylation than somatic 
cell types. Whether there is a common mechanism guarding these cells from the 
negative effects of reduced DNA methylation is not known. Surprisingly, the knockout of 
DNMT1 has a completely different phenotype in both the cell types. Loss of DNMT1 in 
the PGCs led to a precocious terminal differentiation and, in the long term, infertility262. 
In contrast, the depletion of the maintenance DNA methyltransferase, or even all three 
DNA methyltransferases, did not affect mouse embryonic stem cell self-renewal, 
however, it disabled them from differentiating into the three germ layers94. In agreement 
with these observations, DNMT1KO mESCs are unable to form teratomas when injected 
into immunocompromised mice263. Of note, previous studies demonstrated that several 
factors associated with chromatin repression, such as Polycomb Repressive Complex 2 
or Mbd3 subunit of the NuRD deacetylase complex are also dispensable for mouse 
embryonic stem cell self-renewal, but essential for differentiation and in the somatic 
lineages264. The differences in how chromatin is assembled and maintained in embryonic 
stem cells compared to somatic cells to tolerate such deep changes in chromatin 
landscape is an exciting question for future studies. 
How mouse embryonic stem cells specifically cope with the loss of DNA? It is possible 
that even if new transcription factor-binding motifs become accessible in the DNMT1-
deficient mESCs, these cells simply lack the transcription factors to bind them and 
prompt spontaneous differentiation. A study of DNaseI hypersensitive binding sites that 
arise upon DNA demethylation in mESCs found that few transcription factors expressed 
in mESCs created novel binding sites259. How many TFs in somatic cell lines modify their 
binding in vivo in response to global loss of DNA methylation is not known. 
Alternatively, other mechanisms of transcriptional repression, such as by the 
H3K27me3-mediated silencing (a mark mediated by the Polycomb repressive complex) 
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could repress hypomethylated loci in the absence of DNMT1265. The relationship 
between DNA methylation, chromatin accessibility and gene expression is complex. 
DNA methylation and the Polycomb-mediated H3K27me3 chromatin mark are mutually 
exclusive and, in the absence of DNMTs, the Polycomb loci were found to spread during 
the transition from primed (more DNA methylation) to naïve (less DNA methylation) stem 
cell states265. Recent study demonstrated that the “confinement” of the Polycomb 
domains by DNA methylation is necessary for the local compaction and maintaining the 
higher-order chromatin structure266. Strikingly, the depletion of DNMTs led to a loss of 
some higher order chromatin contacts, however, the impact of these changes on gene 
expression was very limited266. Whether the spreading of H3K27me3 occurs in other cell 
types with reduced levels of DNA methylation (for example, DNMT1-deficient somatic 
stem cells), and how that affects both the chromatin structure and gene expression is an 
interesting direction for future studies. 
 
7.5 DNMT1KO in somatic stem cells 
 
Our findings have pronounced implications for the previous studies of DNMT1KO in 
somatic stem cells. The propensity of the DNMT1-deficient cells to transdifferentiate or 
spontaneously differentiate into one of the possible lineages has been reported in 
multiple lineages (described in detail in the Introduction section). For example, the 
preference towards lymphoid versus myeloid differentiation in the DNMT1KO HSCs 
could be dictated by the change in the interpretation of extracellular cues. The interaction 
with bone marrow stromal cells267 and the cytokine-inducted transcription mediated by 
interleukin-7 (IL-7)268 are both important for the differentiation of lymphoid cells. 
Curiously, the DNMT1KO phenotype manifested itself only after knockout HSCs were 
transplanted into wild type donors, but not in the DNMT1KO bone marrow of mutant 
mice. Whether the DNMT1KO HSCs misinterpret the stimuli from the wild type 
environment and prematurely differentiate towards the lymphoid lineage remains to be 
elucidated.  
Could the loss of DNA methylation enable signal transduction that does not specifically 
lead to stem cell self-renewal or differentiation? A study of DNMT1-deficient myoblasts 
demonstrated that myogenic differentiation is impaired in the DNA hypomethylated cells. 
Liu and colleagues observed trans-differentiation of the mutant myoblast cells to 
osteoblasts, which was exacerbated by the BMP signaling101.  
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We previously reported that the knock-out of de novo methyltransferase DNMT3A in 
hESCs led to an aberrant expression of transcription factors (including SOX9) during 
attempts to differentiate these cells into ecto- or mesoderm257. In the experiment 
described here, the LIF treatment of the DNMT1-deficient hESCs caused an activation 
of SOX9 – a downstream JAK-STAT pathway target, which is not normally activated 
during human embryonic stem cell differentiation towards any of the three germ layers. 
DNA methylation could act as a barrier not only to differentiation, but also other cell fate 
changes. Whether an aberrant activation of transcription factors in DNMT1 or DNMT3A-
deficient cells led to the subsequent binding and regulation of their target loci is an 
important follow-up question for future consideration. 
Altogether, our study presents a possible mechanism by which DNMT1 depletion 
induces a range of seemingly dissimilar phenotypes across various stem cell types. The 
knockout of DNA maintenance methyltransferase leads to global DNA hypomethylation 
which, in turn, could render the chromatin more permissive to transcription factor binding. 
This would lead to various gene activation depending on the cell type and extracellular 
environment, thus producing different outcomes.  
 
7.6 Maintaining cell identity 
 
The imperative character of transcription factors in the process of determining cellular 
identity was demonstrated by Yamanaka and colleagues in the Nobel prize-winning 
discovery, that ectopic expression of four transcription factors can reprogram fibroblasts 
into pluripotent stem cells, essentially allowing the cells to “roll upwards” the epigenetic 
landscape of Waddington135.  
Nevertheless, reprogramming to pluripotency happens with a low efficiency. The process 
is inhibited by the barriers, which safeguard somatic cell identity. As a byproduct of 
reprogramming induction, some cells stop at an intermediate stage and fail to reprogram. 
DNA methylation inhibition using AzaC resulted in increased reprogramming 
efficiency269. Moreover, partially reprogrammed cells which failed to form iPSCs were 
characterized by high DNA methylation levels at key pluripotency loci (such as POU5F1) 
and were able to reprogram completely in the presence of DNA methylation inhibitor269.  
Recent RNAi screens identified several other factors, which are refractory to iPSC 
generation. Chromatin assembly factor (CAF-1) is a histone chaperone complex, the 
suppression of which loosened the chromatin structure, reduced H3K9me3 levels at 
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regions normally resistant to reprogramming and thus increased both speed and 
efficiency of reprogramming. Maintaining proper chromatin structure is also refractory to 
changing the cell fate, the equivalent of “rolling sideways” in the epigenetic landscape of 
Waddington. Increasing chromatin accessibility by the means of knocking down the 
subunits of CAF-1 complex enhanced transdifferentiation from the B cells to 
macrophages and from the MEFs to neurons270.  
Multiple studies reported a negative correlation between DNA methylation and chromatin 
accessibility271,272. Notably, when the two variables were compared in pluripotent stem 
cells induced to differentiate, the correlation between them decreased272. This suggests 
that as the cells commit to a somatic lineage, the methylated DNA becomes more 
prevalent. We hypothesize that DNA demethylation during reprogramming induced by 
Mikkelsen and colleagues, as well as by the DNMT1 depletion in this study, promotes 
chromatin relaxation and increased binding of transcription factors269. In agreement with 
our hypothesis, loss of nearly all (95%) total DNA methylation in a DNMT hypomorphic 
cell line increased the number of accessible sites272.  
 
7.7 DNA hypomethylation and cancer 
 
The increased accessibility of unmethylated DNA to transcription factors could not only 
contribute to reprogramming or transdifferentiation, but generally increase transcriptional 
promiscuity, which could be a potential mechanism of tumorigenesis.  
The DNA methylation landscape in cancer cells is characteristic – high local 
hypermethylation of CpG islands combined with global hypomethylation273,274. In 
contrast, the bulk of a healthy methylome is hypermethylated, with puncta of 
unmethylated CpG islands. How that change in the epigenome of cancer cells is 
achieved is not yet understood, however, mutations in DNMTs, as well as their 
overexpression, have been identified in multiple cancer types275–277. Furthermore, 
previous studies in patients with Chronic Lymphocytic Leukemia (CLL) reported that 
changes in the global DNA methylation pattern precede cancer278. A different study of 
tumorigenesis in the haematopoietic lineage identified mutations in DNMT3A which 
confer repopulation advantage to the hematopoietic stem cells and lead to Acute Myeloid 
Leukemia (AML)279. Whether the changes in the DNA methylation landscape are 
causative to the tumorigenic transformation and by what mechanism is not known. 
However, our previous study identified that transcriptional variability is increased in 
DNMT3A and 3B/DKO knockout hESCs providing a potential explanation257. The global 
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DNA hypomethylation of pre-cancer cell could result in an increased transcription of 
various genes followed by positive selection for cells with (1) high expression of self-
renewal genes or (2) silencing of tumor suppressor genes via promoter 
hypermethylation. As both the tissue vascularization and the cell growth are dependent 
on extracellular signaling, investigation into whether a reduction of global DNA 
methylation levels could lead to an increased response to these signals is an interesting 
direction for future studies. 
Despite mutations in DNA methyltransferases reported in cancer, DNA methylation is 
indispensable for transformed cells. In fact, the DNMT1-depletion in cancer cell lines 
results in DNA damage and apoptosis. Curiously, no apoptosis or DNA damage were 
reported in most of DNMT1KO somatic stem cells102,103,105. Likewise, we did not observe 
such a phenotype in the hESCs, despite the extensive investigation of the DNA damage 
markers, as well as the mitotic abnormalities. This difference in the phenotype could 
stem from the use of different models. Cancer cells are known to selectively 
hypermethylate the CGI promoters of tumor suppressor genes280, such as at the Ink4a-
ARF locus281. The loss of DNMT1 could lead to the de-repression of these factors that 
would eventually mediate senescence and apoptosis via imposing cell cycle arrest.  
 
7.8 The role of DNA methylation maintenance in embryogenesis 
 
Nearly three decades ago, Li and colleagues demonstrated that DNMT1 is essential for 
the mouse embryonic development76. Crossing the DNMT1 heterozygous mice yielded 
no homozygous pups brought to term. Further investigation revealed an embryonic 
lethality before the embryonic day 12.5 (E12.5). Compared to their wild-type littermates, 
the E10 DNMT1-knockout embryos were smaller and developmentally delayed. 
Abnormalities observed in these embryos included also defects in somitogenesis, neural 
tube closure, allantois and no blood formation, accompanied by an increase in apoptotic 
cells76. How the loss of DNA methylation resulted in this broad range of developmental 
phenotypes is not known.  
The authors pointed out that the allantois abnormal structures were observed before in 
parthenogenetic and gynogenetic embryos282 and were thus likely caused by loss of 
imprinting. One of the crucial roles of DNA methylation is maintaining monoallelic 
expression of some genes known as imprinted genes. Maternal contribution of oocyte-
specific isoform of Dnmt1 (Dnmt1o) mRNA is essential for the imprint preservation during 
the pre-implantation reprogramming of the global DNA methylation patterns283. Lack of 
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maternal Dnmt1o resulted in loss of imprinting (LOI) on some imprint control regions and 
a variety of phenotypes. The study reported embryo resorption in the last trimester of 
pregnancy or stunted growth of rare pups delivered to term, despite maintaining a high 
level of global DNA methylation and the somatic version of Dnmt1283. In agreement with 
these results, a knockout of Zinc finger protein 57 (Zfp57), which is responsible for 
maintaining imprints on many loci, phenocopies the Dnmt1o depletion284. Altogether, the 
maintenance of imprinted genes is essential for embryonic development, however, the 
LOI does not fully explain the lethality around E10 in the full Dnmt1KO embryos. 
Although the Dnmt1KO embryos were noted to develop normally from E1-7, the analysis 
of E9.5 noted no blood or blood vessel formation, a process which begins at E7, with the 
migration of mesoderm cells to the yolk sac to form hemangioblasts285. These 
progenitors of blood and epithelium develop outside of the embryo in so-called blood 
islands and form structures essential for the transport of nutrients to the developing 
organism. A knockout of Flk1, a gene encoding vascular endothelial growth factor 
(VEGF) receptor is essential for the formation of hemangioblasts. Homozygous Flk1 
knockout embryos fail to form blood vessels and blood and die in utero around E9.5, 
mid-somitogenesis286. The Dnmt1KO embryo lethality could, therefore, also result from 
a lack of blood and vasculature. Whether such lack of blood formation in the Dnmt1KO 
embryo occurs due to the disruption of the VEGF-mediated gene expression or via 
another mechanism remains to be determined. Further studies on the role of DNA 
methylation in the VEGF signaling and early hematopoiesis, for example using in vitro 
cultured hemangioblasts, could shed light on the developmental lethality and delay of 
Dnmt1-deficient embryos. 
The indispensability of DNA methylation for embryo development and tissue 
homeostasis is well-documented, yet the precise mechanisms by which DNA 
methylation exerts its functions in these processes is still unknown. Our work presented 
here opens new study trails for in vitro and in vivo research, which could bring insight 
into how chromatin integrates extracellular signals and helps maintain cell identity, which 
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Table 8. Top 100 up- and downregulated differentially expressed 
genes 
   
Upregulated genes  Downregulated genes 
d1 d2 d3 d5 d6 d7 d8  d1 d2 d3 d5 d6 d7 d8 
B3GNT7 B3GNT7 
NPPB 




1 MT-ND3 MT-ND2 
SYTL2 ARRDC3 MYL7 APOA2 DKK1 LCN15 NPPB  GABRP NACA IFITM2 CLDN11 AMFR RPL19 COX7C 






RHBDD3 MYL7 APOA1 CDH6  RPL13A RPLP2 
MTRNR2L





CBR1 SYTL2 XAGE1B APOA1  HSPD1 RPL4 
AXL 




FAM110D PLSCR2 XAGE1A PRSS2  SLC25A3 TUBA1B 
ZNF688 
HSPD1 RPL10 MT-ND4 UBA52 
AKAP9 DCLRE1C 
SPP1 




RPS4X CFL1 RPS2 MT-CYB 
SLCO1C1 HIST1H4C 
FST 




RACK1 ALDOA MT-ND5 COX5A 
CCND1 AKAP9 PON2 SYTL2 RHBDD3 MAEL XAGE1A  RPL10 RPL7A MT1G PPIA RPS3 GABRP GSTP1 
DHDDS FABP3 
TMEM9
7 CEBPZOS CBR1 GAGE2A APOA2  UBA52 UBE2C 
TNFSF13
B MT-ND2 CD24 ATP5A1 CCT5 
NSMAF ARID4B 
HMGC
S1 STAG3 DDIT3 
FAM110
D LGI1  RPL4 CTSC 
PRRT2 
RPS28 PPIA KRT18 RPL35 
APC BRD8 NODAL VCY MAP3K13 GAGE12F CST1  RPL14 MT-CYB  RPL28 HSPD1 MT-ND4L RPS12 
RAF1 FST ACAT2 VCY1B FAM184A MYL7 GAGE2A  RPL29 ATP1B3  MT-ND5 RACK1 RPS12 TPM3 
C19orf48 MYDGF  CER1 EPHA4 CST1 MAEL  NACA EDF1  
C14orf16
6 AXL RPS5 IFITM1 
STAG3 VSIG10  HAS2 CEBPZOS SYTL2 
GAGE12
F  RPL18 RPS12  KPNA2 HHLA1 UBA52 EIF3M 
SPP1 ANKRD12  LSP1 LEFTY1 RPL10L MYL7  RPS12 RPS2  EPCAM RPL18 MT-CYB RPL11 
DCLRE1C NR6A1  AGAP4 EOMES PLSCR2 RPL10L  MT-CO3 SLC2A3  MT-CYB LDHB UBB RPS2 
RNF121 AGAP4  CCND1 SMARCA2 DSCR8 CXCR4  MT-ND6 RPL10  
HIST1H2
BK RPS4X ENO1 RPS15A 
PEF1 C19orf48  GTSF1 INPP5F 
FAM184
A CROT  RPS2 MT-CO3  DYNLRB1 
HIST1H2
BK HDAC2 ATP5I 
CCNL2 TNFRSF12A TAGLN HAS2 DDIT3 GDF15  RPS3 MT-ND4  MT-ND1 OAT PGAM1 RPL19 










6 HSPA8 UBE2C 
WDR6 CCND1  RASEF AGAP4 RHBDD3 SHISA2  RACK1 EIF1  S100A10 DYNLRB1 MDH2 
NDUFA1
3 
FST MUM1  BAX C12orf4 HAS2 
FAM184
A  MT-CYB CFL1  FH RPS28 RPL4 HSPE1 
SLC5A6 BCL11A  AKAP9 DPPA5 KEL BRDT  MT-ND5 DDX39B  VDAC1 EDF1 PSME2 ATP5A1 
ZNF75A ZNF625  CDK10 FST CER1 TTN  RHOA ATF7IP2  KIN SYPL1 PRDX6 CLDN11 
TNFRSF1
2A SPP1  DPPA5 CADM1 BRDT PRTG  HHLA1 LDHB  CSNK2B S100A10 GPX1 NPM1 
WDR74 RNF34  C19orf48 MAGEA6 LEFTY1 PLSCR2  RPL7A IFITM3  AXL ATP6V1F RPL29 RPLP2 
KANSL2 PAN3  DDX55 TAGLN 
TNFRSF1
2A AMPD2  MT-ND1 MPV17  GDF3 MT-ATP8 PRDX1 SLC25A3 
THOC6 TIMP4  TSPAN4 DCLRE1C 
MAP3K1
3 PLK2  RPS4X HSPD1  CDA EPCAM EIF2S1 NDUFS8 
NSD1 GOLIM4  TRDN STAG3 EPHA4 RAB17  TUBA1C CLDN11  LDHA VIM HNRNPDL PGAM1 
SLC3A2 SRSF6  CCNL2 CER1 P3H4 
FAM110
D  IFITM3 
NADSYN
1  PGK1 PIGU RPL7A RPS25 
ING5 C6orf62  LPP C19orf48 BBS9 VCX  RPS28 MDH2  
SH3BGRL
3 LDHA NACA ATP5G2 
MCM5 STAG3  CYP3A5 CDK10 
SMARCA
2 BBS9  FXYD5 
C17orf4
9  NABP1 
MAPK1IP
1L HHLA1 CUTA 
VSIG10 CENPX  SLFN13 CD58 NSMAF VCX3A  MT-ND2 
HNRNPA
1  FXYD5 EDNRB TUBA1C RPL35A 
IFRD2 EBP  LUZP1 SLC3A2 CEBPZOS CBR1  IFITM2 RPL28  MT-CO1 DCXR EIF3M EIF3C 
RABGAP
1L CTTN  
TMEM10
6C LPP LMO7 SYTL2  MT-ND3 PRDX6  IFITM2 RPL28 PDHB RPL18 
SURF2 ATRX  CADM1 BAX CCND1 DSCR8  MDH2 SLC25A3  MT-ATP8 GDF3 FKBP1A RPL29 
MYDGF SRPRB  ACADVL CCND1 RCOR3 SAXO2  RPL28 RACK1  ZNF688 CSNK2B ILF2 RPL24 
HM13 MCRS1  FSTL4 RASEF STAG3 RHBDD3  CCT8 RPL18  PRRT2 KDELR1 HNRNPA1 COX8A 





TOX4 SYF2  DCLRE1C AKAP9 DCLRE1C CER1  LDHA RPS3  
TNFSF13
B MT-CO1 ATP5G2 BTF3 
MCRS1 
HNRNPH
1  ANKRD12 SPINK9 TNNC1 FN1  
MT-
ND4L RHOA   VDAC1 RPL28 GSTO1 
DDX55 ANKRD10  SLCO1A2 HUWE1 RUNX1T1 ZNF677  CSNK2B MT-ND5   PGK1 PSMB2 
PGRMC
1 
ZWINT KANSL2  SPINK9 DCAF8 FN1 
TMEM6
3A  KIN KDELR1   ZNF688 RHOA GPX1 
BAX METTL1  CHD9 MYDGF TXNRD2 
CCDC14
4A  CSTB SYPL1   KIN MT-ND6 RAN 
GPATCH8 MAP1B  INTS11 MCM5 GTSF1 HAS2  HHLA3 
S100A1
3   CAPNS1 ATP5G3 
WDR83
OS 
IGF2BP1 POLR3E  MCM5 
AC01581
3.2 DPPA5 NFRKB  CRABP1 RPS28   CSTB TPM3 SNRPD3 
AUP1 CCNL2  PDE4DIP ANKRD12 LRIG3 SPATA7  MT-ATP8 BEX4   FXYD5 MT-ND2 RPS3 
BRD8 SURF2  ARID4B GLS TAGLN LEFTY1  VDAC1 TIMP1   CDA TPI1 PSENEN 
WDR73 MRPL1  C19orf60 HIST1H4C APC KEL  DUSP6 AMFR   PRRT2 RPS28 TUBA1B 
NELFCD HMGCS1  INPP5F NODAL FST NDRG4  ZNF688 SUCLA2   
TNFSF13
B BRK1 TUBA1A 
DCP1A DGCR6L  SLC25A37 TRDN INPP5F SHC4  
SH3BGRL
3 FXYD5    BANF1 LSM4 
DGCR6L NELFCD  MRPL28 MTRR APOBEC2 ITGA5  CTSK OAT    CCT8 PSMD6 
MAP1B BAX  FANCA MCRS1 
COMMD
3 LEFTY2  PGK1 CSNK2B    RPL18 RPL38 
TCF7L2 KPNA6  SUOX BCL11A AGAP4 LRIG3  DYNLRB1 RPS4X    RPL10 
TXNDC1
7 
PDCD11 RNF121  LRRTM4 RNF34 GAD1 ACAA1  MT-CO1 IFITM2    RPS3 RPL32 
SERINC5 PIN1  BCL11A DCP1A EOMES SLC38A4  GDF3 PPIH    GANAB ATP5H 
DHCR24 
SLC25A3
7  ZNF124 FSTL4 TSPAN4 
CSNK1G
1  NUDT15 LRRK1    NANS RPL36 
QTRT1 IQCF3  IGF2BP1 YTHDF3 CADM1 RCOR3  
HIST1H2
BK CRABP1    VIM RPL22L1 
TAGLN CTNND1  HMGXB4 WDR74 C19orf48 
RHOBTB
3  CLDN11 
MT-
ND4L    CFL1 
TRAPPC
2L 




S  MT1G CSTB    TIMP1 RPL37 
BRCC3 KANSL1L  NSD1 IFRD2 B3GNT7 STAG3  CDA SNRPA    TUBA1A UBB 
MTRR 
CDC42BP




8 QTRT1  MCRIP2 SERPINB9 AKAP9 LSP1  AMFR TTC9C    GAPDH RPL7A 
PHAX SON  MARK3 GPATCH8 MCRS1 POLE  
TNFSF13
B DCXR    
C14orf11
9 PHB2 




1   DUSP6    C9orf135 CD24 
GPRC5B KNOP1  DCAF8 DCTN5 LPP SYCP3   HIST1H2BK   EDF1 TPI1 
FGFR1 PUS7L  NOL8 SRSF6 SLC3A2 TNNC1   HHLA1    AMFR EPCAM 
SRPRB BAZ2B  FUOM KANSL2 SRSF6 CADM1   EDNRB    
C14orf16
6 RHOA 
ATP2B1 PSMC3  FKBP10 GAD1 CDK10 TNPO2   
S100A1
0    JPT1 PRDX1 
POLR3E TLK1  KIFC3 CBY1 TCF7L2 LAMA1   VDAC1    PPIA HSPA8 
MTG1 ANKIB1  PHAX BRD8 RAF1 CRIM1   GABRP    PCLAF NQO2 
DCTN5 
TMEM20
8  SLC3A2 ESRP1 LPAR6 ANKRD1   MT-ND2    KPNA2 
NDUFB1
1 
LPP NUCB2  GLS NSD1 ZNF84 CDK10   
S100A1
1    TUBA1B PCLAF 
FADS2 FRG1  PDXDC1 ZNF518A SOCS2 EPHA4   PTBP1    RACK1 
C17orf4
9 
CTNND1 TMED1  DGCR6L PHAX SCAF11 LPP   GANAB    MT-ATP8 DECR1 
RSF1 SMC2  NOSIP KNOP1 BRD8 DCAF8   LDHA    RPS4X UBE2I 
ANKRD1
2 FADS1  FGF8 PDE4DIP RNF34 INPP5F   ZNF688    PTBP1 RPL10 
MAP4K5 CDK10  MYDGF SERINC5 SPP1 AGAP4   
MT-
ATP8    
AC08763
2.1 GAL 
SON NKTR  BET1L SON CCNT1 EXOG   MT-ND3    HSPD1 RACK1 
HMGXB4 NUBP2  SPG7 C19orf60 DCAF8 PDXDC1   
SH3BGR
L3    MT-ND1 H3F3A 
CHD9 GPATCH8  HYOU1 SLCO1A2 MYDGF TAGLN   MT-ND1    LDHB SSBP1 
PSMC3 PHAX  CTNND1 SPG7 CYP26A1 RAF1   HHLA3    CDK2AP1 PSMB2 
KNOP1 OTX2  GRB2 BCAS3 SLFN13 LY6E   TUBA1C    DPCD 
HIST1H4
J 





L  MED7 DPY19L4 PAN3 TXNRD2   CTSK    DECR1 POLR3G 
NR6A1 PPP2R2B  C11orf49 SNUPN ZNF518A SUOX   
DYNLRB
1    ZNF688 PIGU 
MAGEA2 FABP7  FRG1 FRG1 
CASP8AP
2 LIFR   KIN    ALDOA SNU13 
RNF34 MTG1  MYO19 SLC11A2 UTRN CCND1   PGK1    DYNLRB1 CFL1 
SCAF11 PWWP2A  MANBAL PWWP2A ERBIN 
ANKRD 
36C  NUDT15    PIGU 
HSD17B
10 
SGPL1 CRBN  FST MED7 BAX PTGR1   GDF3    VSNL1 SUMO2 
ARID4B MCM7  NDUFV1 BET1L PHACTR2 UBE2D4   MT-CO1    SLC25A5 MRPS23 
TMED1 SERINC5  FN1 EXOSC5 RNPC3 SZT2   CAPNS1    OAT NACA 
NDUFV1 
THUMPD
1  BCAS3 
AC00732
6.4 SPINK9 AKAP9   CDA    LDHA ALDOA 
PDE5A DDX55  ZNF808 CTNND1 B2M NR2C2   MT1G    VDAC1 ATP5G3 
MANBAL CCDC66  SCAF11 B9D1 C6orf62 F3   
TNFSF13
B    CSTB MT-ND1 
DKC1 SGPL1  
AC00732
6.4 LAMTOR3 MCM5 CFLAR   PRRT2    
SH3BGRL
3 NME1 
PLEKHA5 HMGXB4  HUWE1 PHACTR2 FSTL4 NFKBIA       KIN CNMD 
LMAN2 TIMM10B  ZNF518A ARL4A ESRP1 BAX       GDF3 KPNA2 
TAX1BP1 RBBP8  MAPK10 C21orf91 DDX55 CYP3A5       FXYD5 CAPNS1 
 
TABLE 9. Top 10 GO terms for differentially expressed genes 
 Upregulated genes    Downregulated genes   
 Top GO terms FDR  Top GO terms FDR 
d1 primary metabolic process  6.43E-09 d1 SRP-dependent cotranslational protein targeting to membrane  9.82E-19 
 cellular metabolic process  5.36E-09  cotranslational protein targeting to membrane 1.02E-18 
 metabolic process 1.64E-08  protein targeting to ER 2.05E-18 
 organic cyclic compound metabolic process 1.46E-08  viral transcription 2.36E-18 
 organic substance metabolic process 1.26E-08  establishment of protein localization to endoplasmic reticulum 2.59E-18 
 
cellular nitrogen compound metabolic process 1.85E-08  
nuclear-transcribed mRNA catabolic process, nonsense-
mediated decay 
3.67E-18 
 gene expression 3.68E-08  viral gene expression 1.28E-17 
 nitrogen compound metabolic process 1.54E-07  protein localization to endoplasmic reticulum 1.94E-17 
 heterocycle metabolic process 7.77E-07  translational initiation 3.61E-17 
 cellular aromatic compound metabolic process 1.50E-07  protein targeting to membrane 6.40E-16 
          
d2 gene expression 1.06E-09 d2 ATP metabolic process 6.68E-09 
 cellular nitrogen compound metabolic process 6.36E-09  viral gene expression 7.84E-09 
 cellular metabolic process  1.05E-08  cotranslational protein targeting to membrane 8.69E-09 
 organic cyclic compound metabolic process 2.27E-08  symbiotic process 8.79E-09 
 metabolic process 2.72E-08  SRP-dependent cotranslational protein targeting to membrane  9.19E-09 
 organic substance metabolic process 1.14E-07  protein localization to endoplasmic reticulum 9.82E-09 
 cellular aromatic compound metabolic process 1.50E-07  translational initiation 1.27E-08 
 nucleic acid metabolic process 3.40E-07  interspecies interaction between organisms 1.32E-08 
 heterocycle metabolic process 4.78E-07  protein targeting to ER 1.44E-08 
 primary metabolic process  6.49E-07  viral transcription 1.69E-08 
          
d5 no statistically significant results   d5 ATP metabolic process 2.93E-09 
      generation of precursor metabolites and energy  5.59E-09 
d6 regulation of execution phase of apoptosis  1.77E-02  oxidative phosphorylation  4.04E-07 
 
negative regulation of execution phase of 
apoptosis 
1.49E-02  ATP synthesis coupled electron transport 2.00E-06 
 negative regulation of molecular function  1.26E-02  cellular respiration 2.30E-06 
      mitochondrial ATP synthesis coupled electron transport  2.33E-06 
d7 nitrogen compound metabolic process 8.14E-08  electron transport chain 4.75E-06 
 cellular metabolic process  9.07E-08  respiratory electron transport chain  5.00E-06 
 macromolecule metabolic process 1.02E-07  energy derivation by oxidation of organic compounds  2.37E-05 
 primary metabolic process  1.22E-07  oxidation-reduction process 2.57E-05 
 organic substance metabolic process 1.41E-07      
 metabolic process 7.49E-07 d6 interspecies interaction between organisms 9.13E-09 
 cellular macromolecule metabolic process 1.69E-05  symbiotic process 1.47E-08 
 nucleic acid metabolic process 3.58E-04  viral process 2.53E-08 
 organic cyclic compound metabolic process 1.03E-03  protein localization to endoplasmic reticulum 6.99E-06 
 cellular component organization  1.20E-03  SRP-dependent cotranslational protein targeting to membrane  1.56E-05 
      cotranslational protein targeting to membrane 1.81E-05 
d8 cellular component organization  2.06E-11  protein targeting to ER 2.55E-05 
 cellular component organization or biogenesis 2.89E-10  viral transcription 2.65E-05 
 cellular metabolic process  2.30E-09  establishment of protein localization to endoplasmic reticulum 2.82E-05 
 
primary metabolic process  4.35E-09  
nuclear-transcribed mRNA catabolic process, nonsense-
mediated decay 
3.16E-05 
 organelle organization 1.25E-08      
 cellular macromolecule metabolic process 1.26E-08 d7 symbiotic process 6.70E-20 
 macromolecule metabolic process 1.32E-08  interspecies interaction between organisms 5.41E-19 
 nitrogen compound metabolic process 1.34E-08  viral process 1.77E-18 
 organic substance metabolic process 3.82E-08  translational initiation 9.31E-15 
 metabolic process 2.19E-07  SRP-dependent cotranslational protein targeting to membrane  2.15E-14 
      cotranslational protein targeting to membrane 3.53E-14 
      viral gene expression 3.86E-14 
      ATP metabolic process 5.58E-14 
      protein targeting to ER 6.56E-14 
      establishment of protein localization to endoplasmic reticulum 9.59E-14 
          
     d8 translational initiation 2.77E-26 
      SRP-dependent cotranslational protein targeting to membrane  4.83E-26 
      cotranslational protein targeting to membrane 9.55E-26 
      protein targeting to ER 3.70E-25 
      establishment of protein localization to endoplasmic reticulum 6.46E-25 
      viral transcription 6.52E-25 
      symbiotic process 1.40E-24 
      
nuclear-transcribed mRNA catabolic process, nonsense-
mediated decay 
1.42E-24 
      viral gene expression 9.00E-24 
      protein localization to endoplasmic reticulum 1.84E-23 
 
Table 10: Top 100 upregulated genes 
overlapping between the listed time points  
Unique Shared 
d5 d6 d7 d8 d5d6 d5d6d7d8 d5d6d7 d6d7d8 d7d8 
VCY C12orf4 RNASE1 C8orf4 DUSP23 MYL7 DPPA5 NPPB LCN15 
VCY1B MAGEA6 P3H4 CDH6 DPPA5 RHBDD3 BCL11A GAGE12F APOA1 
INTS11 CD58 NSMAF PRSS2 TMEM106C CBR1 SERPINB9 PLSCR2 XAGE1B 
MCRIP2 YTHDF3 LMO7 CD48 BCL11A FAM110D PHAX FAM184A XAGE1A 
MARK3 IFRD2 RUNX1T1 LGI1 SERPINB9 LEFTY1 NOSIP EPHA4 MAEL 
FUOM DCTN5 APC CXCR4 PHAX SYTL2 LARP7 EOMES GAGE2A 
DGCR6L KNOP1 APOBEC2 CROT NOSIP CEBPZOS GNL3 MTRR CST1 
HYOU1 DPY19L4 COMMD3 GDF15 HUWE1 STAG3 PSMC3 MCRS1 RPL10L 
PRR11 SNUPN PYCR1 AC270107.8 ETFB CER1 LARS RNF34 DSCR8 
CENPX LAMTOR3 B3GNT7 SHISA2 LARP7 HAS2 SSB DCP1A BRDT 
  C21orf91 TCF7L2 TTN GNL3 AGAP4   GPATCH8 BBS9 
  MPHOSPH6 LPAR6 PRTG PSMC3 CCND1   KANSL2 RCOR3 
  TRA2A ZNF84 AMPD2 LARS TAGLN   SERINC5 LEFTY2 
    SOCS2 PLK2 SSB TNFRSF12A   SON TNNC1 
    CCNT1 RAB17   RASEF   TTC3 TXNRD2 
    CASP8AP2 VCX   BAX   SLC11A2 LRIG3 
    UTRN VCX3A   AKAP9   ANKRD18B RAF1 
    ERBIN SAXO2   CDK10   TAX1BP1 SPP1 
    RNPC3 NFE4   C19orf48   ANXA3 CYP26A1 
    RNF170 ZNF677   TRDN   PCSK5 PTGR1 
    MMS22L TMEM63A   CCNL2   MCM7 PAN3 
    MGST2 CCDC144A   LPP   MTRNR2L8 C6orf62 
    GNS NFRKB   CADM1   FSTL1 FNDC3B 
    PDCD11 SPATA7   FSTL4   ATP2B1 CFLAR 
    ATP1B1 NDRG4   DCLRE1C   MCFD2 TOX4 
    PUS7L SHC4   ANKRD12   MTRNR2L12 NUCB2 
    TIMM23B ITGA5   SLCO1A2   PWP1 USP24 
    RABGAP1L ACAA1   SPINK9     UPP1 
    THAP5 SLC38A4   CHD9     WDR73 
    ERGIC2 CSNK1G1   MCM5     PLCB1 
    TOP3A RHOBTB3   PDE4DIP     CHD4 
    PPIC PHYKPL   C19orf60     ENOSF1 
    CAV1 POLE   INPP5F     KANSL1L 
    RBBP8 SYCP3   MRPL28     MFSD8 
    CENPE TNPO2   LRRTM4     CCDC84 
    AC138811.2 LAMA1   NSD1     NKTR 
    FKBP14 CRIM1   PHACTR2     OTX2 
    SECISBP2L ANKRD1   PWWP2A     FBXO38 
    RIC8B EXOG   DCAF8     CCDC66 
    GAR1 LY6E   SLC3A2     ZNF649 
    ADM HOOK2   GLS     MAP4K5 
    FAM111B LIFR   MYDGF     POLR3E 
    PBRM1 ANKRD36C   BET1L     XPO6 
    IFRD1 UBE2D4   SPG7     SAR1B 
    RND3 SZT2   CTNND1     EIF2AK4 
    PIGP NR2C2   MED7     ZNF420 
    TMEM138 F3   FRG1     TMED1 
    SRPRB RNF213   FST     REV3L 
    CCNDBP1 PTK7   BCAS3     C2orf68 
    ZMYND8 ZKSCAN1   AC007326.4     ALG11 
    CLDN7 TOP3B   ZNF518A     SPINT2 
    TIPIN TAC4   GAD1     AGO3 
    SALL4 ANKRD36   GABRG2     HIST2H2AA4 
    ALG5 ST5   DTNA     ODF2L 
    PPP4R3A PPFIBP1   ANKRD10     ZFC3H1 
    HYAL2 NELFCD   GTF3C3     SPATS2L 
    PSMG3 ZNF160   BRD8     NSFL1C 
    REST FBXO16   LMAN2     ADAMTSL3 
    TMEM208 KDM5A   PIGN     TMEM243 
    MLEC TIGD1   KIAA1328     NPC1 
    NSRP1 ZNF571   CALD1     GPBP1 
    DNMT3A WDR72   BLOC1S6     APOC1 
    KIAA1551 ZNF611   NTS     ZC2HC1A 
    RARS2 SELENOP   B2M     FANCD2 
    CHID1 MOSPD2         LCLAT1 
    OSBPL8 PRMT7         SLC20A1 
    COMMD2 ANKFY1         PON2 
    TTC14 GABBR1         CRBN 
    CCDC59 NAT9         TNRC6B 
    CHD1 ZNF331         LRP6 
    MGEA5 PEAK1         MDK 
    CCL2 MFAP5         MRPS25 
    QPRT PRKAA1         MAP1B 
    ICE2 RAD51B         PLEKHA5 
    TLK1 DDX11         ABCD4 
    SELENOT CENPC         NEPRO 
    SELENOS ZNF614         CLN5 
    BST2 RANBP17         NR6A1 
    TMED3 MGA         ATM 
    CD320 ANK2         FAM133B 
    MAGOHB PSMD5         UBE2B 
    ARL6IP1 GGA1         KTN1 
    ITM2C SIN3A         NEMF 
    DERL2 CD99         TPR 
    CNIH4 DRAM1         NCOR1 
    CAPZA1 ASH1L         TMEM87A 
    ATP6V0B PI4KA         RIMKLB 
    PRDX4 CYR61         PLPP5 
    U2SURP PAAF1         YIF1B 
    CXADR AC256236.1         POLR2E 
 
 
      BMP4         ZCCHC11 
      FSIP2         SERINC3 
      FZD5         USP34 
      ATG13         POGZ 
      BACH1         TMEM41B 
      ENTPD4         LGALS1 
      KIAA0100         ZNF195 
      PABPC1L         CELF1 
      MIPOL1         TBL1XR1 
      PDE7A         CBWD5 





ADD ATRX-DNMT3-DNMT3L  
ALKB2 Alpha-Ketoglutarate Dependent 
Dioxygenase  
AML Acute Myeloid Leukemia 
Amp   ampicillin  
APC/C   Anaphase Promoting Complex / 
Cyclosome  
ATP   adenosine 5ʼtriphosphate  
BAH bromo adjacent homology 
BER base excision repair 
BMP bone morphogenesis factor 
bp   base pairs  
C cytosine 
C.elegans Caernohabditis elegans 
CGI CpG island 
CLL Chronic Lymphatic Leukemia 
CpG cytosine phosphate guanine 
CXXC cytosine-x-x-cytosine 
d day 
DEG differentially expressed gene 
DMSO   dimethylsulfoxide  
DNA deoxyribonucleic acid 
DNAase   deoxyribonuclease  
DNMT DNA methyltransferase 
DNMT3L DNA methyltransferase 3-like 
DSB   double strand break  
DTT   dithiothreitol  
E1   ubiquitin activation enzyme  
E2   ubiquitin conjugation enzyme  
E3   ubiquitin ligase  
E4   ubiquitin chain elongation enzyme  
EDTA   ethylenediaminetetraacidic acid  
ESC embryonic stem cell 
FACS   Fluorescence Activated Cell Sorting  
G guanine 
GFAP Glial Fibrillary Acidic Protein  
h hour 
H3K27 Histone 3 Lysine 27 
H3K36 Histone 3 Lysine 36 
H3K4 Histone 3 Lysine 4 
H3K9 Histone 3 Lysine 9 
HR   homologous recombination  
HRP   Horse Radish Peroxidase  
IAP intracisternal A-particle 
Ig   immunoglobulin  
iPSC induced pluripotent stem cell 
JAK-STAT Janus Kinase – Signal Transducers and 
Activators of Transcription  
KAP1 KRAB-associated protein 1  
kb   kilo base pairs  
kDa   kilo Daltons  
KRAB-ZFP Krüppel-associated box domain zinc finger 
proteins  
LB   Luria Bertani  
LIF leukemia inhibotory factor 
LINE  long interspersed element 
LTR  long terminal repeat 




MEF mouse embryonic fibroblast 
min minute 
MOPS 3-N-Morpholinopropane sulfonic acid 
NEUROG 2 Neurogenin2  
NPC Neural Progenitor Cells 
ORF   Open Reading Frame  
PAGE   Polyacrylamide Gel Electrophoresis  
PBS  phosphate buffered saline  
PCNA Proliferating Cell Nuclear Antigen  
PCNA   Proliferating Cell Nuclear Antigen  
PCR   polymerase chain reaction  
PHD Plant Homeodomain 
PIWI P-element Induced WImpy testis 
PMSF   phenylmethylsulfonyl fluoride  
POL   polymerase  
PROTAC PROteolysis TArgeting Chimera 
PTM posttranslational modification 
PWWP Proline-Tryptophan-Tryptophan-Proline 
RAD   RADiation sensitive  
RFTS replication foci targeting sequence  
RING   Really Interesting New Gene  
RNA ribonucleic acid 
RNase   ribonuclease  
rpm   rounds per minute  
RRBS Reduced Representation Bisulfite 
Sequencing 
RT   room temperature  
sc single cell 
SDS   sodium dodecylsulfate  
seq sequencing 
SINE  interspersed element 
SMAD Small Mothers Against Decapentaplegic 
SOX SRY-related HMG-box genes 
SRA SET- and RING- associated  
TBS  tris buffered saline  
TDG thymine DNA glycosylase  
TE transposable element 
TET ten-eleven-transferase 
TF transcription factor 
Tris   Tris (hydroxymethyl) aminomethane  
Ub   ubiquitin  
UHRF1 Ubiquitin-like with PHD and Ring Finger 
Domains 1  
UV   ultraviolet light  
v/v   volume per volume  
VEGF Vascular endothelial growth factor 
w/v   weight per volume  
WNT Wingless Int-1 
WT   wild type  
XCI X chromosome inactivation  
 
